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ABSTRACT
Introduction: Advanced glycation end-products (AGEs) are implicated in the
pathogenesis of chronic diseases including cancer. AGEs are produced endogenously and
are also consumed from foods. High amounts of AGEs are found in animal products and
processed foods, and AGE formation is accelerated during cooking at high temperatures.
Using data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
(PLCO), we assigned and quantified NƐ-carboxymethyl-lysine (CML)-AGE content in
food and investigated the association between dietary AGE intake and breast cancer
(BrCa) risk. We assessed whether the risk was modified by race/ethnicity, obesity status,
fruit and vegetable intake, BrCa invasiveness and tumor subtype. We also investigated
the association between post-diagnosis CML-AGE intake and mortality from all-causes,
BrCa and cardiovascular disease (CVD) using data from the Women’s Health Initiative
(WHI). Methods: The PLCO enrolled women aged 55 to 74 years into a randomized
controlled trial. Our study sample included only women enrolled in the intervention arm
who were cancer-free at baseline and completed a baseline questionnaire and dietary
questionnaire (DQX). CML-AGE values were assigned and quantified to foods in the
DQX using a published AGE database. The WHI enrolled postmenopausal women aged
50 to 79 years into a clinical trial and observational study (OS). Our study sample
included women diagnosed with invasive BrCa during follow-up who completed a food
frequency questionnaire (FFQ) post-diagnosis, had energy intakes between 600 kcal/day
and 5000 kcal/day and had AGE data in the WHI database. Descriptive analyses
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estimated means and percentages while Pearson correlation estimated correlation
coefficient of CML-AGE intake with dietary factors linked to AGEs. In the PLCO, Cox
proportional hazards modelling was used to estimate the hazard ratios (HRs) and 95%
confidence interval (CIs) of BrCa and was stratified by race/ethnicity, obesity status, fruit
and vegetable intake, invasiveness of disease and hormone receptor status to assess effect
modification. In the WHI, HRs and 95%CI for risk of mortality from all-causes, BrCa
and CVD were assessed and was stratified by fruit and vegetable intake and hormone
receptor status. Results: After a median 11.5 years of follow-up, 1,592 women were
diagnosed with BrCa in the PLCO. The average CML-AGE consumption among all the
women was 6,105 ± 2691 kilounits (KU)/1000 kcal and was highest among non-Hispanic
black (NHB) compared to non-Hispanic white (NHW) and Other race/ethnicity.
Significant positive correlations were observed between CML-AGE intake and dietary
sources of animal protein, monounsaturated fatty acids, polyunsaturated fatty acid and
saturated fatty acids while the correlations between CML-AGE and fructose,
carbohydrates and plant protein were weaker. There was an increased risk of BrCa across
levels of CML-AGE intake. Higher CML-AGE intake was associated with increased risk
of BrCa among NHW but was not statistically significant for other race groups. Increased
CML-AGE intake was associated with increased risk of in situ and hormone receptor
positive BrCa. In the WHI, after a median 15.1 years of follow-up, 642 deaths were
reported including 198 BrCa-specific and 129 CVD-specific deaths. The average postdiagnosis CML-AGE consumption among all women was 6,647 ± 2279 KU/1000 kcal
and ranged from 830 KU/1000 kcal to 20,480 KU/1000 kcal. Compared to the lowest
level of CML-AGE intake, increased mortality risk was observed in highest level of
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CML-AGE intake for mortality from all-causes, BrCa and CVD. Increased post-diagnosis
CML-AGE intake was positively associated with BrCa and CVD mortality among low
consumers of fruits and vegetables and with all-cause mortality among both hormone
receptor positive and negative BrCa. Conclusion: The strong positive correlation
observed between CML-AGE and fat and protein intake reflect the high AGE levels
found in animal products especially those cooked at high temperature. High intake of
dietary CML-AGE may contribute to an increased risk of BrCa and the associations were
stronger in NHW women, and hormone receptor positive and in situ BrCa. High intake of
dietary CML-AGE after BrCa diagnosis in postmenopausal women may contribute to an
increased risk of mortality from all-causes, BrCa and CVD.
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CHAPTER 1
INTRODUCTION
Breast cancer (BrCa) is the most frequently diagnosed malignancy in women and
most commonly diagnosed among women aged 55 and 64 years.1,2 It is estimated that in
2019, approximately 268,600 new BrCa cases will be diagnosed.2 This constitutes
approximately 30% of all cancer diagnoses among women in the United States (US).2
BrCa is the second leading cause of cancer death in women after lung cancer and
constitutes about 14% of total cancer deaths in the US population. BrCa rates have
increased in the past decade with European American (EA) woman having the highest
incident rates of all racial groups in the US.3 The incident rate for invasive BrCa
increased from about 102 per 100,000 to 131 per 100,000 between 1975-1979 to 2016.1
Early detection programs such as increased mammography screening contributed to the
increased BrCa incidence rates observed during that time period.3 Study results from the
Women’s Health Initiative (WHI) revealed an increase in the risk of BrCa among healthy
postmenopausal women aged 50–79 years who were taking postmenopausal hormones
(PMH).4 The study findings were translated into clinical practice and informed medical
decisions concerning the use of hormonal medications in women. From 1999-2003 there
was an estimated 11% decrease in BrCa rates. The decline was attributed to the reduction
in PMH use in women which was typically prescribed to treat postmenopausal
symptoms.
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Declining BrCa mortality rates and increases in survival rates have been observed
over the past decades. Reduced mortality has been attributed to early BrCa screening
which leads to prompt management and treatment. Recent advances in therapeutic
management incorporating precision medicine and targeted therapeutic treatments have
also contributed to the positive health outcomes.5–7 The Surveillance, Epidemiology and
End Results (SEER) data collected from 1975 show the 10-year survival from invasive
BrCa has increased from approximately 63% in 1975 to 86% in 2006.1 The SEER
statistics estimates the overall 5-year BrCa survival between 2009–2015 to be at 91%.
These rates however vary by the stage at diagnosis and type of treatment as women
diagnosed at early stages have higher survival rates than women diagnosed at later
stages.8 The 5-year survival rate at 100% is highest in women diagnosed with carcinoma
in situ (CIS) which has not spread outside of the breasts. Women diagnosed with
localized disease have a 5-year survival of approximately 99%, and a diagnosis of
regional BrCa is estimated at 86%. Women diagnosed with BrCa that has metastasized to
other organs have the worst 5-year survival at approximately 27%.1 Survival rates vary
by racial/ethnic group, with African American (AA) women having overall 5-year
survival of approximately 82% compared to 91% among EA women.
1.1 STATEMENT OF THE PROBLEM
In 2019, it is estimated that about 268,600 new BrCa cases will be diagnosed in
the US, up from 266,000 in 2018.9 Research has been conducted extensively into
identifying the determinants of BrCa, with estrogen-related exposures across the life
course being predominant risk factors. Diet has been studied in relation to BrCa, and the
World Cancer Research Fund and the American Institute for Cancer Research
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(WCRF/AICR) reported alcohol as one of the dietary factors strongly implicated in breast
carcinogenesis.10 Chronic inflammation is an important mechanism by which dietary
factors may affect cancer risk. Studies report that the presence of circulating
inflammatory biomarkers promotes tumor progression and metastasis11 and increases the
risk of BrCa.12,13 Identifying risk factors, particularly those that are modifiable such as
diet, that promote an inflammatory environment is an important area of research in cancer
prevention and control.
Epidemiological findings support a relationship between diet and cancer10, and
the role diet plays in inflammation.14,15 Several studies report consuming a more
proinflammatory diet is associated with increased BrCa risk and mortality,16–20 although
not all studies are supportive.21 It also has been suggested that dietary modification could
impact breast carcinogenesis10,22,23 through influences on oxidation, formation of DNA
adducts, and growth factors which are all involved in breast carcinogenesis.22
Consumption of red meat has been linked to increased risk of cancers. Carcinogens such
as polycyclic aromatic hydrocarbons (PAH) or heterocyclic amines (HCA) may be
introduced into foods through preparation methods. Meat products cooked at high
temperatures such as frying or barbecuing may accelerate the formation of the
carcinogens which could potentially form DNA adducts and cause DNA damage, which
is implicated in carcinogenesis.24,25 Several studies have examined associations between
red meat or PAHs and HCAs and BrCa with mixed results.26,27 Less well-studied are
advanced glycation end-products (AGEs) which are formed during cooking at high
temperatures in a variety of foods. Experimental data suggests AGEs may increase
tumorigenesis, through increasing inflammation and oxidative stress, though studies in
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humans are scarce.28–31 A recent study reported provocative findings that higher intake of
AGEs is associated with increased risk of pancreatic cancer using data from the large
prospective cohort NIH-American Association for Retired Persons (AARP) Diet and
Health Study.32 However, no large epidemiologic studies have reported results on AGEs
and BrCa to date. A study found higher AGE levels in BrCa tissues compared to noncancerous breast tissues33 and serum levels were higher in estrogen receptor (ER)positive BrCa compared to ER-negative BrCa which suggests AGEs may confer a
differential risk on different BrCa subtypes33. Thus, dietary AGE represents a potentially
novel dietary risk factor for BrCa that needs to be examined in large epidemiologic
studies. Identifying a modifiable dietary risk factor for BrCa incidence and mortality
could enhance interventions aimed at BrCa prevention and survival.
1.2 AIMS AND HYPOTHESIS
The study assigned and quantified CML-AGE content in foods consumed by
women and examined the relationship between CML-AGE intake and BrCa risk and
survival in two large prospective cohort studies. We hypothesize that higher intake of
CML-AGE will be associated with an increased risk of BrCa and will be associated with
a shorter survival from BrCa. The specific aims addressed are as follows:
Aim 1: To assign and quantify dietary AGE content in food and investigate the
association between dietary AGE intake and BrCa risk in the Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial (PLCO).
The PLCO is a prospective study and recruited participants from different racial
groups. We obtained information on usual diet using a validated food frequency
questionnaire (FFQ). Dietary AGE content in foods consumed by women in the PLCO
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was assigned and quantified using published food composition tables which measured
CML-AGE in 549 commonly consumed foods in the US.34 The study questions for Aim
1 include the following:
Study Question 1: Is the average daily CML-AGE intake of women similar to other
published estimates from healthy subjects?
Hypothesis: We hypothesize that the average daily CML-AGE intake of women will be
similar to the published estimates from healthy subjects in the US.35
Study Question 2: Is CML-AGE intake associated with the risk of BrCa?
Hypothesis: We hypothesize that increasing levels of CML-AGE intake will be
positively associated with the risk of BrCa.
Aim 2: To investigate the association between CML-AGE intake and risk of BrCa in
the PLCO stratified by race/ethnicity, obesity status, fruit and vegetable intake,
invasiveness and hormone receptor status. We investigated the association between
CML-AGE intake and BrCa risk by race/ethnicity (AA and EA), obesity status (normal
weight, overweight and obese), fruit and vegetable intake (low, moderate and high),
invasiveness (in situ and invasive) and hormone receptor status (estrogen receptor and
progesterone receptor (PR)).
Study Question: Is there a difference in the association of CML-AGE intake and risk of
BrCa by (1) race/ethnicity, (2) obesity status, (3) fruit and vegetable intake, (4)
invasiveness and (5) hormone receptor status?
Hypothesis: We hypothesize that increasing level of CML-AGE intake will be positively
associated with the risk of BrCa and there will be a differential risk between
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races/ethnicities, obesity status, fruit and vegetable intake, invasiveness and hormone
receptor status.
1. We hypothesize that AA women will have a higher intake of CML-AGE and
higher risk of BrCa related to dietary AGE compared to EA women.
2. We hypothesize that CML-AGE associations with BrCa will be higher among
overweight/obese women compared to normal weight women.
3. We hypothesize that CML-AGE associations with BrCa will be higher among
lower consumers of fruit and vegetable compared to moderate and high
consumers.
4. We hypothesize that CML-AGE associations with BrCa will be higher among
women diagnosed with in situ BrCa compared to invasive BrCa
5. We hypothesize that CML-AGE associations with BrCa will be higher among
women diagnosed with hormone receptor positive BrCa (ER-positive and/or PRpositive) compared to women with hormone receptor negative BrCa.
Aim 3: To investigate the association between post-diagnosis CML-AGE intake and
BrCa survival in the Women’s Health Initiative (WHI).
The WHI is a longitudinal study and recruited postmenopausal women from
different racial groups. Dietary AGE values were calculated by researchers in the Fred
Hutchinson Cancer Research Center using the same AGE-database that was used in
calculating the CML-AGE intake in the PLCO.
Study Question: Is CML-AGE intake after BrCa diagnosis associated with survival from
BrCa?
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Hypothesis: We hypothesize that increasing CML-AGE intake after a diagnosis of BrCa
will be associated with poorer survival from BrCa.
1.3 IMPORTANCE OF RESEARCH
Very few studies have investigated the role of dietary AGE in breast
carcinogenesis. The dissertation will fill the gap in the literature and be among the first
epidemiologic studies to prospectively investigate the role of dietary AGE intake in BrCa
risk and survival. Diet plays a role in carcinogenesis and several studies have
demonstrated increased risks of cancers with high intake of unhealthy diet.36 In addition,
the relationship between diet and BrCa may vary according to BrCa hormone receptor
status. Identifying specific risk factors that may impact the risk of developing certain
BrCa subtypes is an important line of research and may help to address racial disparities
in BrCa.
It is anticipated that our study will contribute significantly to the existing evidence
on modifiable risk factors implicated in breast carcinogenesis. The findings from this
study will identify specific food items and preparation methods that could affect the risk
of BrCa and improve survival. If our hypotheses are supported, the results may assist
health care providers and patients in making informed dietary modifications to reduce
BrCa risk and improve survival through limiting the intake of AGE-rich foods and
incorporating food preparation methods that reduce the formation of new AGEs.
The findings from our study may inform the implementation of public health
programs and interventions aimed at sensitizing the general public on the risk factors,
which may be particularly important for high risk populations and groups. Identifying
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these modifiable risk factors would be a significant contribution in developing strategies
to mitigate BrCa risks and to improve BrCa outcomes and prolong survival.
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CHAPTER 2
LITERATURE REVIEW
2.1 ETIOLOLOGY OF BREAST CANCER
BrCa is heterogenous disease with variations in biological and phenotypic
expressions.37 These variations serve as the basis for the different prognosis and
therapeutic approaches identified after a BrCa diagnosis.37 BrCa can occur in men but are
rare,1 thus the focus of the dissertation is on female BrCa. The breast developmental
phases in women include puberty, pregnancy, and lactation. During these periods, the
breast tissues are exposed to reproductive hormones such as estrogen, progesterone, and
growth factors which promote the growth and proliferation of breast tissues.10 Thus,
exposures related to these developmental phases, such as early age at menarche,
nulliparity, and lack of breastfeeding are known risk factors for BrCa.
Estrogen is a steroid reproductive hormone and plays a significant role in breast
carcinogenesis. Estrogen is proposed to increase BrCa risk through enhancing cell growth
and promoting the proliferation of breast tissue.38,39 Researchers have studied the
associations of endogenous and exogeneous sources of estrogen in relation to BrCa risk.
Exogeneous sources of estrogen include the use of oral contraceptives (OCs) and PMH.
About 60% of BrCa in premenopausal women are estrogen dependent (ER-positive
BrCa) compared to 75% in postmenopausal women.40 The aromatization process
converts androgens to estrogen. The suppression of estrogen production through
aromatase inhibition has been identified as a significant strategy in BrCa prevention and
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treatment. Studies supporting the link between estrogen and BrCa and have been
translated into the use of pharmacological agents, such as tamoxifen and aromatase
inhibitors, that inhibit the binding of estrogen to receptors or inhibit the formation of
estrogen through the aromatization process.39
The chronic triggering of an inflammatory response is a biologic process that is
recognized to promote proliferation of malignant tumors and could lead to BrCa.41–43
Studies have reported the presence of circulating inflammatory biomarkers that promote
tumor progression and metastasis11 and contribute to the risk of BrCa.12,13 Some
biomarkers of inflammation identified include adiponectin, interleukin (IL)-6, and tumor
necrosis factor (TNF)-α.44 The biomarkers have been shown to be positively associated
with BrCa. C-reactive protein (CRP) which is produced in response to IL secretion also is
shown to be positively associated with BrCa45 and with worse survival from BrCa.46
2.1.1 Breast Cancer Classification
BrCa cells could be formed either in the milk ducts, as ductal CIS (DCIS), or in
the lobules, as lobular CIS (LCIS).47 CIS are the pre-cancerous and non-invasive forms of
BrCa and are confined to the ducts or lobules where they originate. On the other hand,
BrCa is invasive when it has spread to the surrounding breast tissue.3
BrCa is also classified based on molecular subtypes. These subtypes differ in
receptor status, HR and HER2, and are predictors of clinical outcomes and survival 48.
Information on BrCa subtypes are typically included in pathology reports as they are
important predictors of BrCa risk and outcomes.49,50 It is important to identify BrCa
tumors with different morphological characteristics to inform therapeutic approaches to
optimize clinical management and treatment outcomes. The most commonly identified
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molecular subtypes based on genetic expression in BrCa tumor tissues include luminal A,
luminal B, HER2, and triple negative breast cancer (TNBC).51
Luminal A subtypes account for about 70% of BrCa cases, are the least aggressive of all
subtypes and have a favorable prognosis and low risk of recurrence.49,50,52,53 Luminal A
tumors are generally low grade, HR-positive, and HER2-negative and have a lower
expression of tumor proliferating genes.49,54
Luminal B subtypes are HR-positive and express either ER and/or PR. They may also
express HER2 and show high Ki-67; a marker for tumor proliferation.54 They account for
about 12% of BrCa cases. Luminal B tumors are poorly differentiated, high grade, and
more aggressive than luminal A subtypes.55 As a result, women diagnosed with luminal B
BrCa have slightly poorer outcomes than luminal A tumors.50,50,52,56–58 Evidence also
suggests the outcomes of luminal B BrCa are worse in younger women compared to older
women.59,60
HER2 subtypes are BrCa tumors that are HR-negative and HER2 positive.61 They
account for about 5% of BrCa cases. HER2 BrCa are more aggressive and usually high
grade tumors having poorer prognosis than either luminal A or B BrCa.50
TNBC subtypes lack HR and HER2 expression, have the worst prognosis of all BrCa
subtypes, and account for about 12% of BrCa cases.3 Approximately 56% - 85% of basallike tumors are TNBCs.48 The unavailability of targeted therapies contribute to the poor
prognosis and survival of TNBCs.62,63 The distribution of BrCa subtypes differ by race
and age as the majority of TNBC are found in AA women, younger and premenopausal
women, and in women with BRCA1 mutation.37,64,65 A study reported women diagnosed
with basal-like cancers compared to women with non-basal-like cancers are more often
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premenopausal and younger, aged between 47 and 55 years.48 Women who are diagnosed
at earlier age tend to be diagnosed with more aggressive BrCa subtypes and they tend to
have poorer prognosis because of an increased risk of recurrence and poorer survival.66
TNBC cancers also have been suggested to be strongly associated with a family history
of BrCa compared to other subtypes.53
Evidence suggests that BrCa risk factors may differ across molecular subtypes. A
literature review on risk factors and BrCa subtypes found HR-positive BrCa were more
influenced by reproductive factors compared to TNBC and HER2-positive BrCa.67
Inverse associations were observed between parity and HR-positive BrCa while positive
associations were observed between older age at first birth and PMH use and HR-positive
BrCa. Younger age at menarche was positively associated with HR-positive BrCa. In the
majority of the studies reviewed, breastfeeding was inversely associated with TNBC and
HER2-positive BrCa.67 Differential risks observed for BrCa subtypes may be attributed to
etiological differences and genetic susceptibility of BrCa tumors.68 Reproductive factors
could alter the molecular characteristics of breast tissue in HR-positive BrCa.69
2.2. ADVANCED GLYCATION END-PRODUCTS (AGEs)
AGEs are complex reactive compounds formed in the body by the non-enzymatic
reaction of proteins or lipids with sugars.34,70,71 Exposure to environmental factors such as
cigarette smoking can serve as significant contributors to AGE in the body.72 AGEs are
present in food and consuming AGE rich foods can contribute substantially to circulating
AGEs in the body.34,71,73 The series of complex reactions involved in the formation of
AGEs have been described by the Maillard effect which occurs when food is heated
especially at high temperatures resulting in a browning of food that enhances its distinct
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flavor, aroma, and texture.74 Preparation methods influence the levels of AGEs formed in
foods.34 High temperature cooking such as grilling or frying, or cooking for long periods
of time contribute significantly to the AGE content in food.34,35,71,75–77 The Western diet is
high in sugar and saturated fats and has been shown to have high AGE content.34 The
adverse biological effects of AGEs are propagated through promotion of oxidative stress
and chronic inflammation which could promote DNA damage.78–82
2.2.1 AGEs in Disease Development
The biological activities of AGEs occur through direct effects on tissue cells or
through the activation of the receptor for AGE (RAGE).83,84 Activation of the AGEsRAGE pathway could promote oxidative stress and secretion of inflammatory
biomarkers; TNF-α, IL-6, and IL-1α, through the activation of nuclear factor-κB (NF-κB)
and are implicated in pathogenesis of chronic diseases78,83,85 (Figure 2.1). RAGE has been
markedly expressed in cells of the colon, kidney74,86,87, breast, and prostate tumors.88 It is
also implicated as a factor that drives chronic disease development and progression.78
High endogenous AGE levels have been observed in hyperglycemic conditions
and have been studied in type II diabetes mellitus (T2DM) and metabolic syndrome.89
AGE accumulation in cells and tissues is implicated in micro and macrovascular
complications in diabetes72,90–93 and cardiovascular diseases (CVD).71,72,78,83,89,93 AGEs
have also been observed at the sites of neuronal degeneration and implicated in the
ageing process and neurodegenerative diseases such as Alzheimer’s disease.72,94,95 The
well-known AGEs that have been identified include NƐ -carboxymethyl-lysine (CML),
Nε-1-carboxyethyl-lysine (CEL) pentosidine, methyl-glyoxal (MG), and Nδ-(5-hydro-5methyl-4-imidazolon-2-yl)-ornithine (MG-H1). The more commonly measured AGE that
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has been identified in tissue protein is CML and acts as a biomarker for AGE
exposure.76,90 CML is formed from the nonenzymatic glycation of proteins and lipids96,97
and may be an important biomarker of oxidative stress and long term damage to
proteins.96
Laboratory studies have researched the effects of AGE accumulation in breast
tumors. AGE enhances the proliferation and invasion of BrCa cells through the increased
expression of RAGE.29,30 Higher serum levels of AGE have been detected in women with
BrCa compared to healthy women.33,98 Another study found high accumulation of CML
in about 70% of BrCa tissues.99 In the same study, high CML accumulation in BrCa
tissue cell lines was related to ER expression.
The study of dietary AGE in cancer is an emerging field of nutrition research and
current data in humans are limited. Most of the research conducted on AGEs are
laboratory-based studies focused on RAGE and serum AGE levels. These experimental
studies support the biological plausibility of higher AGE exposure leading to an increase
in BrCa risk.29–31 AGE has been identified in larynx, breast, and colon tumors and high
levels have been observed in aggressive prostate cancer tumors.28 Very few studies have
proposed to investigate the role of dietary AGE in breast carcinogenesis. One
epidemiological study on dietary AGE found high intake levels were associated with
elevated pancreatic cancer risk.32 To date, this is the only known study that has attempted
to estimate dietary AGE intake and the relationship with a cancer endpoint in humans in a
large epidemiologic study. High AGE rich diet has been correlated with high plasma
AGEs and supports the hypothesis of high dietary AGE intake being positively correlated
with inflammatory biomarkers.79
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2.2.2 AGE Database
Several analytical methods have been used to measure AGE contents in a variety
of foods.100 These methods involve enzyme-linked immunosorbent assay (ELISA), high
performance liquid chromatography with ultraviolet-or fluorescence detection (HPLCUV/FD), ultra-performance liquid chromatography with tandem mass spectrometry
detection (UPLC-MS/MS) or gas chromatography with mass spectrometry (GC-MS).100
ELISA methods typically estimate the AGE equivalents in units per food while other
analytical methods estimate the AGE concentrations in mg per food.100 Conversion to a
single unit could lead to imprecise estimates.100 However, a definitive approach to
measuring AGEs has not yet been established and could explain the variations in AGEs
content obtained through the analytical methods.100
The AGE database developed by Goldberg et al. in 2004 was the first attempt to
estimate AGE content in food using ELISA technique.75 The database included the CMLAGE content of 250 foods. In 2010, an updated AGE database was developed by a
research team at Mount Sinai School of Medicine (NY) and Nutrition Options Inc. The
database contains CML-AGE content of 549 foods analyzed by ELISA method.34 Shortly
after in 2012, another AGE database was developed and contained CML-AGE content of
257 foods commonly consumed among Northern Irish population. The CML contents
were analyzed using UPLC-MS/MS methods.101 The database by Scheijen et al.
examined CML-AGE, CEL-AGE, and MG-H1- AGE contents in 190 foods using UPLCMS method.102 They found the CML contents to be similar to the CEL content in food
but lower compared to MG-H1 content. In all the AGE databases, AGE content was
found to be negligible in fruits, and highest in processed and high fat or high protein
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foods.100 Some of the analytical assessment methods produced some variations in CML
contents of some foods such as butter and food products high in fat.103 For example, food
products high in fat appeared to contain higher CML contents when analyzed by ELISA
compared to analysis by UPLC-MS/MS while CML tended to be lower for carbohydraterich foods measured by ELISA.100 However, significant correlations were observed for
CML contents using ELISA and LC-MS.100
Cooking preparation methods, water content in food, and pH levels of foods are
determinants of the level of AGE in food.100 Foods that are prepared with high
temperatures such as grilling or frying and for longer periods tend to have higher AGElevels. Water content in food and acidity levels of foods also affect the AGE content.
Foods that are low in water content speed up the formation of AGE. Food products that
are marinated, for example in vinegar-based marinades, and acidic foods typically have
lower pH values and AGEs are generated at reduced rates upon cooking.
2.2.3 Uribarri et al. AGE-Database
The AGE database created by Uribarri et al. is the largest and most commonly
used AGE database in the literature to date.100 The database contains CML content of 549
foods and MG contents of selected foods commonly consumed in the northeastern
metropolitan region of the US. The preparation methods of the food products are also
included in the database.34 Foods were tested for CML equivalent using an ELISA
method34,100 and CML-AGE contents are expressed in AGE kU/100g of food. MG
equivalents in a sample of the foods were evaluated and MG-AGE contents are expressed
as nmol/100g of food.
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In the AGE database, meat products and foods high in fat and dairy products such
as butter, cream, and margarine had high AGE contents. The extraction and
pasteurization processes which may involve heating for prolonged periods could have
contributed to the formation of AGE resulting in the high AGE contents observed.34 Meat
marinated with lemon and/or vinegar prior to cooking were observed to have lower AGE
level compared to non-marinated meat.34 Previous studies have shown significant linear
correlations between dietary AGE intake and serum AGE levels in subjects.75,104,105 In the
proposed study, dietary AGE content based on the Uribarri et al. database will be
appropriately assigned to match the food items in the PLCO dataset using a method
previously utilized in a prior study.32
2.2.4. Racial Disparities in AGE Intake
Residents of low-income neighborhoods are especially prone to higher
consumption of processed foods and less consumption of fruits and vegetables.28 Poor
dietary practices may be due to the lack of healthy food stores and abundance of fast food
restaurants in the neighborhood.106 Poverty rates have been reported to be higher in the
AA population compared to EA population and AAs are at a higher risk of consuming
low-quality foods rich in AGEs, further contributing to the health disparities observed
between racial groups.28
2.3 DIET AND BREAST CANCER
The contribution of diet to the etiology of BrCa has been well-studied.10 This
section provides a summary of the epidemiological evidence evaluating the role of
dietary factors such as fruits and vegetables, carotenoids, fat, red and processed meat, and
phytoestrogens in relation to BrCa risk. Experimental studies in mice investigating
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dietary factors have provided evidence of an association with tumorigenesis.22 Other
epidemiologic studies in humans have produced inconsistent results.107
Fruits and vegetables contain high amounts of antioxidants and fiber and may be
protective of BrCa.107 In the report published by the WCRF/AICR, findings from the
extensive review of literature showed limited evidence that consumption of non-starchy
vegetables may reduce the risk of ER-negative and ER-positive BrCa.10 Data from the
Nurses’ Health Study (NHS) revealed that a usual daily intake of at least 5 servings of
fruits and vegetables had a modest inverse association with premenopausal BrCa when
compared to daily intake of <2 servings of fruits and vegetables.108 The association was
more pronounced in women who had a family history of BrCa. High fruit and vegetable
diets also tend to be high in carotenoids and vitamin A. Findings from the NHS support
the role of intakes of carotenoids and vitamin A from foods and supplements in reducing
the risk of BrCa. A dose response relationship with carotenoid intake was also
observed.108 β-carotene has been the most studied carotenoid in association with cancer
risk.22 High serum levels of β-carotene and lutein were shown to be inversely associated
with BrCa.22 However, studies looking at dietary intakes of vitamins A, C, E and βcarotene have not all been supportive and some have produced null results for
associations with BrCa.108–118
The Western diet is generally characterized by high intake of red/processed meat,
refined grains, and high fat dairy and has been linked to increased risk of BrCa.22
However, increased intake of calcium, of which dairy is a major source, was also
reported to be associated with decreased risk of BrCa based on a meta-analyses of
prospective cohort studies.119 Several studies evaluating the effect of dairy products in
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BrCa have been conducted with mixed results. Some studies have reported that intake of
whole milk120,121 and dairy products122 are associated with reduced BrCa risk. Dairy
products contain substantial amounts of calcium and vitamin D which are proposed to
have anti-carcinogenic properties and may explain the inverse associations observed with
BrCa risk.123 However, not all studies assessing dairy intake have been supportive.123
Among premenopausal women, increased BrCa risk was observed for high intakes of
high fat dairy foods.121 Increased mortality risk after a BrCa diagnosis was also observed
with intakes of high-fat dairy foods.124 Dairy products contain significant amounts of
total fat123,125 and may contain hormones and growth factors which promote breast
carcinogenesis such as Insulin-like Growth Factor (IGF-1) which has been identified as a
promoter of carcinogenesis.126,127
The association between fat intake and BrCa risk has been studied extensively,
with weak or inconsistent evidence in epidemiologic studies, even in the presence of
large amounts of supportive experimental evidence.128 Explanations for the null or weak
associations observed have been posited, such as those related to imprecise measurement
of dietary fat intake. Positive associations have been reported when measurement is
improved, such as with the use of food records rather than food frequency
questionnaires.129 These findings are supported by evidence for a potential biological
mechanism that fatty acids increase the levels of circulating estrogen in the body.130
However, studies evaluating total fat intake and BrCa have not all been positive.131
Relationships between specific types of dietary fats and BrCa risk have been identified. A
review and meta-analysis reported that a higher intake of ω-3 polyunsaturated fatty acids
(PUFA) from seafood is associated with a reduced risk of BrCa.132 A dietary assessment
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in an Asian population revealed a higher intake of ω-3 PUFA from fish consumption
could be attributed to the low incidence of BrCa in Asia compared to what is observed in
the US populations.133 The effects of saturated fats on BrCa risk has also been studied,
with increased risk being reported.128 Comparing the highest intake level of saturated fats
to the lowest intake levels, positive associations were observed for the risk of BrCaspecific mortality.134 When stratified by BrCa subtype, higher dietary intakes of total and
saturated fats were positively associated with ER-positive and PR-positive BrCa
suggesting the involvement of dietary fat in the development and promotion of HRpositive breast tumors.135 However, the positive associations of saturated fats from
animal sources on BrCa was not supported by all studies.136 The inconsistencies in the
studies evaluating dietary fat intake and BrCa risk could be due to narrow ranges in
intake of fat within populations being studied or the assessment of total fat intake as
opposed to assessing the contribution of specific types of fats to BrCa risk.137
Carbohydrates also have been suggested to play a role in breast carcinogenesis.
Results from the WHI suggested higher risk of BrCa with increased consumption of a
diet high in carbohydrates138 and the conclusions were supported by a study conducted in
a Mexican population where approximately 64% of dietary intake is from a carbohydrate
based diet.139 High refined carbohydrate and glycemic load diets and subsequent effects
on insulin and IGF-1 are likely to be the main culprits. In contrast, dietary fiber has been
associated with reduced risk of BrCa in a pooled analysis of prospective studies when
comparing the highest level of fiber intake to the lowest intake level.140 The results were
in accordance with the NIH-AARP Diet and Health Study which examined the influence
of diet on BrCa stratified by BrCa subtypes.141 Inverse associations for intakes of dietary
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fiber were stronger in ER-negative and PR-negative BrCa tumors compared to ERpositive or PR-positive tumors.
Red meat from animal products such as beef, pork, or lamb, and processed meat
(meat prepared through curing, salting or smoking with the aim to preserve and/or
enhance flavor) have also been implicated in breast carcinogenesis.142 Epidemiological
findings have been reported in several studies and in pooled analyses.26 The International
Agency for Research on Cancer (IARC) classified red meat as ‘probably carcinogenic’
(Group 2A) and processed meat as carcinogenic (Group 1).142,143 In particular, substantial
evidence supports the involvement of red meat intake in colorectal cancer.144 N-Nitroso
compounds (NOC) may be formed during the processing of processed meat.
Consumption of red and/or processed meat increases the endogenous levels of the
carcinogens NOC, and are able to form DNA-adducts which can induce
carcinogenesis.107 HCAs and PAHs are carcinogens that are produced during the
preparation/cooking of meat products. The levels of these carcinogens are increased when
meat is prepared with high temperatures and to high doneness levels, such as in panfrying or grilling.107 Positive associations with BrCa have been reported in studies
examining the exposure to HCA and PAH26,145–147 but not all findings have been
supportive.148–151 A study evaluating survival after BrCa diagnosis found increased
mortality with high intakes of grilled/barbecued and smoked meat.152 Findings of positive
associations with BrCa also were observed in a case-control study which estimated BrCa
risk in postmenopausal women with higher level of total meat intake.146 Additionally,
increased BrCa risk was observed for intakes of stewed/prepared meat and meat cooked
till well done, and the associations were stronger among HR-positive and HER2-negative
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BrCa. For TNBCs, the positive associations were strongest for intakes of processed/cured
meats.146
Phytoestrogens include isoflavones and lignans and are found occurring naturally
in plants.153 Phytoestrogens are similar in chemical structure to estrogen but exert weaker
estrogenic effects in addition to anti-inflammatory properties.153,154 Soy has been linked
to BrCa because of estrogenic effects exhibited by soy containing food products, a very
popular source of isoflavones.153 However, a systematic review analysis demonstrated
that soy may be associated with reduced BrCa risk and be protective of BrCa.155 In a
meta-analysis, pre-diagnosis intake of isoflavone and soy products were associated with
reduced risk of total mortality and BrCa recurrence and the association was pronounced
in postmenopausal women.156 However, the WCRF/AICR report concluded that there
exists limited evidence to date to support reduced risk of BrCa risk with increasing soy
intake.10
Some limitations are encountered in dietary assessment and include measurement
error and the lack of knowledge about the most relevant etiologic period of exposure to
the dietary factors.22 The results of some epidemiological studies have supported the role
of certain foods in the development of BrCa, while others have been less than
conclusive.22 The proposed study will address a rather novel area of dietary exposures,
that of dietary AGE, and potentially suggest new dietary recommendations centered
around food preparation methods for disease prevention.
2.4 BREAST CANCER RISK FACTORS
The effect of BrCa risk factors is cumulative over a woman’s lifespan.
Experimental studies have demonstrated that environmental exposures especially during

22

the developmental period significantly contribute to the risk of BrCa.157 Ongoing research
seeks to understand the causes of BrCa. Several factors have been identified that may
contribute to the risk of BrCa, and these risk factors may affect BrCa subtypes
differently.
The most common risk factors identified include:
•

Demographic factors: Age, race/ethnicity

•

Reproductive factors: Age at menarche and menopause, menopausal status,
breastfeeding, parity, age at first birth, and use of hormones (OC and PMH)

•

Dietary/lifestyle factors: Alcohol, obesity, physical activity, and smoking

•

Other factors: Family history of BrCa and genetic factors
The following sections summarize the evidence for and the direction of effect for

the above risk factors, which may be important covariates to consider in the proposed
study.
2.4.1 Demographic Factors
Age
Age is a well-known risk factor in the development BrCa.158 The risk of BrCa
increases with age,3 and age at BrCa diagnosis may be associated with survival from
BrCa.159–162 BrCa is diagnosed at a median age of 65 years,1 and the highest rates are
observed in women between 60 and 69 years.3 The declining rates observed in women
aged 70 years or older may be associated with reduced screening in women older than 75
years.1,3 The U.S. Preventive Services Task Force (USPSTF) recommends
mammography screening every 2 years for women aged between 50 and 74 years163 as
benefits of screening are observed among women with moderate risk of BrCa. The SEER
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program evaluating the effect of age on BrCa prognosis found more aggressive BrCa
among younger women which partially explains poor BrCa outcomes observed in
younger women diagnosed with BrCa.60 Generally, younger women aged 30 years and
younger, and older women aged 60 years and older, had worse prognosis compared to
middle aged women aged between 50 years and 59 years.164 Other studies have also
reported poorer outcomes among older women compared to younger women.165,166
Race/ethnicity
Differences exist in BrCa incidence and mortality across racial groups in the US.
Generally, non-Hispanic whites (NHW) or EAs have the highest incidence of BrCa but
mortality rates are highest among non-Hispanic black (NHB) or AA women.3,9 The 5year survival of overall BrCa in NHW is 91% which is higher than 81% observed among
NHB.1 This could be due to the fact that AA women usually present at later stages,167,168
have higher tumor grades,167,169 and worse clinical outcomes compared to other racial
groups.54,170 AA women are more likely to be diagnosed with BrCa at younger ages
compared to EA women.1 The median age of BrCa diagnosis in AA women is 59 years
compared to 63 years in EA women.1 The prevalence of BRCA1 or BRCA2 mutations
was observed to vary across racial groups.171 Among women with a strong family history
of breast or ovarian cancers or male BrCa, prevalence of BrCa gene mutation in AA
women was 16-44% which was higher than the prevalence of 5-12% observed in EA
women. A study found that about 25% of AA women diagnosed with an early onset of
BrCa or had a family history of breast or ovarian cancer or TNBC had a BRCA1, BRCA2
or BrCa gene mutation.171 The prevalence of the BrCa gene mutations could explain the
increased risk in aggressive disease documented among younger and AA women
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compared to EA women.64 A study using the PAM50 assay to analyze risk of recurrence
found significantly increased risk of BrCa recurrence among AA women compared to EA
women, supporting the occurrence of aggressive disease in AA women.172
2.4.2 Reproductive Factors
Age at menarche and menopause
Menarche represents the start of the menstrual cycle during the lifecycle of a
woman. Early onset of menarche and older age at menopause are factors that have been
linked to BrCa risk173,174 through the prolonged exposure of reproductive hormones
including estrogen and progesterone which have been associated with increased BrCa
risk.175 Results from a meta-analysis found menarche at ≥15 years was associated with a
13% reduction in BrCa risk compared to menarche at 13 years.176 In addition, the risk of
BrCa is increased in women who reach menopause after 55 years of age.177 During the
postmenopausal phase, production of estrogen by the ovaries reduces and most of the
circulating estrogen is produced from the aromatization of adrenal androgens which
include testosterone.178
Breastfeeding, parity, and age at first birth
The report from the WCRF/AICR provide strong evidence to support
breastfeeding as a protective factor of BrCa.10 Epidemiological studies show that
breastfeeding may reduce the risk of BrCa179 and the risk reduces further for every one
year increase in breastfeeding.176,180 The Carolina Breast Cancer Study (CBCS), a case
control study, revealed breastfeeding had a stronger effect on the risk of TNBC compared
to luminal A BrCa.181 The use of lactation suppressants was positively associated with the
risk of developing TNBC. In the analysis comparing TNBC cases to BrCa free controls,
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breastfeeding for four months or longer compared to never breastfeeding was associated
with a significantly reduced risk of developing TNBC. The study also examined women
who had never breastfed for associations with BrCa. Results found that three or more
births compared with no births was positively associated with TNBC but inversely
associated with luminal A BrCa. Similar findings were observed in the pooled study
using two large prospective cohorts; Life After Cancer Epidemiology (LACE) and the
Pathways Study.182 Among women that had never breastfed, having three or more
children when compared to having no children was positively associated with the risk of
TNBC compared to luminal A BrCa.
A meta-analysis on women aged between 40 and 49 years was conducted and
showed a 16% increased risk of BrCa among nulliparous women when compared to
women who had given birth.176 Another meta-analysis showed women who had a
pregnancy had a 25% reduced risk of luminal BrCa compared to women who had never
been pregnant,179 but there was no significant association with HR-negative BrCa in
previous studies.183,184
Age at first birth has also been linked to BrCa. Studies show that compared to
women younger than 30 years, women who had a first birth at 30 years or older were at
an increased risk of developing HER2-positive and ER-positive BrCa.185 Generally,
increasing age at first birth has been shown to be positively associated with BrCa.3,176,186
Hormones, postmenopausal hormone therapy (PMH) and oral contraceptives (OC)
Estrogen is the most extensively studied reproductive hormone due to its well
documented implication in mammary development and the female reproductive cycle.
Estrogen is produced endogenously in the ovaries and from aromatization of
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androgens.187 A higher lifetime exposure to exogenous estrogen through OCs or PMH
may contribute to the risk of BrCa.178,188 The use of OCs have been associated with a
modest increase in BrCa and this risk remained after approximately 15 years of
stoppage.189,190 The risks accompanying the use of OC appear to be greater in younger
women or when used prior to pregnancy191 and during ongoing development of breast
tissues.38 Increased risks of BrCa have been observed in postmenopausal women
receiving PMH and are correlated with higher circulating estrogen levels.192–195 Some of
the strongest evidence arose from the WHI randomized controlled trial which revealed an
increase in BrCa risk among women randomized to receive PMH.4 However, a metaanalysis combining data from forty cohort and two case control studies evaluating the
association between the use of PMH and the risk of BrCa-specific mortality found
significantly inverse associations.196 The study also found better survival among those
with current use prior to BrCa diagnosis compared to former users. The study evaluated
the effects of the use of PMH after BrCa diagnosis and the results revealed longer
survival for women who used PMH. However, the authors acknowledge that there might
have been residual confounding as the results were not adjusted for confounders in the
meta-analysis, therefore care should be taken while interpreting the study results.
Breast density
Women with dense breasts usually have more fibrous and glandular tissue
compared to fatty tissues.157 About 43% of women aged 40-74 years were reported to
have heterogeneous or extremely dense breast.197,198 Genetics, diet, obesity, medication,
and hormone use could affect breast density. Evidence suggests that breast density is a
predictive risk factor for BrCa,187 with increased risk reported for denser breasts,176,199–202
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though not all studies have been supportive.157 The biological plausibility of increased
breast density as a risk factor for BrCa can be explained by the presence of more cells
which may increase the secretion of hormones that are implicated in breast
carcinogenesis.
2.4.3 Other Dietary and Lifestyle Factors
Lifestyle factors such as alcohol intake, obesity, and physical activity are
generally modifiable and have been suggested to affect BrCa risk and survival.10
Alcohol
The Third Expert Report from the WCRF/AICR reported strong evidence to
suggest consumption of alcohol increases the risk of BrCa among pre and
postmenopausal women.10 Alcohol promotes tumor growth and may modify the tumor
environment through increasing estrogen levels.187,203,204 Numerous studies have
observed that premenopausal women who are alcohol consumers are more likely to have
high estrogen levels and testosterone levels when compared to non-alcohol
consumers.205–212 This suggests the development of BrCa through the ER pathway which
could explain the increased risks observed, particularly in HR-positive tumors.213–215
Reactive oxygen species produced through the metabolism of alcohol also could lead to
oxidative stress which promotes DNA damage.216,217 On average, about 4-10% of BrCa
cases are attributed to alcohol consumption.204,218,219 It is also important to consider the
type of alcoholic beverage consumed. Red wine is produced from grapes which contain
an abundance of polyphenols. Polyphenols have anti-inflammatory properties which may
confer cardiovascular and tumor suppressing properties by blocking the formation of
estrogen.40,220 This lends some support to recommendations on the consumption of red
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wine in preventing certain health outcomes. Generally, epidemiological evidence strongly
suggests alcohol as a contributing risk factor for BrCa.157 Studies evaluating pre and postdiagnosis intake of alcohol suggest positive associations with overall BrCa and HRpositive BrCa,221–224 and BrCa recurrence in postmenopausal women.221 The risks
observed were significant with moderate alcohol intake and increased with increasing
alcohol consumption.222 A pooled analysis of 53 epidemiological studies showed that the
risk of BrCa increased by about 7% for every 10 g increase in daily alcohol intake.225 The
study also found daily alcohol intake between 35g and 44g was associated with a 32%
increased risk when compared to women with no alcohol intake and the risk increased to
46% among women with daily intakes of 45g or more.
Obesity and physical activity
The prevalence of obesity in the US has increased over the past decades.226,227 The
Centers for Disease Control and Prevention (CDC) defines obesity as body mass index
(BMI) ≥30 kg/m2. Overweight is defined as BMI 25.0-29.9 kg/m2 and normal weight
BMI as 18.5-24.9 kg/m2. Between 2011 and 2014, about 36% of the US population were
categorized as obese.227 Among racial groups, the prevalence of obesity was lowest
among non-Hispanic Asian adults at 12%. The prevalence of obesity among NHW
women was reported at 36%, with 46% in Hispanics. NHB women had the highest
prevalence of obesity at 57%.227 Multiple adverse health outcomes have been associated
with obesity, most commonly CVD.226 Epidemiological studies have supported the
relationship between obesity and cancers including esophageal, pancreatic, colorectal,
prostate, ovarian, and postmenopausal BrCa.10 About 20% of cancer deaths among
women are linked to obesity and increasing risks of female reproductive cancers have
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been observed with higher BMI.228 A meta-analysis found that weight gained after BrCa
diagnosis was positively associated with all-cause mortality.229 In contrast, the
WCRF/AICR report revised in 2018 provides strong evidence that being overweight
between the ages of 18 and 30 years actually decreases the risk of pre and
postmenopausal BrCa.10 The biological mechanism driving the inverse associations
observed is still not clear. An explanation is that early exposure to estrogen derived from
adipose tissues may lead to modifications in breast tissues making the tissues immune to
the carcinogenic effects of estrogen later in life.10 Another explanation is that childhood
obesity is associated with reduced production of hormones such as IGF-1 which plays a
role in body growth and is suggested to be a tumor promoter. Lower levels of IGF-1 may
be observed in women who were obese during childhood and could explain the protective
effect of childhood obesity on BrCa risk.10 Results from a meta-analysis examining BrCa
risk by menopausal status found a 2% increase in risk for every one unit increase in BMI
among postmenopausal women and a 25% increase in BrCa risk among obese
postmenopausal women compared to normal weight postmenopausal women.230
However, weak inverse associations were observed for BrCa among premenopausal
women for a one unit increase in BMI. The results were supported by the WCRF/AICR
report stating being overweight or obese in adulthood before menopause is inversely
associated with premenopausal BrCa.10 These findings support obesity as a risk factor for
postmenopausal BrCa, and could worsen the prognosis in both premenopausal and
postmenopausal women.231,232
Various biological mechanisms have been proposed for the relationship between
obesity postmenopausal BrCa. Cytokines and inflammatory mediators are produced from
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adipocytes which are endocrine cells found in adipose tissues. These inflammatory
mediators have been linked to tumor invasion and carcinogenesis.231 Cytokines produced
include IL-6, IL-8, IL-1β, TNF-α and vascular endothelial growth factor (VEGF)233,234
which increase angiogenesis and promotion of an inflammatory microenvironment
conducive to tumor growth.233 In the Health, Eating, Activity and Lifestyle Study
(HEALS), levels of proinflammatory biomarkers were observed to be higher in obese
women than in normal and overweight women.235 Physical activity seemed to mediate the
effect as the levels of inflammatory mediators were lower among women with BrCa who
were obese and had a higher level of physical activity.235 Other studies also demonstrate
reduced levels of circulating inflammatory biomarkers and reduced risk of BrCa among
women who exercise regularly.10 High level of physical activity was associated with a
20-40% risk reduction in BrCa in women.236 Evidence from the NHS suggests physical
activity after a BrCa diagnosis may have beneficial effects in improving survival.237
Significantly higher levels of reproductive hormones such as estrogen and
testosterone which have been identified to promote the proliferation of breast tissues have
been observed in obese BrCa survivors when compared to non-obese women.238
Aromatization of fatty tissues could lead to the formation of estrogen further increasing
the level of circulating estrogen. These hormones have been detected in BrCa tissues and
are linked to worse health outcomes.239 Obese women are at a higher risk of BrCa
recurrence and decreased survival. The adverse effects are observed to be stronger among
women with ER-positive BrCa.240 The plethora of evidence informed the ACS
recommendation of weight control in women who have been diagnosed with BrCa. The
WCRF/AICR report also stated there is convincing evidence to support the role of
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physical activity in decreasing BrCa risk and improving survival in premenopausal and
postmenopausal women.10
Smoking
Tobacco smoking is linked to increased morbidity and mortality from various
causes and is responsible for millions of deaths annually. Smoking has been extensively
researched in cancer and is a major risk factor for lung and other cancers.241–243 The
association between smoking and BrCa has been studied extensively and results have
been generally supportive of a modest increased risk, however some studies report null
associations among non-alcohol drinkers and suggest the relationship to be confounded
by alcohol intake.225 Nicotine, an active component in tobacco was observed to induce
tumor proliferation in human BrCa cell lines and may be a major contributing risk
factor.244 Carcinogens such as PAH, HCA, and N-nitrosamines are produced from
tobacco smoking245,246 and have been detected in breast fluids247,248. These carcinogens
could potentially bind to DNA to form DNA-adducts, and cause mutations in DNA
thereby increasing risk of cancer.249 Modest increase in risk of BrCa have been observed
among current246,250–260 and former246,250–256,261 smokers. The risks also seemed to be
different depending on menopausal status at time of smoking. The NHS found smoking
before first birth among premenopausal women was associated with a higher risk of BrCa
but the association was not observed among postmenopausal women.246 Dose response
associations between smoking and BrCa have also been observed.262 Smoking at a higher
intensity and lifetime is linked to an increased risk263 and higher mortality from BrCa.
However, studies have been mixed, and increases in the risk of osteoporosis264,265 and
menopause at an early age266 have been observed among smokers which supports a
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proposed anti-estrogenic effect of smoking267 potentially indicating that smoking may be
associated with lower BrCa risk. The effects of smoking in BrCa patients has not been
extensively studied.268 In cancer patients receiving treatment, smoking was associated
with a higher severity of symptoms related to cancer chemotherapy/radiation
treatment.269 Some studies show that smoking increases the risk of BrCa specific deaths
among BrCa survivors.262 A study found a 41% increase in risk of BrCa recurrence and
60% increased risk of mortality from BrCa among current BrCa survivor smokers
compared to non-smokers.270
2.4.4 Other Factors
Family history of breast cancer
Approximately 10% of women diagnosed with BrCa are estimated to have a
family history of BrCa.173 Numerous studies have examined the contribution of a family
history to developing BrCa. Women with a family history of BrCa especially women
with a first-degree relative diagnosed with BrCa have an almost doubled risk compared to
women with no family history of BrCa.3,173,176 The risk also increases with the number of
relatives as having more than one first-degree relative who developed BrCa increases the
risk by 3-4 times.3,173,176 The risk is further increased if a first-degree relative is
diagnosed with BrCa at a younger age.173 A study attempted to measure family history of
BrCa as a risk factor for BrCa using a family history score in a prospective cohort.271 The
study found that women with the highest family history score were more likely to
develop BrCa.

33

Genetic factors
The most commonly known inherited susceptibility genes for BrCa are the
BRCA1 and BRCA2 genes. Mutations in the genes are inheritable and have been
observed in 5% to 10% of BrCa cases.3 The gene mutations appear to be less prevalent in
the US population272 but have a higher prevalence among women of Ashkenazi Jewish
ancestry.272 Women with BRCA1 or 2 mutations have significantly higher risk of
developing BrCa by age 70 years compared to the general US population273–275 and these
mutations account for about 40-80% lifetime risk of developing BrCa.276277
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2.5 TABLES AND FIGURES

Figure 2.1 Advanced glycation end product (AGE) formation and disease outcome
AGE: advanced glycation end-product; RAGE: receptor for AGE; IL: interleukin; Tnf:
tumor necrosis factor
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CHAPTER 3
METHODS
3.1 RESEARCH AIMS
The overall goal of the proposed study is to assign and quantify dietary AGE
content in foods consumed by women and examine the effect of dietary AGE intake on
BrCa risk and survival. We hypothesis that higher dietary AGE intake will be positively
associated with BrCa risk and poorer survival from BrCa. Two large prospective cohort
studies, the PLCO and WHI datasets, were used to investigate the proposed study goals.
In Specific Aim 1, dietary AGE values were assigned and quantified to foods
consumed by women in the PLCO and the association between dietary AGE intake and
BrCa risk was investigated. The PLCO analytical sample included women randomized
into the intervention arm without a prior diagnosis of cancer (except non-melanoma skin
cancer) and who completed a baseline questionnaire (BQ) and dietary questionnaire
(DQX) at baseline. PLCO did not collect dietary intake data after diagnosis, thus, the
WHI was utilized to examine Specific Aim 3 related to BrCa survival. The WHI
analytical sample included women diagnosed with BrCa and followed up till death or lost
to follow-up or end of study. In the PLCO, DQX responses was linked to the dietary
AGE food composition database to estimate total dietary AGE intake. In the WHI,
dietary AGE values were calculated by WHI investigators at the Fred Hutchinson Cancer
Research Center. The data included participants who had a completed and valid FFQ
collected after diagnosis.
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3.2 STUDY POPULATION
PLCO (Specific Aims 1 and 2)
The PLCO was a randomized controlled trial designed to assess the efficacy of
screening modalities and was conducted across 10 screening centers in the US.
Enrollment occurred between 1993 and 2001 and more than 78,000 women aged 55 to 74
years were recruited. Women were equally randomized and stratified by age to an
intervention and control group. Participants in the intervention group received chest Xray, flexible sigmoidoscopy, cancer antigen (CA) 125, and transvaginal ultrasound
(TVU) screenings at regular intervals while women in control arm received their usual
medical care. TVU and X-rays were performed at baseline and annually for the next 3
years. Sigmoidoscopy was performed at baseline and in the 5th year of the trial.
Participants were excluded if they were undergoing treatment for cancers excluding basal
or squamous cell melanoma, enrolled in other clinical trials or not able provide informed
consent. Participants were followed up for a median of 13 years. The average age of all
the women in the trial was estimated at 63 years. The sample was somewhat racially
diverse consisting of NHW (86%), NHB (6%), Hispanic (2%), Asian (3%) and other
races (1%). An estimated 14% of the female participants had an immediate family
member diagnosed with BrCa. About 67% reported they were married, 14% widowed,
13% divorced, 1% separated, and 3% never married.
The study protocol was approved by the Institutional Review Board (IRB) of the
National Cancer Institute (NCI) and screening centers, and informed consent was
obtained from all study participants.

37

WHI (Specific Aim 3)
The WHI was a clinical trial and observational study (OS) developed to address
the causes of morbidity and mortality in postmenopausal women.278 Female participants
were enrolled from 1993 to 1998 into the one of the three randomized controlled clinical
trials (n=68,132) or OS (n=93,676). The PMH trial was designed to examine the role of
hormonal use in CVD and BrCa. The dietary modification (DM) trial examined the
effects of low-fat, high fruit and vegetable diet in CVD and BrCa. The calcium and
vitamin D supplement (CaD) trial examined the role of calcium and vitamin D intake in
osteoporosis and colorectal cancer. Participants not eligible or unwilling to participate in
the clinical trials were enrolled in the OS which examined lifestyle factors on disease
outcomes.279 Enrolled participants were postmenopausal women, aged 50 to 79 years, and
were recruited from 40 centers in the US. Participants completed questionnaires at
baseline on demographic, medical, family and reproductive history. Participants were
excluded if they had a medical history with an expected survival less than 3 years, were
enrolled in other randomized clinical trials, or had a previous history of BrCa. The
sample population comprised EAs (81%), AAs (9%), Asians (3%), Hispanics (4%) and
American Indians (0.5%).279 Participants who gave informed consent were enrolled in the
WHI extension study I & II and were followed-up between 2005-2010 and 2010-2015,
respectively. Questionnaires were mailed annually to obtain information on annual
surveys on health outcomes.
The study was approved by institutional review boards at the clinical centers and
participants provided written informed consent.
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3.3 OUTCOME ASSESSMENT
In the PLCO, the outcome of interest is the incidence of invasive or in situ BrCa.
Information on BrCa incidence was obtained through self-reports using the mailed annual
study updates and confirmed through the national death index (NDI), state cancer
registries or reports from physicians and next of kin.280 A BrCa supplemental (BCS) form
was administered from 2007, to capture more information on confirmed BrCa diagnosis.
Information on tumor grade, stage, and subtype were obtained for all confirmed BrCa
diagnoses and through the administration of BCS forms for BrCa diagnosed after 2007. A
total of 76,121 participants returned completed the BQ out of which 4,304 participants
had a confirmed diagnosis of BrCa.
In the WHI, participants enrolled in the OS were mailed annual questionnaires to
request update on medical history. The outcome of interest in the WHI is survival from
BrCa. Outcomes were self-reported using the medical history update form which was
administered twice yearly to participants in the clinical trials, and annually to participants
in the OS. Participants were further contacted to provide more information on the medical
diagnosis. Cause of death was ascertained through death certificates, medical records, and
autopsy reports.281 Data was linked to National Death Index of the National Center for
Health Statistics to ascertain survival, unreported deaths and cause of death outcomes.281
3.4 EXPOSURE ASSESSMENT
In the PLCO, women who were eligible to participate in the trial were requested
to complete the BQ at the start of the trial. The BQ solicited information on demographic
and medical history. There were 78,215 women recruited in the PLCO and about 97% of
participants returned the BQ. The DQX was administered at baseline to participants in the
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intervention group and solicited information on usual diet in the previous year. A separate
diet history questionnaire (DHQ) was introduced 5 years into the trial and was
administered to women in both the intervention and control study arms. Study updates
were mailed yearly to obtain information on cancer diagnosis in the previous year. Our
study will utilize data from only women enrolled in the intervention arm (n =39,104)
because they were administered the same DQX at baseline and screened regularly for a
cancer outcome. Utilizing this group of women is recommended by the PLCO to promote
uniformity of the dietary information obtained. The DQX is a FFQ designed for the
PLCO which obtained information on regular dietary intake in the last 12 months based
on intake frequency on 137 food items and estimated portion sizes.282 The DQX also
obtained information on meat preparation practices and vitamin/supplement intake.
Nutrient intake was calculated using the US Department of Agriculture’s (USDA)
pyramid food group and national dietary database.283 DQXs were deemed invalid if
participants reported extreme energy intakes, were missing ≥ 8 FFQ responses, or did not
complete the DQX. Approximately 75% of the 39,104 women randomized into the
intervention arm had a completed and valid DQX.
In the WHI, demographic information was obtained at baseline at the clinic
centers through interviewer-administered or self- administered questionnaires. A FFQ
was created from instruments used previously in dietary intervention studies.284 It was
administered at baseline and used to obtain dietary information in the past 3 months. The
FFQ comprised three sections which included 19 adjustment questions on nutritional
content in food, preparation methods and added fats, 122 food or food groups soliciting
information on usual dietary intake frequency and portion size and four summary
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questions on usual intake of fruits and vegetables.284 The University of Minnesota
Nutrition Coordinating Center’s nutrition database was used to derive the nutrients from
the FFQ responses.284 Participants with incomplete FFQ were contacted by trained
dietary staff to obtain missing dietary information. FFQs were administered to
participants in the WHI-DM clinical trial at baseline and after one year. A random sample
was selected from the participants and FFQs were administered annually. Participants in
the WHI-OS were administered FFQs at baseline and 3 years later. In our analyses, we
will include participants who were cancer free at baseline, had a first primary diagnosis
of invasive BrCa during follow-up, completed a FFQ after BrCa diagnosis, and had
energy intakes between ≥600 kcal/day and ≤5000 kcal/day. Participants in the WHIHormone Replacement Therapy (HRT) and WHI-CaD clinical trials were excluded from
our analysis because they did not complete FFQs at follow-up. In the post-diagnosis
dietary assessment, we will utilize the first FFQ participants complete after BrCa
diagnosis.16
3.4.1 Assessment of Dietary AGE Intake
In the PLCO, we utilized a published database to estimate and assign dietary AGE
values to each food item on the DQX. The database is the largest and most commonly
used AGE database100 and contains CML content of 549 foods and MG contents of
selected foods commonly consumed in the northeastern metropolitan region of the US.34
CML contents in foods were tested for AGE equivalent using ELISA method34,100 and
AGE contents were measured in AGE KU/100g of food. CML-AGE content has been
used in previous studies and are the more commonly measured and stable of all the
AGEs74. Dietary AGE contents based on CML measurements were appropriately
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assigned to match the food items in the DQX as has been done in a previous study related
to pancreatic cancer32. We categorized total CML-AGE values into quintiles and tertiles
with the lowest quintile/tertile representing the lowest CML-AGE intake level which
served as the referent group in the analyses.
In the WHI, CML-AGE values were calculated by WHI investigators at the Fred
Hutchinson Cancer Research Center using the same AGE database and method. The data
were made available to the project through established collaborations with coinvestigators, and an approved WHI manuscript proposal.
3.4.2 Covariates
Potential confounders were identified through extensive literature review on BrCa
risk factors and information was obtained from study participants through questionnaires
as described below for the two different study cohorts.
In the PLCO, information obtained include age (years), BMI (kg/m2),
race/ethnicity (NHB, NHW, or other races/ethnicities), marital status (married/living as
married, widowed, divorced/separated or never married), education (less than high
school, high school and some college, college graduate, or postgraduate degree), duration
of OC use, PMH use, age at birth of first child, age at menarche, postmenopausal status,
number of pregnancies, study center, smoking status (never, former, or current), first
degree family history of BrCa (no, yes, or possibly), alcohol intake (g/day), total energy
intake (kcal/day), and physical activity.
The information on covariates obtained from the WHI were similar to the PLCO.
Other potential confounders identified in the WHI included age at BrCa diagnosis, family
income, and history of breast feeding. Because we examined BrCa survival for Specific
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Aim 3, we considered variables related to prognosis including stage and hormone
receptor status of diagnosed BrCa, which were used as proxy for treatment information as
type of treatment received may depend on BrCa hormone receptor.285,286
3.5 STATISTICAL METHOD
3.5.1 Power Calculation
The NCI’s Power software was used to calculate the sample and effect size for the
study which aimed to analyze the association between dietary AGE intake and BrCa
incidence in the PLCO and survival from BrCa in the WHI.287 The type 1 error was set at
α=0.05.
In the PLCO dataset, using a Cox proportional hazards model we estimated a
hazard ratio (HR) of 1.25 for BrCa risk when the third tertile, which represents the
highest level of dietary AGE intake, is compared to the first tertile. We needed an
analytical sample of 20,642 women and 992 BrCa cases to achieve at least 80% power.
Our analytical sample contained an estimated 28,438 women and 1,568 incident BrCa
cases288 (Figure 3.1). Therefore, the PLCO dataset was adequate to meet our sample size
requirement. Power estimations for a range of effect sizes and probabilities of BrCa risk
are provided in Table 3.1.
In the WHI, the Cox proportional hazards model was used to estimate the HR. To
detect a HR of 1.9 for BrCa death when the third tertile of dietary AGE intake is
compared to the first tertile, we needed an analytical sample of approximately 2,053
women and 124 deaths to achieve at least 80% power. Our analytical sample included
approximately 2,242 women (Figure 3.1). There were approximately 212 cases of BrCa
deaths and 580 cases of deaths from all causes.289 We anticipated that the WHI dataset

43

was adequate to meet our sample size requirement. Power estimations for a range of
effect sizes and probabilities of all-cause and BrCa-specific mortality are provided in
Table 3.1.
3.5.2 Statistical Analytical Methods
Statistical method for Specific Aim 1: CML-AGE content was assigned to food and
statistical analyses estimated the association between CML-AGE intake and risk of BrCa.
The analytical sample included women enrolled in the intervention arm of the PLCO.
Women were excluded if they had a prior history of cancer (except non-melanoma skin
cancer), incomplete BQ and DQX at baseline and missing covariate information on BQ.
CML-AGE intake was the main exposure of interest and was categorized into quintiles
and tertiles with the lowest quintile/tertile representing the lowest CML-AGE intake and
referent. Descriptive statistics were used to compute the means and standard deviation
(SD) for continuous variables and frequencies for baseline categorical variables by the
quintiles and tertiles of CML-AGE intake. Differences in baseline characteristics were
assessed across the quintiles and tertiles of CML-AGE intake. To estimate the
associations between CML-AGE intake and BrCa, a Cox proportional hazards model was
used to estimate HRs and 95% confidence intervals (CIs) and person-time was estimated
from the date of completion of the BQ and DQX until a diagnosis of BrCa or end of
follow-up. Both the continuous CML-AGE variable and the quintile and tertile CMLAGE variables were examined in separate models. A directed acyclic graph (DAG) was
used to identify a minimally sufficient set of confounders for adjustment in the
multivariable analysis (Figure 3.2). Non-violation of the proportional hazards assumption
was assessed using Schoenfeld residual test.290
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Statistical method for Specific Aim 2: Statistical analyses was aimed at assessing
associations between CML-AGE and BrCa in the PLCO stratified by race/ethnicity, fruit
and vegetable intake, obesity status, invasiveness, and hormone receptor status. For the
race-stratified analysis, the analytical sample included women of AA, EA and other
races/ethnicities. The BrCa hormone receptor status stratified analysis utilized a sample
consisting of all women with information on ER-status and PR-status. The means and SD
for continuous variables were computed using descriptive statistics. We utilized a Cox
proportional hazards model to estimate the association between CML-AGE intake and
the risk of BrCa and the analyses was carried out similar to Specific Aim 1.
Statistical method for Specific Aim 3: The analytical sample included women in the
WHI dataset and the association between post-diagnosis CML-AGE intake and BrCa
survival was investigated. Means and SD were calculated from baseline continuous
variables and frequencies were estimated for categorical variables by the tertiles of CMLAGE intake. The association between CML-AGE intake after BrCa diagnosis and
mortality risk from all-causes, BrCa and CVD was estimated using a Cox proportional
hazards model to calculate HRs and 95% CIs. Person-time was estimated from the date of
diagnosis of primary invasive BrCa until death, loss to follow-up or the end of follow-up
or whichever occurred first. Similar to Specific Aim 1, a DAG was used to identify a
minimally sufficient set of confounders for adjustment in the multivariable analysis
(Figure 3.3). Non-violation of the proportional hazard assumption was assessed using
Schoenfeld residual test.290 Statistical significance was set at α= 0.05 and all analyses was
conducted using SAS version 9.4.
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3.5.3 Alternate Analyses Plan Using Marginal Structural Models (MSM)
We planned to utilize a MSM to control for selection bias induced from loss to
follow up and confounding bias from time-varying confounders.291,292 Using a weighted
Cox proportional hazard model, the HRs and 95% CIs will be estimated comparing the
different categories of dietary AGE intake. Inverse probability (IP) weights are created by
calculating the inverse probability of the exposure given the confounders and can
effectively adjust for confounding and selection bias. A stabilized IP weighted model will
be included in the MSM to adjust for risk factors that may have confounded the
association between dietary AGE intake and BrCa. The stabilized weights will produce
estimates with narrower CIs.
SWA = f (A) / f (A|L)
The MSM entails using a logistic regression to create a pseudo-population where
a causal interpretation of the effect of dietary AGE on BrCa risk can be made.
3.6 STRENGTHS AND LIMITATIONS
The PLCO and the WHI are two large prospective cohort studies with relatively
long follow-up. The use of these large prospective cohorts provides major strengths as
they contain an adequate sample size to examine the associations between dietary AGE
intake and BrCa risk and survival. We utilized a published AGE database to assign CMLAGE intakes in the PLCO and WHI datasets. Utilization of the AGE database will
enhance reproducibility of the study and similar assignment methods can be employed to
other epidemiological datasets to obtain dietary AGE estimates. In our study, the true
dietary AGE content present in food may be underestimated or overestimated, though
studies evaluating plasma levels of AGE show significant positive linear correlations
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with estimated dietary AGE intake.75,104,105 We did not anticipate the occurrence of recall
bias since dietary information was obtained prior to the occurrence of BrCa using the
PLCO dataset or prior to death using the WHI dataset. To minimize discrepancies in the
quality and measurement of dietary information obtained, only participants with a
completed DQX at baseline were included in the PLCO analysis and participants with a
completed post-diagnosis FFQ in the WHI analysis.
We anticipated some limitations in our study. The prospective study design may
induce selection bias from loss to follow-up of study participants. The PLCO enrolled
participants from 1993-2001 and in our analytic sample, women were followed up for a
median of 11.5 years. In the WHI, participants were enrolled starting from 1993. The
WHI extension study followed up consenting participants till 2015 for a median followup time of 15.1 years in our analytic sample.289 We proposed to utilize a MSM as
described in the previous section to adjust for selection bias. Results will give statistically
unbiased estimates and a causal interpretation of the study results. As with any
observational study, there is the potential for unmeasured or residual confounding. In
addition, the sample sizes may be limited for race-stratified or BrCa subtype analyses.
The study populations are predominantly NHW women who experience the highest
incidence of BrCa so results will still be of public health relevance. There may also have
been measurement error from the dietary exposure obtained through the administered
FFQ, which was likely to be non-differential. Our results were carefully interpreted with
these limitations in mind. We anticipate the results of the study will provide more
information on dietary AGE as a dietary risk factor for BrCa. This may lead to new
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targets for future dietary interventions aimed at cancer prevention and improving cancer
survival.
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3.7 TABLES AND FIGURES

Figure 3.1 Flow chart of selected participants
WHI: Women’s Health Initiative; PMH: postmenopausal hormones; DM: dietary
modification; CaD: calcium and vitamin D supplement; OS: observational study
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Table 3.1 Power to detect association between dietary advanced glycation endproduct (AGE) intake and breast cancer risk and survival
Baseline Probability of Breast Cancer (PLCO) or Breast
Cancer Death (WHI)
Study
Effect size
0.03
0.04
0.05
0.06
0.07
PLCO
1.2
0.61
0.73
0.81
0.87
0.91
1.3
0.90
0.97
0.98
0.99
0.99
1.4
0.99
0.99
>0.99
>0.99
>0.99
1.5
>0.99
>0.99
>0.99
>0.99
>0.99
WHI
1.7
0.50
0.62
0.71
0.78
0.83
1.8
0.60
0.72
0.81
0.86
0.91
1.9
0.69
0.80
0.88
0.92
0.95
2.0
0.77
0.87
0.93
0.96
0.97
PLCO: Prostate, Lung, Colorectal and Ovarian AGE: advanced glycation endproduct; BrCa: breast cancer; BMI: body mass index; PMH: postmenopausal
hormones
α=0.05; PLCO n=28,438; WHI n=2,242
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Figure 3.2 Directed Acyclic Graph (DAG) showing covariate selection in the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial (PLCO)
AGE: advanced glycation end-products; BMI: body mass index; BrCa: breast cancer
Minimally sufficient adjustment set: age, energy intake, alcohol, race/ethnicity, marital status, education,
study center, smoking status
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Figure 3.2 Directed Acyclic Graph (DAG) showing covariate selection in the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial (PLCO)

AGE: advanced glycation end-products; BMI: body mass index; BrCa: breast cancer; PMH:
postmenopausal hormones; BrCa: breast cancer; FFQ: food frequency questionnaire; ER: estrogen
receptor; PR: progesterone receptor; WHI: Women’s Health Initiative
Minimally sufficient adjustment set: age at BrCa diagnosis, dietary intake of total fat, energy intake,
income, race/ethnicity, red and processed meat intake, WHI components and time from breast cancer
diagnosis to FFQ
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4.1 ABSTRACT
Introduction: Advanced glycation end-products (AGEs) are implicated in the
pathogenesis of chronic diseases including cancer. AGEs are produced endogenously but
can also be consumed from foods. High amounts of AGEs are found in animal products
and processed foods, and AGE formation is accelerated during cooking at high
temperatures. The objective of the study was to assign and quantify NƐ-carboxymethyllysine (CML)-AGE content in food and assess the association between dietary AGE
intake and breast cancer (BrCa) risk in the Prostate, Lung, Colorectal and Ovarian Cancer
Screening Trial (PLCO). Methods: The PLCO enrolled women aged 55 to 74 years into
a randomized controlled trial examining various cancer screening modalities. In this
prospective analysis, the study sample included only women enrolled in the intervention
arm who were cancer-free at baseline and completed a baseline questionnaire and food
frequency questionnaire (DQX). CML-AGE values were assigned and quantified to foods
in the DQX using a published AGE database. Descriptive analysis was used to obtain
means and percentages and Pearson correlation was used to obtain correlation coefficient
of CML-AGE intake with dietary factors linked to AGEs. Cox proportional hazards
model estimated the hazard ratios (HR) and 95% CIs of BrCa by quintiles of CML-AGE
intake with adjustment for multiple potential confounders. Results: After a median 11.5
years of follow-up, 1,592 women were diagnosed with BrCa. The average CML-AGE
consumption among all the women was 6,105 ± 2691 kilounits (KU)/1000 kcal and
ranged between 867 KU/1000 kcal per day to 43,387 KU/1000 kcal per day. Significant
positive correlations were observed between CML-AGE intake and dietary sources of
animal protein (r=0.46), monounsaturated fatty acids (MUFA) (r=0.39), polyunsaturated
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fatty acid (PUFA) (r=0.25) and saturated fatty acids (SF) (r=0.41) while the correlations
between dietary AGE and fructose (r=10.25), carbohydrates (r=-0.19) and plant protein
(r=-0.12) were weaker. There was an increased risk of BrCa across quintiles of dietary
AGE intake (HRQ3 VS Q1:1.19, 95% CI: 1.002-1.42, HRQ4 VS Q1:1.24, 95% CI: 1.02-1.50,
and HRQ5 VS Q1:1.30, 95% CI: 1.04-1.62; P-trend: 0.04). Conclusion: The strong positive
correlation observed between CML-AGE and fat and protein intake reflect the high AGE
levels found in animal products especially those cooked at high temperature. High intake
of dietary CML-AGE may contribute to an increased risk of BrCa
4.2 INTRODUCTION
Breast cancer (BrCa) is the most diagnosed malignancy and second leading cause
of cancer death among women in the U.S.2 The chronic triggering of an inflammatory
response is a biologic process that is recognized to promote carcinogenesis41–43 and the
presence of circulating inflammatory biomarkers promote tumor development and
progression.11
Advanced glycation end-products (AGEs) are complex compounds formed by the
irreversible glycation of proteins or lipids with reducing sugars.34,70,71 The adverse
biological effects of AGEs are propagated through direct effects on tissues or activation
of the receptor for AGE (RAGE) to induce oxidative stress and chronic inflammation.78–
81,293

AGEs occur naturally in the body and are also contained in food products.34,71

Preparation methods involving high temperature, such as frying or grilling, for prolonged
periods of time accelerate the formation of AGEs and ingestion of such foods contributes
to the already existing AGEs in the body.34,71 There is a growing body of evidence to
suggest a role of AGEs in cancer development and progression.32,294 High levels of AGEs
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have been detected in serum of women with BrCa compared to healthy women33,98 and
RAGE has been shown to be markedly expressed in breast tumors.88
While there is some evidence in preclinical experimental models, there is a
paucity of data on dietary AGE intake in relation to BrCa risk among human populations.
Our study (1) estimated dietary AGE intake by linking responses on dietary information
provided by participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial (PLCO) to a published database containing AGE contents of food products,34 and
(2) examined the association between dietary AGE intake and BrCa risk. We hypothesize
that increasing levels of dietary AGE intake will be positively associated with BrCa risk.
4.3 METHODS
4.3.1 Study Population
We utilized data from the PLCO, a randomized controlled trial designed to assess
the efficacy of cancer screening modalities in the U.S. Enrollment occurred from
November 1993 to September 2001 across 10 screening centers. The study enrolled over
78,000 women aged between 55 and 74 years and randomized them to an intervention or
control arm (Figure 4.1). Participants in the intervention arm received chest X-ray,
flexible sigmoidoscopy, cancer antigen (CA) 125, and transvaginal ultrasound screenings
at regular intervals while women in the control arm received their usual medical care.
Exclusions were made from the trial if participants were undergoing treatment for cancer
excluding basal or squamous cell melanoma, enrolled in other clinical trials or unable to
provide informed consent.295 The study protocol was approved by the Institutional
Review Board (IRB) of the National Cancer Institute (NCI) and screening centers, and
informed consent was obtained from all study participants.
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4.3.2 Data Collection
Participants enrolled in the intervention arm were requested to complete baseline
questionnaires (BQ) and dietary questionnaires (DQX) administered at baseline. The BQ
obtained information on demographics, height and weight, from which body mass index
(BMI) was calculated, smoking, and medical history. DQX captured usual dietary intake
in the previous year including information on meat preparation practices and
vitamin/supplement intake. The DQX is a food frequency questionnaire (FFQ) developed
for the PLCO which solicits information on intake frequency on 137 food items and
estimated portion sizes of 77 food items.282 A separate diet history questionnaire (DHQ)
was introduced 5 years into the trial and administered to participants in both the
intervention and control arms. The DHQ solicited dietary information in the previous
year on intake frequency of 114 food items and estimated portion sizes of 109 food items.
Our study utilized only data from the intervention arm in order to ensure consistency in
dietary assessment as well as control for potential confounding effects of the intervention.
Utilizing this group of women is recommended by the PLCO to promote uniformity of
the dietary information obtained. Nutrient intake was calculated based on DQX responses
using the U.S. Department of Agriculture’s (USDA) pyramid food group and national
dietary database.283 We excluded women with a personal history of cancer except nonmelanoma skin cancer, incomplete BQ and invalid DQX (extreme energy intake, missing
≥ 8 FFQ responses and incomplete DQX) at baseline (Figure 4.1). Further exclusions
were made for participants with missing covariates on: BMI (n=253), age at menopause
(n=200), use of oral contraceptives (OC) (n=13), age at menarche (n=19), family history
of BrCa (n=171), use of postmenopausal hormones (PMH) (n=14), oophorectomy (n=3),
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hysterectomy (n=4), number of pregnancies (n=39), number of live births (n=2),
education (n=13), marital status (n=7), age at first birth (n= 67), and hours spent in
vigorous activity (n=111). The final analytical sample contained 27,464 participants from
which 1,592 BrCa cases were diagnosed during the follow-up period.
4.3.3 Assessment of Dietary AGE Intake
A published database was used to assign dietary AGE values to each food item on
the DQX. The database contained NƐ-carboxymethyl-lysine (CML) content of 549 foods
and methyl-glyoxal (MG) contents of selected foods commonly consumed in the
northeastern metropolitan region of the U.S. was used to assign CML-AGE values to
each food item on the DQX.34
In the database, AGE content was estimated using enzyme-linked immunosorbent
assay (ELISA) based on monoclonal anti-CML antibody for CML-AGE content and
monoclonal anti-MG antibody for MG-AGE content.34 CML-AGE is the more stable and
commonly measured of all the AGEs and has been used in previous studies to estimate
dietary AGE intake.74 CML-AGE values were appropriately assigned to match the food
items in the DQX (Figure 4.2) as has been done in a previous study.32 Where CML-AGE
values for foods were not available in the database, values of similar foods or the average
CML-AGE of foods within the food group were used. For example, a DQX response of
canned tomatoes was assigned CML-AGE values of tomato sauce while a DQX response
of fresh plums was assigned the average CML-AGE value of all fruits in the database.
For foods with multiple preparation methods, CML-AGE values in the database were
averaged. For example, CML-AGE of “beef steak, pan fried w/olive oil”; “beef steak,
strips, stir fried with 1 T canola oil, 15 min” and “beef steak, strips, stir fried without oil,
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7 min” were averaged to create a value for pan-fried steak. Where CML-AGE values of
mixed foods were not available, values of individual food components were summed up
to create a CML-AGE value for the mixed food. Total CML-AGE values were adjusted
for energy intake using the energy density method and then categorized into quintiles,
with the lowest quintile representing the lowest intake level and serving as the referent
group in regression analyses.
4.3.4 Covariate Assessment
Potential confounders were identified through extensive literature review on BrCa
risk factors. Confounders identified include age (years), BMI (kg/m2) [<18.5, 18.5-<25,
25-<30, or ≥30], hours spent in vigorous activity such as swimming or brisk walking
(none,<1 hour/week, 1 hour/week, 2 hours/week, 3 hours/week, or 4+ hours/week),
race/ethnicity (non-Hispanic white [NHW], non-Hispanic black [NHB], or other
races/ethnicities), marital status (married/living as married, widowed, divorced/separated,
or never married), education (less than high school, high school and some college,
college graduate, or postgraduate degree), study center, smoking status (never, former, or
current), first degree family history of BrCa (no, yes, or possibly), age at menarche (<10,
10-11, 12-13, 14-15, or 16+), age at menopause (<40, 40-44, 45-49, 50-54, or 55+),
number of live births (0, 1,2,3,4, or 5 or more), age at first birth (nulliparous, ≤19, 20-24,
25-29, 30-34, or >35), PMH use (never, former, or current), OC use (no or yes),
oophorectomy (no/don’t know, one ovary, or both ovaries), hysterectomy (no/don’t know
or yes), alcohol intake (g/day), total energy intake (kcal/day), total fat from diet (g/day)
and red meat (g/day). To allow a causal interpretation of the results, a directed acyclic
graph (DAG) was used to identify a minimally sufficient set of confounders for
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adjustment (Figure 3.2) 296 and included age, energy intake, alcohol, education, marital
status, race/ethnicity, smoking status, and study center. Education was used as a measure
of socioeconomic status and as a proxy for income because information on income was
not available in the PLCO.297,298
4.3.5 Outcome Assessment
BrCa incidence was assessed by self-report using mailed annual study updates for
in situ and invasive BrCa confirmed by state cancer registries or reports from physicians
and next of kin, and the national death index (NDI) for fatal cases.280 Breast cancer
supplemental (BCS) forms were administered starting from 2007 to obtain detailed
clinical characteristics of BrCa tumors such as tumor grade, stage, and subtype.
4.3.6 Statistical Analyses
Descriptive analyses estimated means and standard deviations (SD) for
continuous variables and percentages for categorical variables. Categories were created
for similar food products: fruits, vegetables, grains, dairy, red meat, white meat,
processed meat, mixed foods, fish, fat & oil, nuts, or others and the contribution of food
products to total CML-AGE intake was estimated as percentages. Pearson’s correlation
coefficient was used to estimate the correlation between CML-AGE intake and nutrients
suggested to contribute to dietary AGE formation. Cox proportional hazards regression
estimated hazard ratios (HR) and 95% confidence interval (CI) of BrCa by quintiles of
CML-AGE intake, and person-time was calculated from the date of completion of
baseline questionnaires to the end of follow-up or BrCa diagnosis. Given that physical
activity was not measured optimally in the PLCO, we calculated the E-value in a
sensitivity analysis to evaluate the robustness of our results to potential residual
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confounding from physical activity.299,300 Simple models were adjusted for age and
energy intake. A second multivariable Cox model adjusted for DAG identified
confounders and included age, energy intake, alcohol, race/ethnicity, marital status,
education, study center and smoking status. A third multivariable Cox model adjusted for
age, energy intake, alcohol, BMI, hours spent in vigorous activity, race/ethnicity, marital
status, education, study center, smoking status, family history of BrCa, age at menarche,
age at menopause, age at first birth, number of live birth, PMH use, OC use,
oophorectomy and hysterectomy. The fourth multivariable model adjusted for all
aforementioned covariates in addition to intakes of total fat and red meat.
Linear trends were assessed for BrCa risk across quintiles of CML-AGE intake by
using the continuous median CML-AGE intake value in each quintile. Schoenfeld
residual test was used to evaluate violation of proportional hazards assumption290 and no
major violations were observed. We examined nonlinear and linear relationships between
CML-AGE intake and BrCa risk using restricted cubic splines.301 Nonlinearity was tested
using the likelihood ratio test comparing the model with only the linear term to the model
with the linear and cubic spline terms. All statistical analyses were conducted using SAS
version 9.4 and statistical significance was set at α=0.05.
4.4 RESULTS
During a median follow-up time of 11.5 years, we identified 1,592 incident cases
of BrCa diagnosed in 27,464 women at risk (Figure 4.1). The average daily CML-AGE
consumption was 6,105 ± 2691 kilounits (KU)/1000 kcal and ranged between 867
KU/1000 kcal and 43,387 KU/1000 kcal (Table 4.1). A large proportion of women
enrolled in the study were NHW and had no family history of BrCa. Women in the
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highest quintile of CML-AGE intake were younger, had higher daily energy intake, and
lower daily alcohol intake compared to the lowest quintile (Table 4.1). A higher
proportion of women in the highest quintile of CML-AGE intake were obese, divorced or
separated, current cigarette smokers, had five or more live births, were OC users, had
undergone a hysterectomy and oophorectomy of both ovaries, were aged 14-15 years at
menarche, and were aged <44 years or 55+ years at menopause. Women in the highest
quintile of CML-AGE intake were least likely to engage in vigorous activity 4+ hours a
week, have a graduate education or higher, be current PMH users, and be aged 35 years
or more at first birth. Fat and oil, and red meat were the food groups that contributed the
most to total CML-AGE intake while nuts, grains, and fruits contributed the least (Figure
4.3). As shown in Table 4.2, positive correlations were observed between energy adjusted
CML-AGE intake and dietary sources of animal protein (r=0.46), saturated fatty acids
(SF) (r=0.41), monounsaturated fatty acids (MUFA) (r=0.39), and polyunsaturated fatty
acid (PUFA) (r=0.25) while negative correlations were observed between energy adjusted
CML-AGE and fructose (r=-0.25), carbohydrates (r=-0.19), calcium (r=-0.14), plant
protein (r=-0.12), and protein from dairy (r=-0.07) .
The results of the multivariable Cox proportional hazard regression are presented
in Table 4.3. After adjusting for DAG-identified confounders, increased BrCa risk was
found in the upper quintiles of CML-AGE intake (HRQ3VSQ1: 1.20, 95% CI: 1.02-1.40;
HRQ4VSQ1: 1.22, 95%CI: 1.04-1.43 and HRQ5VSQ1: 1.28, 95%CI: 1.09-1.41; P-trend:
0.004). In multivariable model 3 adjusting for additional potential confounders, positive
associations were observed in the upper quintiles of CML-AGE intake (HRQ4VSQ1: 1.19,
95%CI: 1.01-1.40 and HRQ5VSQ1: 1.23, 95%CI: 1.04-1.46; P-trend: 0.022). The positive
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associations persisted after further adjustment for dietary fat and red meat intake
(HRQ3VSQ1: 1.19, 95%CI: 1.002-1.42; HRQ4VSQ1: 1.24, 95%CI: 1.02-1.50 and HRQ5VSQ1:
1.30, 95%CI: 1.04-1.62; P-trend: 0.04). After adjusting for covariates included in model
4, there was no evidence of a nonlinear association between continuous CML-AGE
intake and BrCa risk (P for nonlinearity: 0.290) (Figure 4.4). However, we found some
evidence of a linear relationship (P for linearity: 0.051) showing an increase in BrCa risk
with increasing CML-AGE intake (Figure 4.5).
Compared to women who died, were lost to follow up or completed the study,
women diagnosed with BrCa during the study period had higher daily CML-AGE intake,
energy intake, and alcohol intake (Table 4.4). A higher proportion of women diagnosed
with breast cancer were overweight, married or living as married, more educated, had a
family history of BrCa, aged 50 years or older at menopause, aged 25 years or more at
first birth and were current PMH users. Women diagnosed with breast cancer were least
likely to be current smokers, aged <10 years at menarche, have five or more live births,
have undergone a hysterectomy and oophorectomy of both ovaries.
The estimated E-value was 1.67 (lower limit of CI: 1.11) and represents the
minimum strength of association between physical activity and CML-AGE and between
physical activity and BrCa, required to explain away the association observed between
CML-AGE and BrCa risk.299,300 The magnitude of association of measured vigorous
activity with both CML-AGE (HR 1.08) and BrCa (HR 1.04) was lower than the E-value.
Thus, we do not expect that our risk estimates will be explained away by residual
confounding from physical activity.
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4.5 DISCUSSION
In these secondary analyses of the large prospective PLCO study, increasing
levels of CML-AGE intake were positively associated with BrCa risk. We utilized a
published AGE database containing CML-AGE values of foods to derive estimates of
total CML-AGE intake. The estimated average daily CML-AGE intake reported in a
different study of healthy older women using the Uribarri et al. AGE database was quite
similar to the estimate in our study.32,302 Foods rich in fats and protein such as meat, have
been reported to contain high AGE content especially if cooked at high
temperatures.34,35,71 In our study, we found fats and oil such as margarine and cheese
sauce, and red meat were the highest contributors to total daily CML-AGE intake while
fruits contributed the least amount. Animal protein and dietary fatty acids were strongly
correlated with CML-AGE while plant protein, dairy protein, carbohydrates, and calcium
were negatively correlated.
Few large epidemiologic studies have been published on the association between
dietary AGEs and cancer risk. In analyses of the National Institutes of Health-American
Association of Retired Persons (NIH-AARP) Diet and Health Study, a positive
relationship between dietary AGE intake and pancreatic cancer risk in men was
observed.32 More recently, the NIH-AARP Diet and Health Study was used to examine
associations between CML-AGE intake and BrCa, in which an increased risk of invasive
BrCa was reported but the association was attenuated to the null after adjusting for
potential confounders including intakes of dietary fat and total meat.294 In contrast, we
observed an increased risk in overall BrCa which persisted even with adjustment for
multiple confounders including intake of total fat and red meat.
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AGEs when deposited in tissue cells induce damage to protein structure, or
activate RAGE to promote oxidative stress and chronic inflammation through secretion
of inflammatory biomarkers which could induce DNA damage.78–82 RAGE has been
markedly expressed in breast tumors88 and increased RAGE expression enhances the
proliferation and invasion of BrCa cells.29,30 High accumulation of CML in BrCa tissues99
and elevated serum CML levels have been observed in women with BrCa.33
Our study is strengthened by the use of a large prospective dataset with an
adequate sample size, long follow-up period (median 11.5 years) and information on
multiple confounders. Measurement error from the FFQ is a possibility, though the error
is likely to be non-differential since dietary information was obtained prior to the
occurrence of BrCa. We utilized only the DQX completed at baseline among the
intervention arm to enhance uniformity of the dietary assessment within the PLCO
dataset. The database developed by Uribarri et al. which assessed CML-AGE content of
over 500 foods and beverages using ELISA was used to estimate total CML-AGE
intake.34 A definitive approach to measuring AGEs has not yet been established as some
analytical methods produced variations in CML contents for certain foods.100 Thus, the
true AGE content present in food may be under- or over-estimated.74,100 In some previous
studies, estimated dietary AGE intake was correlated with serum AGE levels,75,104,105
though one study which averaged two measurements taken 13 weeks apart of serum
CML measured by ELISA reported no correlation between intake of foods considered
high in dietary AGE and serum CML-AGE.303 Thus far. the Uribarri et al. AGE database
is the most frequently utilized in epidemiologic studies to estimate dietary AGE intake
from FFQ responses,32,294 which will enhance comparability of our results with other

65

studies. As in any prospective cohort study, selection bias from loss to follow-up is a
potential limitation since participants were enrolled in the study for a long period of time.
Our findings suggest that dietary AGEs may contribute to the risk of developing
BrCa. Further studies are needed to establish the role of dietary AGEs in BrCa and
explore differential associations based on racial groups and BrCa subtypes.
4.6 CONCLUSION
We observed strong positive correlations between CML-AGE and fat and protein
intake which reflects the high CML-AGE levels found in meats, particularly those
cooked at high temperatures. Dietary AGE intake may increase BrCa risk and
incorporating cooking methods involving low temperatures and moisture such as boiling,
and marinating foods prior to cooking are strategies that could reduce AGE content in
food.34,71 Reducing AGE content in the diet may be an important dietary intervention in
BrCa prevention.
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4.7 TABLES AND FIGURES

Figure 4.1 Flow chart for participants in the Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial (PLCO)
BQ: baseline questionnaire; DQX: dietary questionnaire; BMI: body mass index; OC:
oral contraceptives; BrCa: breast cancer; PMH: postmenopausal hormones
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Figure 4.2 Flow chart detailing linkage of advanced glycation end-product (AGE)
database to the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
(PLCO) dietary questionnaire (DQX)
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Table 4.1. Baseline characteristics by quintiles of NƐ-carboxymethyl-lysine (CML)-advanced glycation end-products (AGE)
(KU/1000 kcal)
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CML-AGE, KU/1000 kcal
Alcohol intake, (g/day)
Total energy intake, (kcal/day)
Age, (years)
Breast cancer, n (%)
No
Yes
BMI (kg/m2), n (%)
< 18.5
18.5-< 25
25-< 30
>= 30
Vigorous activity, n (%)
None
<1 hour/week
1 hour/week
2 hours/week
3 hours/week
4+ hours/week
Race/ethnicity, n (%)
Non-Hispanic white
Non-Hispanic black
Other

Quintile 1
(n=5494)
< 4057
5.7 (15.3)
1694.5 (573.4)
63.6 (5.5)

Quintile 2
(n=5499)
4057-< 5137
5.7 (12.9)
1706.1 (570.8)
63 (5.4)

Quintile 3
(n=5491)
5137-<6209
5.6 (11.9)
1730.9 (578.3)
62.4 (5.3)

Quintile 4
(n=5491)
6209-7732
5.5 (11.5)
1766.0 (619)
62 (5.2)

Quintile 5
(n=5489)
>7732
5.4 (11.1)
1813.8 (652.9)
61.2 (5.0)

5209 (94.8)
285 (5.2)

5175 (94.1)
324 (5.9)

5161 (94.0)
330 (6.0)

5165 (94.1)
326 (5.9)

5162 (94.0)
327 (6.0)

80 (1.5)
2883 (52.5)
1735 (31.6)
796 (14.5)

60 (1.1)
2380 (43.3)
1984 (36.1)
1075 (19.6)

55 (1.0)
2097 (38.2)
1970 (35.9)
1369 (24.9)

48 (0.9)
1858 (33.8)
2018 (36.8)
1567 (28.5)

44 (0.8)
1639 (29.9)
1924 (35.1)
1882 (34.3)

547 (10.0)
773 (14.1)
567 (10.3)
937 (17.1)
1071 (19.5)
1599 (29.1)

648 (11.8)
909 (16.5)
639 (11.6)
998 (18.2)
986 (17.9)
1319 (24.0)

740 (13.5)
1042 (19.0)
666 (12.1)
985 (17.9)
959 (17.5)
1099 (20.0)

922 (16.8)
1121 (20.4)
725 (13.2)
942 (17.2)
845 (15.4)
936 (17.1)

1367 (24.9)
1253 (22.8)
683 (12.4)
756 (13.8)
707 (12.9)
723 (13.2)

4878 (88.8)
217 (4.0)
399 (7.3)

5068 (92.2)
176 (3.2)
255 (4.6)

5089 (92.7)
190 (3.5)
212 (3.8)

5032 (91.6)
239 (4.4)
220 (4.0)

4935 (89.9)
346 (6.3)
208 (3.8)

4036 (73.5)
663 (12.1)
640 (11.7)
152 (2.8)
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Marital status, n (%)
Married or living as married
Widowed
Divorced or separated
Never married
Education, n (%)
Less than high school
High school grad and some college
College graduate
Postgraduate
Study center, n (%)
University of Colorado
Georgetown University
Pacific Health Research and
Education Institute (Honolulu)
Henry Ford Health System
University of Minnesota
Washington University in St Louis
University of Pittsburgh
University of Utah
Marshfield Clinic Research
Foundation
University of Alabama at
Birmingham
Smoking status, n (%)
Never
Former cigarette smoker
Current cigarette smoker
Family history of breast cancer,
n (%)
No

3757 (68.4)
818 (14.9)
689 (12.5)
230 (4.2)

3981 (72.4)
710 (12.9)
616 (11.2)
192 (3.5)

4078 (74.3)
664 (12.1)
606 (11.0)
143 (2.6)

3893 (70.9)
687 (12.5)
758 (13.8)
151 (2.8)

257 (4.7)
3320 (60.4)
926 (16.9)
991 (18.0)

260 (4.7)
3389 (61.6)
955 (17.4)
895 (16.3)

275 (5.0 )
3513 (64.0)
930 (16.9)
773 (14.1)

302 (5.5)
3614 (65.8)
843 (15.4)
732 (13.3)

462 (8.4)
3756 (68.4)
669 (12.2)
602 (11.0)

381 (6.9)
389 (7.1)
254 (4.6)

357 (6.5)
279 (5.1)
178 (3.2)

371 (6.8)
233 (4.2)
145 (2.6)

359 (6.5)
194 (3.5)
131 (2.4)

310 (5.7)
172 (3.1)
96 (1.8)

830 (15.1)
863 (15.7)
550 (10.0)
605 (11.0)
760 (13.8)
595 (10.8)
267 (4.9)

818 (14.9)
882 (16.0)
674 (12.3)
668 (12.2)
688 (12.5)
683 (12.4)
272 (5.0)

749 (13.6)
995 (18.1)
704 (12.8)
689 (12.6)
653 (11.9)
663 (12.1)
289 (5.3)

755 (13.8)
979 (17.8)
666 (12.1)
675 (12.3)
650 (11.8)
772 (14.1)
310 (5.7)

877 (16.0)
904 (16.5)
717 (13.0)
696 (12.7)
554 (10.1)
807 (14.7)
360 (6.6)

3401 (61.9)
1797 (32.7)
296 (5.4)

3255 (59.2)
1896 (34.5)
348 (6.3)

3213 (58.5)
1888 (34.4)
390 (7.1)

3073 (56.0)
1904 (34.7)
514 (9.4)

2745 (50.0)
1875 (34.2)
869 (15.8)

4700 (85.6)
736 (13.4)

4645 (84.5)
796 (14.5)

4647 (84.6)
809 (14.7)

4665 (85.0)
781 (14.2)

4657 (84.8)
757 (13.8)
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Yes
Possibly
Age at menarche, n (%)
<10
10-11
12-13
14-15
16+
Age at menopause, n (%)
<40
40-44
45-49
50-54
55+
Number of live births, n (%)
0
1
2
3
4
5 or more
Age at first birth, n (%)
Nulliparous
≤19
20-24
25-29
30-34
≥35
Postmenopausal hormone use, n
(%)
Never / unknown

58 (1.1)

58 (1.1)

35 (0.6)

45 (0.8)

75 (1.4)

86 (1.6)
1038 (18.9)
2927 (53.3)
1180 (21.5)
263 (4.8)

68 (1.2)
992 (18.0)
3023 (55.0)
1159 (21.1)
257 (4.7)

82 (1.5)
991 (18.1)
3053 (55.6)
1167 (21.3)
198 (3.6)

79 (1.4)
1016 (18.5)
3005 (54.7)
1155 (21.0)
236 (4.3)

83 (1.5)
999 (18.2)
2972 (54.2)
1201 (21.9)
234 (4.3)

690 (12.6)
752 (13.7)
1295 (23.6)
2129 (38.8)
628 (11.4)

683 (12.4)
781 (14.2)
1319 (24.0)
2092 (38.0)
624 (11.4)

732 (13.3)
742 (13.5)
1251 (22.8)
2145 (39.1)
621 (11.3)

792 (14.4)
747 (13.6)
1286 (23.4)
2051 (37.4)
615 (11.2)

868 (15.8)
807 (14.7)
1301 (23.7)
1873 (34.1)
640 (11.7)

597 (10.9)
396 (7.2)
1305 (23.8)
1359 (24.7)
930 (16.9)
907 (16.5)

501 (9.1)
365 (6.6)
1314 (23.9)
1392 (25.3)
953 (17.3)
974 (17.7)

451 (8.2)
396 (7.2)
1305 (23.8)
1406 (25.6)
966 (17.6)
967 (17.6)

443 (8.1)
370 (6.7)
1292 (23.4)
1424 (25.9)
902 (16.4)
1060 (19.3)

455 (8.3)
402 (7.3)
1261 (23.0)
1379 (25.1)
921 (16.8)
1071 (19.5)

593 (10.8)
704 (12.8)
2502 (45.6)
1265 (23.0)
326 (5.9)
104 (1.9)

496 (9.0)
787 (14.3)
2650 (48.2)
1184 (21.5)
279 (5.1)
105 (1.9)

446 (8.1)
796 (14.5)
2640 (48.0)
1227 (22.4)
281 (5.1)
101 (1.8)

432 (7.9)
945 (17.2)
2735 (49.8)
1046 (19.1)
247 (4.5)
86 (1.6)

449 (8.2)
1242 (22.6)
2570 (46.8)
892 (16.3)
257 (4.7)
79 (1.4)

1737 (31.6)
936 (17.0)

1710 (31.1)
889 (16.2)

1742 (31.7)
849 (15.5)

1854 (33.7)
834 (15.2)

1825 (33.3)
911 (16.6)

Former
Current
Oral contraceptive use, n (%)
No
Yes
Oophorectomy, n (%)
No/ don't know
One ovary
Both ovaries
Hysterectomy, n (%)
No/ don't know
Yes

2821 (51.4)

2900 (52.7)

2900 (52.8)

2803 (51.1)

2753 (50.2)

2878 (52.4)
2616 (47.6)

2619 (47.6)
2880 (52.4)

2448 (44.6)
3043 (55.4)

2395 (43.6)
3096 (56.4)

2175 (39.6)
3314 (60.4)

4514 (82.2)
335 (6.1)
645 (11.7)

4421 (80.4)
348 (6.3)
730 (13.3)

4409 (80.3)
346 (6.3)
736 (13.4)

4413 (80.4)
333 (6.1)
745 (13.6)

4340 (79.1)
375 (6.8)
774 (14.1)

3614 (65.8)
1880 (34.2)

3528 (64.2)
1971 (35.8)

3555 (64.7)
1936 (35.3)

3505 (63.8)
1986 (36.2)

3487 (63.5)
2002 (36.5)

AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine
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Table 4.2. Correlation coefficient between daily intakes of NƐ-carboxymethyl-lysine (CML)-advanced glycation end-products
(AGE) KU/1000 kcal and selected nutrients

CML-AGE
KU/1000kcal

Dairy
protein
-0.07

Dietary protein
Animal
Plant
protein
protein
0.46
-0.12

Dietary
carbohydrate
-0.19

Dietary
Fructose
-0.25

Calcium
-0.14

Dietary
MUFA
0.39

Dietary
PUFA
0.25

Note: All P values are <0.0001
AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; MUFA: monounsaturated fatty acids; PUFA:
polyunsaturated fatty acid; SF: saturated fatty acid

Dietary
SF
0.41
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Figure 4.3. Percentage contribution of food groups to total NƐ-carboxymethyl-lysine
(CML)advanced
Fat
and oil:
Butter, glycation
margarine,end-products
white sauce,(AGE)
cheeseintake
sauce, sour cream, sweet cream,
salad dressing, gravy
Cancer Screening Trial (PLCO)
Red meat: Beef roast, pork chop, pork roast, hamburger, liver, meat loaf, steak
Mixed foods: Mixed dish, pizza, spaghetti, lasagna, potpie
White meat: Chicken or turkey
Processed meat: Cold cut, ham, sausage, bacon, hotdog
Dairy and eggs: Ice cream, cheese, cottage cheese, milk, yogurt, eggs
Fish: Fish, shellfish, tuna
Others: Cake, candy, donut, pie, biscuit, beer, coffee, liquor, soda, tea, wine, chip,
cracker, sugar, fruit punch, juice, tomato juice, apple juice, ketchup, jelly, pancake
Vegetables: Broccoli, brussel sprout, cabbage, carrots, cauliflower, celery, cucumber,
greens, green pepper, lettuce, pea, spinach, squash, tomato, tomato sauce, mixed
vegetables, beet, beans, chili, onion, garlic, potatoes, sweet potatoes, soup, tofu
Nuts: Peanut and peanut butter
Grains: Grains, brown rice, white rice, corn, bread, cereal, cookie
Fruits: Apple, applesauce, apricot, banana, cantaloupe, grapefruit, grapes, orange, peach,
plum, prune, raisin, strawberry, pineapple, watermelon, fruit mixtures
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Table 4.3. Hazard ratio (HRs) and 95% confidence interval (CI) for quintiles of NƐ-carboxymethyl-lysine (CML)-advanced
glycation end-products (AGE) intake and breast cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer
Screening Trial (PLCO)

CML-AGE,
KU/1000 kcal
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
HR (95%CI)d

Q1
867-4056

Q2
4057-5136

Q3
5137-6208

Q4
6209-7731

Q5
7732-43387

285
Ref
Ref
Ref
Ref

324
1.15 (0.98-1.34)
1.15 (0.98-1.35)
1.14 (0.97-1.34)
1.16 (0.98-1.37)

330
1.17 (1.00-1.37)
1.20 (1.02-1.40)
1.16 (0.99-1.37)
1.19 (1.002-1.42)

326
1.18 (1.004-1.38)
1.22 (1.04-1.43)
1.19 (1.01-1.40)
1.24 (1.02-1.50)

327
1.20 (1.02-1.41)
1.28 (1.09-1.51)
1.23 (1.04-1.46)
1.30 (1.04-1.62)

P-trend

0.047
0.004
0.022
0.041
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AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; DAG: directed acyclic graph
a
Adjusted for age and energy intake
b
Adjusted for DAG identified covariates: age, energy intake, alcohol, race/ethnicity, marital status, education, study
center, smoking status
c
Adjusted for covariates: age, energy intake, alcohol, BMI, vigorous activity, race/ethnicity, marital status,
education, study center, smoking status, family history, age at menarche, age at menopause, age at first birth, no. of
live birth, PMH use, OC use, oophorectomy, hysterectomy
d
Adjusted for all covariates in c and dietary intake of total fat and red meat

Figure 4.4. Nonlinear relationship between NƐ-carboxymethyl-lysine (CML)-advanced
glycation end-products (AGE) intake and breast cancer risk
P value for nonlinearity = 0.290
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Figure 4.5. Linear relationship between NƐ-carboxymethyl-lysine (CML)-advanced
glycation end-products (AGE) intake and breast cancer risk
P value for linearity = 0.051
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Table 4.4 Baseline characteristics by breast cancer status
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n (%)
CML-AGE, KU/1000 kcal
Alcohol intake, (g/day)
Total energy intake, (kcal/day)
Age, (years)
BMI (kg/m2), n (%)
< 18.5
18.5-< 25
25-< 30
>= 30
Vigorous activity, n (%)
None
<1 hour/week
1 hour/week
2 hours/week
3 hours/week
4+ hours/week
Race/ethnicity, n (%)
Non-Hispanic white
Non-Hispanic black
Other
Marital status, n (%)
Married or living as married
Widowed
Divorced or separated
Never married
Education, n (%)

Breast cancer
1592 (5.8)
6175.2 (2619.5)
6.8 (14.8)
1778.9 (600.5)
62.6 (5.2)

Death
2160 (7.9)
6083.8 (2646.3)
5.3 (13.8)
1711.6 (613.1)
65.4 (5.3)

Others
23712 (86.3)
6102.7 (2700.5)
5.5 (12.4)
1742.5 (600.1)
62.2 (5.3)

12 (0.8)
598 (37.6)
588 (36.9)
384 (24.8)

46 (2.1)
819 (37.9)
687 (31.8)
608 (28.2)

229 (1.0)
9440 (39.8)
8356 (35.2)
5687 (24.0)

236 (14.8)
307 (19.3)
199 (12.5)
254 (16.0)
292 (18.3)
304 (19.1)

533 (24.7)
409 (18.9)
256 (11.9)
305 (14.1)
303 (14.0)
354 (16.4)

3455 (14.6)
4382 (18.5)
2825 (11.9)
4059 (17.1)
3973 (16.8)
5018 (21.2)

1466 (92.1)
51 (3.2)
75 (4.7)

1961 (90.8)
111 (5.1)
88 (4.1)

21575 (91.0)
1006 (4.2)
1131 (4.8)

1174 (73.7)
188 (11.8)
176 (11.1)
54 (3.4)

1299 (60.1)
462 (21.4)
311 (14.4)
88 (4.1)

17272 (72.8)
2892 (12.2)
2822 (11.9)
726 (3.1)
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Less than high school
High school grad and some college
College graduate
Postgraduate
Study center, n (%)
University of Colorado
Georgetown University
Pacific Health Research and Education Institute (Honolulu)
Henry Ford Health System
University of Minnesota
Washington University in St Louis
University of Pittsburgh
University of Utah
Marshfield Clinic Research Foundation
University of Alabama at Birmingham
Smoking status, n (%)
Never
Former cigarette smoker
Current cigarette smoker
Family history of breast cancer, n (%)
No
Yes
Possibly
Age at menarche, n (%)
<10
10-11
12-13
14-15
16+
Age at menopause, n (%)
<40

75 (4.7)
928 (58.3)
319 (20.0)
270 (17.0)

211 (9.8)
1433 (66.3)
266 (12.3)
250 (11.6)

1270 (5.4)
15231 (64.2)
3738 (15.8)
3473 (14.6)

120 (7.5)
106 (6.7)
51 (3.2)
206 (13.1)
281 (17.7)
192 (12.1)
183 (11.5)
164 (10.3)
211 (13.3)
76 (4.8)

133 (6.2)
92 (4.3)
50 (2.3)
341 (15.8)
318 (14.7)
275 (12.7)
259 (12.0)
304 (14.1)
280 (13.0)
108 (5.0)

1525 (6.4)
1069 (4.5)
703 (3.0)
3480 (14.7)
4024 (17.0)
2840 (12.0)
2891 (12.2)
2837 (12.0)
3029 (12.8)
1314 (5.5)

887 (55.7)
579 (36.4)
126 (7.9)

970 (44.9)
783 (36.3)
407 (18.8)

13830 (58.3)
7998 (33.7)
1884 (8.0)

1293 (81.2)
282 (17.7)
17 (1.1)

1812 (83.9)
316 (14.6)
32 (1.5)

20209 (85.2)
3281 (13.8)
222 (0.9)

13 (0.8)
301 (18.9)
875 (55.0)
335 (21.0)
68 (4.3)

40 (1.9)
440 (20.4)
1145 (53.0)
436 (20.2)
99 (4.6)

345 (1.5)
4295 (18.1)
12960 (54.7)
5091 (21.5)
1021 (4.3)

199 (12.50)

324 (15.0)

3242 (13.7)
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40-44
45-49
50-54
55+
Number of live births, n (%)
0
1
2
3
4
5 or more
Age at first birth, n (%)
Nulliparous
≤19
20-24
25-29
30-34
≥35
Postmenopausal hormone use, n (%)
Never / unknown
Former
Current
Oral contraceptive use, n (%)
No
Yes
Oophorectomy, n (%)
No/ don't know
One ovary
Both ovaries
Hysterectomy, n (%)
No/ don't know

217 (13.6)
338 (21.2)
614 (38.6)
224 (14.1)

341 (15.8)
537 (24.9)
787 (36.4)
171 (7.9)

3271 (13.8)
5577 (23.5)
8889 (37.5)
2733 (11.5)

158 (9.9)
123 (7.7)
393 (24.7)
409 (25.7)
268 (16.8)
241 (15.1)

227 (10.5)
159 (7.4)
472 (21.9)
479 (22.2)
355 (16.4)
468 (21.7)

2062 (8.7)
1647 (7.0)
5612 (23.7)
6072 (25.6)
4049 (17.1)
4270 (18.0)

157 (9.9)
233 (14.6)
678 (42.6)
385 (24.2)
106 (6.7)
33 (2.1)

225 (10.4)
407 (18.8)
927 (42.9)
444 (20.6)
110 (5.1)
47 (2.2)

2034 (8.6)
3834 (16.2)
11492 (48.5)
4783 (20.2)
1174 (5.0)
395 (1.7)

453 (28.5)
222 (13.9)
917 (57.6)

917 (42.5)
412 (19.1)
831 (38.5)

7498 (31.6)
3785 (16.0)
12429 (52.4)

730 (45.9)
862 (55.1)

1233 (57.1)
927 (42.9)

10552 (44.5)
13160 (55.5)

1322 (83.0)
87 (5.5)
183 (11.5)

1745 (80.8)
151 (7.0)
264 (12.2)

19030 (80.3)
1499 (6.3)
3183 (13.4)

1070 (67.2)

1395 (64.6)

15224 (64.2)

Yes

522 (32.8)
Ɛ

765 (35.4)

AGE: advanced glycation end-products; CML: N -carboxymethyl-lysine; BMI: body mass index

8488 (35.8)
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5.1 ABSTRACT
Introduction: Advanced glycation end-products (AGEs) are implicated in the
pathogenesis of chronic diseases and cancer. AGEs are produced naturally in the body
but can also be consumed from foods. We previously reported an increased risk of breast
cancer with higher dietary AGE intake. The objective of the study was to investigate
whether the association between NƐ-carboxymethyl-lysine (CML)-AGE intake and breast
cancer (BrCa) risk is modified by race/ethnicity, obesity status, fruit and vegetable intake,
invasiveness of the cancer, or tumor subtype among women in the Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial (PLCO). Methods: The PLCO enrolled
women aged 55 to 74 years into a randomized controlled trial. Our study sample included
only women enrolled in the intervention arm who were cancer-free at baseline and
completed a baseline questionnaire and food frequency questionnaire (DQX). CML-AGE
values were assigned and quantified to DQX food responses using a published AGE
database. Descriptive analysis was used to obtain means and percentages while Cox
proportional hazards model estimated the hazard ratios (HRs) and 95% CIs of BrCa
stratified by race/ethnicity, obesity status, fruit and vegetable intake, invasiveness of
disease and hormone receptor status. Results: After a median 11.5 years of follow-up,
1,592 women were diagnosed with breast cancer, including 1,466 non-Hispanic white
(NHW), 51 non-Hispanic black (NHB), and 75 Other race/ethnicity. The average CMLAGE consumption among all the women was 6,105 kilounits (KU)/1000kcal per day
(SD: 2692 KU/1000kcal per day) and was highest among NHB (6760 ± 3359
KU/1000kcal per day) compared to NHW (6100 ± 2649 KU/1000kcal per day) and Other
race/ethnicity (5612 ± 2724 KU/1000kcal per day). Higher CML-AGE intake was
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associated with increased risk of BrCa among NHW (HRT3 VS T1: 1.21, 95% CI: 1.021.44), but was not statistically significant for other race groups. Increased CML-AGE
intake was associated with increased risk of in situ (HRT3 VS T1: 1.49, 95% CI: 1.11-2.01)
and hormone receptor positive (HRT3 VS T1: 1.24, 95% CI: 1.01-1.53) BrCa. Conclusion:
High intake of dietary AGE may contribute to increased BrCa. The associations were
stronger in NHW women, and hormone receptor positive and in situ BrCa.
5.2 INTRODUCTION
Breast cancer (BrCa) is a heterogenous disease with variations in biological and
phenotypic expressions,37 and is the most commonly diagnosed cancer among women in
the U.S.2 The chronic triggering of an inflammatory response is a biologic process that is
recognized to promote proliferation of malignant tumors and could lead to BrCa.41–43
Advanced glycation end-products (AGEs) are compounds formed by a complex series of
non-enzymatic reactions of proteins or lipids with reducing sugars.34,70,71 The adverse
biological effects of AGEs are propagated through the direct effects on tissues or
activation of the receptor for AGE (RAGE), promoting oxidative stress and chronic
inflammation.78–81,293 In addition to being produced naturally in the body, AGEs are also
contained in food products.34,71 Preparation methods influence the levels of AGEs formed
in foods. Cooking at high temperatures such as grilling or frying or cooking for long
periods of time contribute significantly to the AGE content in foods. Consumption of
AGE-rich foods further contribute to the endogenous accumulation of AGEs in the
body.34,71
Majority of the research conducted on AGEs are laboratory-based studies focused
on RAGE and serum AGE levels.29,30,33,98 These experimental studies support the
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biological plausibility of higher AGE exposure leading to an increase in BrCa risk. Also,
a differential effect of AGE on BrCa subtypes by hormone receptor status has been
hypothesized.33,99
Our current study examined the association between CML-AGE intake and BrCa
risk using data from the large prospective Prostate, Lung, Colorectal and Ovarian Cancer
Screening Trial (PLCO) and examined whether the relationship differed by
race/ethnicity, obesity status, fruit and vegetable intake, invasiveness and hormone
receptor status. We hypothesize that associations between dietary AGE intake and BrCa
risk may be stronger among racial/ethnic minority populations, among obese subjects,
those with lower fruit and vegetable intake, and among less invasive and hormone
receptor positive tumors, based on findings from previous research.
5.3 METHODS
5.3.1 Study Population
Our study utilized data from the intervention arm of PLCO, a randomized
controlled trial designed to assess the efficacy of cancer screening modalities in the U.S.
Enrollment occurred from November 1993 to September 2001 across 10 screening
centers. The study enrolled over 78,000 women aged between 55 and 74 years who were
randomized into an intervention or control arm (Figure 5.1). Participants in the
intervention arm received chest X-ray, flexible sigmoidoscopy, cancer antigen (CA) 125,
and transvaginal ultrasound screenings at regular intervals while women in the control
arm received their usual medical care. Participants were excluded from the trial if they
were undergoing treatment for cancers (except for basal or squamous cell melanoma),
enrolled in other clinical trials, or unable to provide informed consent.295 Study
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participants were followed-up until December 31, 2009. The study protocol was
approved by the Institutional Review Board (IRB) of the National Cancer Institute (NCI)
and screening centers, and informed consent was obtained from all study participants.
5.3.2 Data Collection
Participants enrolled in the intervention arm were requested to complete baseline
questionnaires (BQ) and dietary questionnaires (DQX) administered at baseline. The BQ
obtained information on demographics, height, weight from which body mass index
(BMI) was calculated, smoking and medical history. DQX captured usual dietary intake
in the previous year including information on meat preparation practices and
vitamin/supplement intake. The DQX is a food frequency questionnaire (FFQ) developed
for the PLCO which solicits information on intake frequency on 137 food items and
estimated portion sizes of 77 food items.282 A separate diet history questionnaire (DHQ)
was introduced 5 years into the trial and administered to participants in both the
intervention and control arms. The DHQ solicited dietary information in the previous
year on intake frequency of 114 food items and estimated portion sizes of 109 food items.
Our study utilized only data from the intervention arm in order to ensure consistency in
dietary assessment as well as control for potential confounding effects of the intervention.
Utilizing this group of women is recommended by the PLCO to promote uniformity of
the dietary information obtained. Nutrient intake was calculated based on DQX responses
using the U.S. Department of Agriculture’s (USDA) pyramid food group and national
dietary database.283 We excluded women with a personal history of cancer except nonmelanoma skin cancer, incomplete BQ and invalid DQX (extreme energy intake, missing
≥ 8 FFQ responses and incomplete DQX at baseline) (Figure 5.1). Further exclusions
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were made for participants with missing covariates on: BMI (n=253), age at menopause
(n=200), use of oral contraceptives (OC) (n=13), age at menarche (n=19), family history
of BrCa (n=171), use of postmenopausal hormone (PMH) (n=14), oophorectomy (n=3),
hysterectomy (n=4), number of pregnancies (n=39), number of live births (n=2),
education (n=13), marital status (n=7), age at first birth (n= 67), and hours spent in
vigorous activity (n=111). The final analytical sample contained 27,464 participants from
which 1,592 BrCa cases were diagnosed during the follow-up period. In analyses
examining the risk of specific BrCa subtypes, women who had missing information on
hormone receptor status of diagnosed BrCa were excluded (n=378).
5.3.3 Assessment of Dietary AGE Intake
A published database containing NƐ-carboxymethyl-lysine (CML) content of 549
foods commonly consumed in the northeastern metropolitan region of the U.S. was
previously used to assign CML-AGE values to each food item on the DQX.34 In the
database, AGE content was estimated using enzyme-linked immunosorbent assay
(ELISA) based on monoclonal anti-CML antibody.34 CML-AGE values were
appropriately assigned to match the food items in the DQX. Details of AGE-CML
assignment can be found in the previous chapter (chapter 4.3.3). Total CML-AGE values
were adjusted for energy intake using the energy density method and then categorized
into tertiles, with the lowest tertile representing the lowest intake level and serving as the
referent group in regression analyses.
5.3.4 Covariate Assessment
Potential confounders were identified through extensive literature review on BrCa
risk factors. Confounders identified include age (years), BMI (kg/m2) [<18.5, 18.5-<25,
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25-<30, or ≥30], hours spent in vigorous activity such as swimming or brisk walking
(none, <1 hour/week, 1 hour/week, 2 hours/week, 3 hours/week, or 4+ hours/week),
race/ethnicity (non-Hispanic white [NHW], non-Hispanic black [NHB], or Other
races/ethnicities), marital status (married/living as married, widowed, divorced/separated,
or never married), education (less than high school, high school and some college,
college graduate, or postgraduate degree), study center, smoking status (never, former, or
current), first degree family history of BrCa (no, yes, or possibly), age at menarche (<10,
10-11, 12-13, 14-15, or 16+ years), age at menopause (<40, 40-44, 45-49, 50-54, or 55+
years), number of live births (0, 1, 2, 3, 4, or 5 or more), age at first birth (nulliparous,
≤19, 20-24, 25-29, 30-34, or >35 years), PMH use (never, former, or current), OC use (no
or yes), oophorectomy (no/don’t know, one ovary, or both ovaries), hysterectomy
(no/don’t know or yes), alcohol intake (g/day), total energy intake (kcal/day), total fat
from diet (g/day) and red meat intake (g/day).
5.3.5 Stratified Sample Population
The analytical sample was stratified by race/ethnicity (NHW, NHB or Others),
BMI (kg/m2) (normal weight: 18.5-<25, overweight: 25-<30 or obese: ≥30), fruit and
vegetable intake (low intake: 16-463 g/day, medium intake: 464-686 g/day, or high
intake: 687-3142 g/day), estrogen receptor (ER)-status and progesterone receptor (PR)status.
5.3.6 Outcome Assessment
Incidence of in situ and invasive BrCa were self-reported using the mailed annual
study updates and BrCa was confirmed by state cancer registries or reports from
physicians and next of kin, and the national death index (NDI) for fatal cases.280 Breast
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cancer supplemental (BCS) forms were administered starting from 2007 to obtain
detailed clinical characteristics of BrCa tumors such as tumor grade, stage, and subtype.
5.3.7 Statistical Analyses
Descriptive analysis was used to obtain means and standard deviations (SD) for
continuous variables and percentages for categorical variables. Categories were created
for similar food products: fruits, vegetables, grains, dairy, red meat, white meat,
processed meat, mixed foods, fish, fat & oil, nuts, or others and the contribution of food
products to total CML-AGE intake was estimated as percentages. Cox proportional
hazards regression estimated hazard ratios (HR) and 95% confidence interval (CI) of
BrCa by tertiles of CML-AGE intake and person-time was calculated from the date of
completion of questionnaires administered at baseline to the end of follow-up or BrCa
diagnosis.
Simple models were adjusted for age and energy intake. A second multivariable
Cox model adjusted for age, energy intake, alcohol, BMI, hours spent in vigorous
activity, race/ethnicity, marital status, education, study center, smoking status, family
history of BrCa, age at menarche, age at menopause, age at first birth, number of live
birth, PMH use, OC use, oophorectomy, and hysterectomy. A third multivariable model
adjusted for all aforementioned covariates in addition to intakes of total fat and red meat.
Cox proportional hazards models were used to assess the risks of overall BrCa, and by
invasiveness and hormone receptor status (ER and PR).304 Effect modification by
race/ethnicity, obesity status, and fruit and vegetable intake was examined in stratified
analyses. Schoenfeld residual test was used to evaluate violation of proportional hazards
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assumption290 and no major violations were observed. All statistical analyses were
conducted using SAS version 9.4 and statistical significance was set at α= 0.05.
5.4 RESULTS
After a median follow-up time of 11.5 years, there were 1,592 BrCa cases (in
situ=327; invasive=1,265) diagnosed in 27,464 women at risk (Figure 5.1). The average
daily CML-AGE consumption was 6,105 ± 2691 kilounits (KU)/1000 kcal and ranged
between 867 KU/1000 kcal and 43,387 KU/1000 kcal (Table 5.1). A large proportion of
women enrolled in the study were NHW and had no family history of BrCa. Women in
the highest tertile of CML-AGE intake were younger, had higher daily energy intake, and
lower daily alcohol intake compared to the lowest tertile (Table 5.1). A higher proportion
of women in the highest tertile of CML-AGE intake were obese, divorced or separated,
current cigarette smokers, had five or more live births, were OC users, had undergone a
hysterectomy and oophorectomy of both ovaries, were aged 10-11 years at menarche, and
were aged <44 years at menopause. Women in the highest tertile of CML-AGE intake
were least likely to engage in vigorous activity 4+ hours a week, have a graduate
education or higher, be current PMH users, and be aged 35 years or more at first birth.
In all the racial/ethnic groups, fat and oil was the food group that contributed the
most to total CML-AGE intake while nuts, grains, and fruits contributed the least (Figure
5.2). Red meat and mixed foods represented high proportion of CML-AGE intake among
NHW women, white and processed meat in NHB women, and red and white meat among
women of Other races/ethnicities.
The results of the multivariable Cox proportional hazard regression for all women
in the dataset and stratified by race are presented in Table 5.2. In the adjusted model 2,
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positive associations were observed in the upper tertile of CML-AGE intake (HRT3VST1:
1.16, 95%CI: 1.02-1.32). After further adjustment for dietary fat and red meat intake,
model 3, the positive association persisted (HRT3VST1: 1.19, 95%CI: 1.003-1.40). When
stratified by race/ethnicity, positive associations were observed in the upper tertile but
were only statistically significant in NHW women (HRT3VST1: 1.21, 95%CI: 1.02-1.44).
Associations between CML-AGE and breast cancer were strongest among obese
participants as compared to associations among normal weight or overweight participants
but were not statistically significant (obese, model 3: HRT3VST1: 1.32, 95%CI: 0.93-1.87)
(Table 5.3). In the associations between CML-AGE and BrCa by fruit and vegetable
intake (Table 5.4), the associations were strongest among high consumers (HRT3VST1:
1.36, 95%CI: 0.999-1.85) as compared to associations among low consumers (HRT3VST1:
1.27, 95%CI: 0.95-1.71) and moderate consumers (HRT3VST1: 1.02, 95%CI: 0.76-1.36) of
fruits and vegetables but were also not statistically significant.
As shown in Table 5.5, higher intakes of CML-AGE were associated with
increased risk of in situ and invasive BrCa but were statistically significant only for in
situ BrCa (HRT3VST1: 1.49, 95%CI: 1.11-2.01). Weak positive associations were observed
for the risks of ER+ cancers (HRT3VST1: 1.18, 95%CI: 0.97-1.45) and ER- cancers
(HRT3VST1: 1.21, 95%CI: 0.82-1.79) (Table 5.6). Higher intake levels of CML-AGE were
significantly associated with increased risk of PR+ breast cancer (HRT3VST1: 1.24, 95%CI:
1.01-1.53) but not PR- breast cancer. When ER and PR status were combined, there was
a significant increased risk of ER+/PR+ breast cancer in the highest tertile of CML-AGE
intake (HRT3VST1: 1.24, 95%CI: 1.01-1.53). On the other hand, weak inverse associations
were observed for the risk of ER+/PR- breast cancers (HRT3VST1: 0.83, 95%CI: 0.53-
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1.31). There were too few cases with ER-/PR- or ER-/PR+ tumors to examine
associations separately for these groups.
5.5 DISCUSSION
In these secondary analyses of the large prospective PLCO study, increasing
levels of CML-AGE intake were positively associated with overall BrCa risk. The
increased risk was more prominent in NHW women and women diagnosed with in situ
and hormone receptor positive (ER+/PR+) BrCa. We utilized a published AGE database
containing CML-AGE values of foods to derive estimates of total CML-AGE intake. The
estimated average daily CML-AGE intake reported in a different study of healthy older
women using the Uribarri et al. AGE database were quite similar to the estimates in our
study. 32,302 Foods rich in fats and protein such as meat, have been reported to contain
high AGE content especially if cooked at high temperatures.34,35,71 In our study, fats and
oil such as margarine and cheese sauce, and meat products were the highest contributors
to total daily CML-AGE intake while fruits contributed the least amount. Contribution of
meat products to CML-AGE intake varied by race/ethnicity with red meat being the
highest meat contributor for NHW and Other races/ethnicities, while white and processed
meats where the highest meat contributors for NHB.
Few large epidemiologic studies have been published on the association between
dietary AGEs and cancer risk. In analyses of the National Institutes of Health-American
Association of Retired Persons (NIH-AARP) Diet and Health Study, a positive
relationship between CML-AGE intake and pancreatic cancer risk in men was
observed.32 More recently, the NIH-AARP Diet and Health Study was used to examine
associations between CML-AGE intake and BrCa, in which an increased risk of invasive
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BrCa was reported but the association was attenuated to the null after adjusting for
potential confounders including intakes of dietary fat and total meat.294 However, the
positive associations remained statistically significant in regional and distant BrCa. In
contrast, we observed an increased risk in overall BrCa which persisted even with
adjustment for multiple confounders including intake of total fat and red meat. In the
joint Cox model assessing the risk by BrCa subtypes, the positive association was
stronger for in situ BrCa and weaker for invasive BrCa. Our study also showed stronger
associations in NHW women, but null associations were found in women of other
races/ethnicities (NHB and Other races/ethnicities). The null associations could have
been due to the smaller number of NHB participants and women of other races/ethnicities
enrolled in the PLCO.
We also observed stronger but non-significant positive associations among obese
participants and high consumers of fruits and vegetables. Obesity is a risk factor for BrCa
among postmenopausal women.10 Fruits are natural sources of fructose and high
consumption may contribute to serum CML-AGE levels.305,306 Nevertheless, fruits and
vegetables contain high amounts of antioxidants and fiber, and may be protective of
BrCa.107 The positive associations observed among high consumers of fruits and
vegetables may be driven more by the overall pattern of intake of CML-AGE-rich foods
and less by the intake of fruits and vegetables.
AGEs when deposited in tissue cells induce damage to protein structure, or
activate RAGE to promote oxidative stress and chronic inflammation through secretion
of inflammatory biomarkers which could induce DNA damage.78–82 Inflammatory
mediators are also produced from adipose tissues and AGE induced inflammation is
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increased in obesity states.307–309 This may explain the slightly stronger positive
associations observed for BrCa risk among obese women. RAGE has been markedly
expressed in breast tumors88 and increased RAGE expression enhances the proliferation
and invasion of BrCa cells.29,30 The presence of AGEs may also activate the ERα
signaling pathway in BrCa cell lines.33 High accumulation of CML in BrCa tissues 99 and
elevated serum CML levels have been observed in women with BrCa.33 Previous studies
have reported higher circulating levels of AGEs in patients with ER+ BrCa compared to
ER- BrCa,33 and high CML accumulation in BrCa tissue cell lines was related to ER
expression.99 We found significant increased risks for PR+ breast tumors and for
ER+/PR+ combinations which support the potential role of dietary AGE in promoting
hormone receptor positive breast tumors.
Our study is strengthened by the use of a large prospective dataset with an
adequate sample size, long follow-up period (median 11.5 years) and information on
multiple confounders. Measurement error from the FFQ is a possibility, though the error
is likely to be non-differential since dietary information was obtained prior to the
occurrence of breast cancer. We utilized only the DQX completed at baseline among the
intervention arm to enhance uniformity of the dietary assessment within the PLCO
dataset. We used the database developed by Uribarri et al. which assessed AGE content
of more than 500 foods and beverages using ELISA to estimate total CML-AGE intake.34
A definitive approach to measuring AGEs has not yet been established as some analytical
methods produced variations in CML contents for certain foods.100 Thus, the true AGE
content present in food may be under- or over-estimated.74,100 In some previous studies,
estimated dietary AGE intake was correlated with serum AGE levels,104,105 though one
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study which averaged two measurements taken 13 weeks apart of serum CML measured
by ELISA reported no correlation between intake of foods considered high in dietary
AGE and serum CML-AGE.303 The Uribarri et al. AGE database is the most frequently
utilized method to estimate dietary AGE intake from FFQ responses in epidemiologic
studies,32,294 which will enhance comparability of our results with other studies. As in any
prospective cohort study, selection bias from loss to follow-up is a potential limitation
since participants were enrolled in the study for a long period of time. Finally, the racestratified analyses were limited by small sample sizes among NHB and Other
racial/ethnic groups. Future studies with more diverse populations are warranted.
Our findings suggest that dietary AGEs may contribute to the risk of developing
overall BrCa including in situ and hormone receptor positive BrCa. Hormone receptor
positive cancers comprise over 70% of BrCa diagnosis3 and reducing dietary AGEs may
be an important intervention in prevention. Future studies to confirm the effects of AGEs
in BrCa and explore the differential associations among racial groups and BrCa subtypes
are warranted.
5.6 CONCLUSION
The Western diet has been shown to be high in AGE content and is characterized
by high intakes of saturated fats and processed foods.34 Incorporating cooking methods
involving low temperatures and moisture such as boiling, and marinating foods prior to
cooking may be practical strategies that could reduce AGE content in food,34,71 and aid in
the prevention of BrCa.
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5.7 TABLES AND FIGURES

Figure 5.1. Flow chart for participants in the Prostate Lung Colorectal and Ovarian
Cancer Screening Trial (PLCO)
BQ: baseline questionnaire; DQX: dietary questionnaire; BMI: body mass index; OC:
oral contraceptives; BrCa: breast cancer; PMH: postmenopausal hormones
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Figure 5.2. Percentage contribution of food groups to total NƐ-carboxymethyl-lysine
(CML)- advanced glycation end-products (AGE) intake
NHW: non-Hispanic white; NHB: non-Hispanic black
Fat and oil: Butter, margarine, white sauce, cheese sauce, sour cream, sweet cream,
salad dressing, gravy
Red meat: Beef roast, pork chop, pork roast, hamburger, liver, meat loaf, steak
Mixed foods: Mixed dish, pizza, spaghetti, lasagna, potpie
White meat: Chicken or turkey
Processed meat: Cold cut, ham, sausage, bacon, hotdog
Dairy and eggs: Ice cream, cheese, cottage cheese, milk, yogurt, eggs
Fish: Fish, shellfish, tuna
Others: Cake, candy, donut, pie, biscuit, beer, coffee, liquor, soda, tea, wine, chip,
cracker, sugar, fruit punch, juice, tomato juice, apple juice, ketchup, jelly, pancake
Vegetables: Broccoli, brussel sprout, cabbage, carrots, cauliflower, celery, cucumber,
greens, green pepper, lettuce, pea, spinach, squash, tomato, tomato sauce, mixed
vegetables, beet, beans, chili, onion, garlic, potatoes, sweet potatoes, soup, tofu
Nuts: Peanut and peanut butter
Grains: Grains, brown rice, white rice, corn, bread, cereal, cookie
Fruits: Apple, applesauce, apricot, banana, cantaloupe, grapefruit, grapes, orange,
peach, plum, prune, raisin, strawberry, pineapple, watermelon, fruit mixtures
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Table 5.1. Baseline characteristics by tertiles of NƐ-carboxymethyl-lysine (CML)-advanced glycation end-products
(AGE) (KU/1000 kcal)
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CML-AGE, KU/1000 kcal
Alcohol intake, (g/day)
Total energy intake, (kcal/day)
Age, (years)
Breast cancer, n (%)
No
Yes
BMI (kg/m2), n (%)
< 18.5
18.5- < 25
25- < 30
>= 30
Vigorous activity, n (%)
None
<1 hour/week
1 hour/week
2 hours/week
3 hours/week
4+ hours/week
Race/ethnicity, n (%)
White, non-Hispanic
Black, non-Hispanic
Other
Marital status, n (%)

Tertile 1
(n=9155)
<4806
5.7 (14.6)
1698.3 (573.2)
63.4 (5.4)

Tertile 2
(n=9156)
4806-6639
5.5 (11.9)
1727.0 (577.9)
62.5 (5.3)

Tertile 3
(n=9153)
>6639
5.4 (11.3)
1801.4 (645.4)
61.5 (5.1)

8661 (94.6)
494 (5.4)

8604 (94.0)
552 (6.0)

8607 (94.0)
546 (6.0)

126 (1.4)
4525 (49.4)
3017 (33.0)
1487 (16.2)

88 (1.0)
3513 (38.4)
3337 (36.5)
2218 (24.2)

73 (0.8)
2819 (30.8)
3277 (35.8)
2984 (32.6)

951 (10.4)
1382 (15.1)
969 (10.6)
1632 (17.8)
1744 (19.1)
2477 (27.1)

1255 (13.7)
1692 (18.5)
1143 (12.5)
1624 (17.7)
1573 (17.2)
1869 (20.4)

2018 (22.1)
2024 (22.1)
1168 (12.8)
1362 (14.9)
1251 (13.7)
1330 (14.5)

8246 (90.1)
340 (3.7)
569 (6.2)

8479 (92.6)
319 (3.5)
358 (3.9)

8277 (90.4)
509 (5.6)
367 (4.0)
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Married or living as married
Widowed
Divorced or separated
Never married
Education, n (%)
Less than high school
High school grad and some college
College graduate
Postgraduate
Study center, n (%)
University of Colorado
Georgetown University
Pacific Health Research and Education Institute (Honolulu)
Henry Ford Health System
University of Minnesota
Washington University in St Louis
University of Pittsburgh
University of Utah
Marshfield Clinic Research Foundation
University of Alabama at Birmingham
Smoking status, n (%)
Never
Former cigarette smoker
Current cigarette smoker
Family history of breast cancer, n (%)
No
Yes
Possibly
Age at menarche, n (%)
<10
10-11

6413 (70.1)
1280 (14.0)
1093 (11.9)
369 (4.0)

6745 (73.7)
1123 (12.3)
1037 (11.3)
251 (2.7)

6587 (72.0)
1139 (12.4)
1179 (12.9)
248 (2.7)

422 (4.6)
5548 (60.6)
1572 (17.2)
1613 (17.6)

455 (5.0)
5883 (64.3)
1515 (16.6)
1303 (14.2)

679 (7.4)
6161 (67.3)
1236 (13.5)
1077 (11.8)

628 (6.9)
589 (6.4)
375 (4.1)
1373 (15.0)
1421 (15.5)
1009 (11.0)
1070 (11.7)
1211 (13.2)
1030 (11.3)
449 (4.9)

601 (6.6)
374 (4.1)
238 (2.6)
1282 (14.0)
1644 (18.0)
1144 (12.5)
1121 (12.2)
1115 (12.2)
1153 (12.6)
484 (5.3)

549 (6.0)
304 (3.3)
191 (2.1)
1374 (15.0)
1558 (17.0)
1154 (12.6)
1142 (12.5)
979 (10.7)
1337 (14.6)
565 (6.2)

5580 (61.0)
3051 (33.3)
524 (5.7)

5346 (58.4)
3141 (34.3)
669 (7.3)

4761 (52.0)
3168 (34.6)
1224 (13.4)

7817 (85.4)
1243 (13.6)
95 (1.0)

7738 (84.5)
1351 (14.8)
67 (0.7)

7759 (84.8)
1285 (14.0)
109 (1.2)

131 (1.4)
1666 (18.2)

135 (1.5)
1672 (18.3)

132 (1.4)
1698 (18.6)
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12-13
14-15
16+
Age at menopause, n (%)
<40
40-44
45-49
50-54
55+
Number of live births, n (%)
0
1
2
3
4
5 or more
Age at first birth, n (%)
Nulliparous
≤19
20-24
25-29
30-34
≥35
Postmenopausal hormone use, n (%)
Never / unknown
Former
Current
Oral contraceptive use, n (%)
No
Yes
Oophorectomy, n (%)

4949 (54.1)
1968 (21.5)
441 (4.82)

5079 (55.5)
1926 (21.0)
344 (3.8)

4952 (54.1)
1968 (21.5)
403 (4.4)

1150 (12.6)
1265 (13.8)
2179 (23.8)
3509 (38.3)
1052 (11.6)

1210 (13.2)
1261 (13.8)
2107 (23.0)
3542 (38.7)
1036 (11.3)

1405 (15.4)
1303 (14.2)
2166 (23.7)
3239 (35.4)
1040 (11.4)

951 (10.4)
636 (7.0)
2184 (23.9)
2275 (24.9)
1571 (17.2)
1538 (16.8)

746 (8.2)
647 (7.1)
2169 (23.7)
2350 (25.7)
1598 (17.5)
1646 (18.0)

750 (8.2)
646 (7.1)
2124 (23.2)
2335 (25.5)
1503 (16.4)
1795 (19.6)

943 (10.3)
1231 (13.5)
4259 (46.5)
2045 (22.3)
506 (5.5)
171 (1.9)

734 (8.0)
1355 (14.8)
4462 (48.7)
1985 (21.7)
435 (5.0)
167 (1.8)

739 (8.1)
1888 (20.6)
4376 (47.8)
1582 (17.3)
431 (4.7)
137 (1.5)

2865 (31.3)
1560 (17.0)
4730 (51.7)

2949 (32.2)
1382 (15.1)
4825 (52.7)

3054 (33.4)
1477 (16.1)
4622 (50.5)

4614 (50.4)
4541 (49.6)

4140 (45.2)
5016 (54.8)

3761 (41.1)
5392 (58.9)

No/ don't know
7469 (81.6)
One ovary
569 (6.2)
Both ovaries
1117 (12.2)
Hysterectomy, n (%)
No/ don't know
5943 (64.9)
Yes
3212 (35.1)
AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine

7357 (80.4)
560 (6.1)
1239 (13.5)

7271 (79.4)
608 (6.6)
1274 (13.9)

5913 (64.6)
3243 (35.4)

5833 (63.7)
3320 (36.3)
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Table 5.2. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐcarboxymethyl-lysine (CML)-advanced glycation end-products (AGE) intake and
breast cancer risk by race/ethnicity in the Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial (PLCO)

CML-AGE KU/1000 kcal
All (n=27,464)
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
NHW (n=25,002)
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
NHB (n=1,168)
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
Others (n=1,294)
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c

CML-AGE Tertiles
T2
T3
4806-6638
6639-43387

T1
867-4805
494
Ref
Ref
Ref

552
1.13 (1.002-1.28)
1.13 (0.998-1.28)
1.14 (1.00-1.31)

546
1.15 (1.01-1.30)
1.16 (1.02-1.32)
1.19 (1.003-1.40)

445
Ref
Ref
Ref

515
1.14 (1.000, 1.29)
1.13 (0.99, 1.29)
1.15 (0.999, 1.32)

506
1.16 (1.02, 1.32)
1.17 (1.03, 1.34)
1.21 (1.02, 1.44)

16
Ref
Ref
Ref

14
1.07 (0.52, 2.19)
1.05 (0.49, 2.26)
1.09 (0.47, 2.52)

21
1.06 (0.55, 2.06)
1.03 (0.50, 2.12)
1.11 (0.43, 2.87)

33
Ref
Ref
Ref

23
1.14 (0.67, 1.94)
1.15 (0.65, 2.02)
1.12 (0.61, 2.06)

19
0.94 (0.53, 1.66)
1.11 (0.59, 2.10)
1.05 (0.47, 2.34)

AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; BMI: body
mass index; PMH: postmenopausal hormones; OC: oral contraceptive
a
Adjusted for age and energy intake
b
Adjusted for covariates: age, energy intake, alcohol, BMI, vigorous activity, marital
status, education, study center, smoking status, family history, age at menarche, age at
menopause, age at first birth, no. of live birth, PMH use, OC use, oophorectomy,
hysterectomy (for NHW, NHB and Others) and race/ethnicity (for all)
c
Adjusted for all covariates in b and dietary intake of total fat and red meat
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Table 5.3. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐcarboxymethyl-lysine (CML)-advanced glycation end-products (AGE) intake and
breast cancer risk by obesity status in the Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial (PLCO)

T1
867-4805

CML-AGE Tertiles
T2
T3
4806-6638
6639-43387

CML-AGE KU/1000 kcal
Normal weight (n=10,857)
18.5-24.9 kg/m2
Cases, n
224
211
163
a
HR (95%CI)
Ref
1.22 (1.01, 1.47) 1.19 (0.97, 1.46)
b
HR (95%CI)
Ref
1.22 (1.01-1.48)
1.25 (1.01-1.54)
HR (95%CI)c
Ref
1.18 (0.96, 1.46) 1.17 (0.88, 1.54)
Overweight (n=9,631)
25.0-29.9 kg/m2
Cases, n
186
194
208
a
HR (95%CI)
Ref
0.96 (0.78, 1.17) 1.07 (0.88, 1.31)
HR (95%CI)b
Ref
0.96 (0.78, 1.17) 1.08 (0.88, 1.33)
c
HR (95%CI)
Ref
0.98 (0.79, 1.22) 1.14 (0.87, 1.50)
Obese (n=6,689)
≥30 kg/m2
Cases, n
80
141
173
HR (95%CI)a
Ref
1.21 (0.92-1.59)
1.13 (0.86-1.47)
HR (95%CI)b
Ref
1.24 (0.94-1.64)
1.18 (0.90-1.56)
HR (95%CI)c
Ref
1.31 (0.97, 1.75) 1.32 (0.93, 1.87)
AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; PMH:
postmenopausal hormones; OC: oral contraceptive
a
Adjusted for age and energy intake
b
Adjusted for covariates: age, energy intake, alcohol, vigorous activity, race/ethnicity,
marital status, education, study center, smoking status, family history, age at
menarche, age at menopause, age at first birth, no. of live birth, PMH use, OC use,
oophorectomy, hysterectomy
c
Adjusted for all covariates in b and dietary intake of total fat and red meat

103

Table 5.4. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐcarboxymethyl-lysine (CML)-advanced glycation end-products (AGE) intake and
breast cancer risk by fruit and vegetable intake in the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial (PLCO)

T1
867-4805

CML-AGE Tertiles
T2
T3
4806-6638
6639-43387

CML-AGE KU/1000 kcal
Low intake (n=9,163)
16-463 g/day
Cases, n
103
177
244
a
HR (95%CI)
Ref
1.23 (0.96, 1.57)
1.21 (0.96, 1.53)
b
HR (95%CI)
Ref
1.22 (0.96, 1.57)
1.25 (0.98, 1.59)
HR (95%CI)c
Ref
1.24 (0.96, 1.60)
1.27 (0.95, 1.71)
Medium intake (n=9,162)
464-686 g/day
Cases, n
159
196
177
HR (95%CI)a
Ref
1.03 (0.84, 1.28)
1.00 (0.80, 1.25)
HR (95%CI)b
Ref
1.03 (0.83, 1.27)
1.01 (0.80, 1.26)
c
HR (95%CI)
Ref
1.04 (0.82, 1.30)
1.02 (0.76, 1.36)
High Intake (n=9,139)
687-3142 g/day
Cases, n
232
179
125
a
HR (95%CI)
Ref
1.14 (0.94, 1.39)
1.23 (0.98, 1.54)
b
HR (95%CI)
Ref
1.17 (0.96, 1.43)
1.30 (1.03, 1.64)
HR (95%CI)c
Ref
1.20 (0.96, 1.50) 1.36 (0.999, 1.85)
AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; BMI: body
mass index; PMH: postmenopausal hormones; OC: oral contraceptive
a
Adjusted for age and energy intake
b
Adjusted for covariates: age, energy intake, alcohol, BMI, vigorous activity,
race/ethnicity, marital status, education, study center, smoking status, family history,
age at menarche, age at menopause, age at first birth, no. of live birth, PMH use, OC
use, oophorectomy, hysterectomy
c
Adjusted for all covariates in b and dietary intake of total fat and red meat
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Table 5.5. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐcarboxymethyl-lysine (CML)-advanced glycation end-products (AGE) intake and
breast cancer risk by invasiveness in the Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial (PLCO)

CML-AGE KU/1000 kcal
In Situ
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
Invasive
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c

T1
867-4805

CML-AGE Tertiles
T2
T3
4806-6638
6639-43387

89
Ref
Ref
Ref

115
1.31 (0.99-1.73)
1.31 (0.99-1.72)
1.32 (0.997-1.75)

123
1.43 (1.09-1.88)
1.46 (1.11-1,92)
1.49 (1.11-2.01)

405
Ref
Ref
Ref

437
1.09 (0.95-1.25)
1.09 (0.95-1.25)
1.10 (0.95-1.28)

423
1.08 (0.94-1.24)
1.10 (0.96-1.27)
1.13 (0.94-1.35)

AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine
a
Adjusted for age and energy intake
b
Adjusted for covariates: age, energy intake, alcohol, vigorous activity, race/ethnicity,
marital status, education, study center, smoking status, family history, age at
menarche, age at menopause, age at first birth, no. of live birth, PMH use, OC use,
oophorectomy, hysterectomy
c
Adjusted for all covariates in b and dietary intake of total fat and red meat
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Table 5.6. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐ-carboxymethyllysine (CML)-advanced glycation end-products (AGE) intake and breast cancer risk by hormone
receptor status in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)

T1

106

ER-status
ER+
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
ERCases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
PR-status
PR+
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
PRCases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c

CML-AGE Tertiles
T2

T3

320
Ref
Ref
Ref

359
1.13 (0.97-1.32)
1.13 (0.97-1.31)
1.14 (0.97-1.34)

355
1.14 (0.98-1.33)
1.16 (0.99-1.36)
1.18 (0.97-1.45)

54
Ref
Ref
Ref

65
1.22 (0.85-1.75)
1.21 (0.84-1.74)
1.22 (0.85-1.77)

61
1.17 (0.81-1.68)
1.19 (0.82-1.72)
1.21 (0.82-1.79)

275
Ref
Ref
Ref

320
1.18 (0.9996-1.38)
1.17 (0.993-1.38)
1.18 (0.993-1.41)

320
1.20 (1.02-1.41)
1.22 (1.03-1.44)
1.24 (1.01-1.53)

99
Ref
Ref
Ref

104
1.06 (0.81-1.40)
1.06 (0.80-1.39)
1.07 (0.81-1.42)

96
0.999 (0.75-1.33)
1.02 (0.77-1.35
1.04 (0.76-1.41)

ER/PR combinations
ER+/PR+
Cases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
ER+/PRCases, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c

274
Ref
Ref
Ref

317
1.17 (0.993-1.37)
1.16 (0.99-1.37)
1.18 (0.99-1.40)

319
1.20 (1.02-1.41)
1.22 (1.03-1.44)
1.24 (1.01-1.53)

46
Ref
Ref
Ref

42
0.92 (0.61-1.40)
0.92 (0.60-1.39)
0.93 (0.61-1.41)

36
0.80 (0.52-1.24)
0.82 (0.53-1.27)
0.83 (0.53-1.31)
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AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; BMI: body mass index;
PMH: postmenopausal hormones; OC: oral contraceptive
a
Adjusted for age and energy intake
b
Adjusted for covariates: age, energy intake, alcohol, BMI, vigorous activity, race/ethnicity, marital
status, education, study center, smoking status, family history, age at menarche, age at menopause,
age at first birth, no. of live birth, PMH use, OC use, oophorectomy, hysterectomy (for NHW, NHB
and Others) and race/ethnicity (for all)
c
Adjusted for all covariates in b and dietary intake of total fat and red meat
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6.1 ABSTRACT
Introduction: Breast cancer (BrCa) is the second leading cause of cancer death in
women after lung cancer and constitutes about 14% of total cancer deaths in the US
population. Advanced glycation end-products (AGEs) are produced naturally in the body
and are also consumed from foods. AGEs are implicated in the pathogenesis of chronic
diseases including cardiovascular diseases (CVD) and cancer. In the previous chapters (4
and 5), we reported an increased risk of BrCa with higher dietary AGE intake using data
from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
(Chapters 4 and 5). The objective of the current study was to investigate the association
between post-diagnosis NƐ-carboxymethyl-lysine (CML)-AGE intake and mortality from
all-causes, BrCa and CVD among women in the Women’s Health Initiative (WHI). We
also examined whether mortality risk was modified by fruit and vegetable intake and
BrCa hormone receptor status. Methods: The WHI enrolled postmenopausal women
aged 50 to 79 years into a clinical trial and observational study (OS). Our study sample
included 2,073 women diagnosed with invasive BrCa during follow-up who completed a
food frequency questionnaire (FFQ) post-diagnosis, had energy intakes between ≥600
kcal/day and ≤5000 kcal/day and had AGE data in the WHI database. Descriptive
analysis was used to obtain means and percentages of baseline characteristics while Cox
proportional hazards model estimated the hazard ratios (HRs) and 95% confidence
interval (CI) of mortality risk from all-causes, BrCa and CVD, and was stratified by fruit
and vegetable intake and hormone receptor status. Results: After a median 15.1 years of
follow-up, 642 deaths were reported including 198 BrCa-specific and 129 CVD-specific
deaths. The average post-diagnosis CML-AGE consumption among all women was 6,647
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± 2279 KU/1000 kcal and ranged from 830 KU/1000 kcal to 20,480 KU/1000 kcal.
Compared to the lowest tertile of CML-AGE intake, increased mortality risk was
observed in the upper tertile of CML-AGE intake for mortality from all-causes
(HRT3VST1: 1.51, 95% CI: 1.17-1.94), BrCa (HRT3VST1: 1.86, 95% CI: 1.19-2.91) and CVD
(HRT3VST1: 2.14, 95% CI: 1.19-3.84). Increased post-diagnosis CML-AGE intake was
positively associated with BrCa and CVD mortality among low consumers of fruits and
vegetables (BrCa: HRT3VST1: 2.75, 95%CI: 1.04-7.30 and CVD: HRT3VST1: 2.91, 95%CI:
1.04-8.13) and with all-cause mortality among both hormone receptor positive BrCa
(HRT3VST1: 1.45, 95%CI: 1.08-1.94) and hormone receptor negative BrCa (HRT3VST1:
2.59, 95%CI: 1.23-5.44). Conclusion: High intake of dietary AGE after BrCa diagnosis
in postmenopausal women may contribute to an increased risk of mortality from allcauses, BrCa and CVD.
6.2 INTRODUCTION
BrCa is the second leading cause of cancer death after lung cancer and constitutes
about 14% of total cancer deaths among women in the US population.2 In 2019, it is
estimated that about 268,600 new cases of invasive BrCa will be diagnosed in women.3
The increase in BrCa survival rates over the past decades has been attributed to early
screening and detection practices prompting medical treatment, and advances in
therapeutic management.5–7 Comorbid disease conditions among BrCa survivors may
negatively impact treatment and survival outcomes.165,310 Dietary modifications have
been reported in women who have been diagnosed with BrCa311 and some studies suggest
a healthy dietary pattern may contribute to improved prognosis after BrCa diagnosis.312–
314
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Advanced glycation end-products (AGEs) are complex compounds occurring
naturally in the body.34,70,71 AGEs are formed by the irreversible glycation of proteins or
lipids with reducing sugars and are also contained in foods.34,71 The adverse biological
effects of AGEs are propagated directly on tissues or through activation of the receptor
for AGE (RAGE) to induce oxidative stress and chronic inflammation.78–81,293 There is a
growing body of evidence to suggest the involvement of AGEs in cancer development
and progression.32,294 In experimental studies high serum AGE levels have been detected
in women with BrCa compared to healthy women33,98 and RAGE has been shown to be
markedly expressed in breast tumors.88 A differential effect of AGE on BrCa subtypes by
hormone receptor status has been hypothesized33,99 and AGE has been suggested to
inhibit the effects of tamoxifen treatment in hormone receptor positive BrCa, leading to
poorer survival outcomes.33
Studies on dietary AGEs in relation to mortality after BrCa diagnosis are scarce.
Using data from the Women’s Health Initiative (WHI), we examined the association
between post-diagnosis intake of dietary AGEs and all-cause and cause-specific mortality
among postmenopausal women diagnosed with invasive BrCa. We hypothesized that
increasing dietary AGE intake will be associated with an increased risk in mortality from
all-causes, BrCa and cardiovascular diseases (CVD).
6.3 METHODS
6.3.1 Study Population
The WHI is a clinical trial and observational study (OS) that was developed to
address the causes of morbidity and mortality in postmenopausal women.278,279,315 The
study enrolled over 161,000 postmenopausal women aged between 50 and 79 years from
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1993 to 1998 across 40 clinic centers into the clinical trials (n=68,132) or WHI-OS
(n=93,676). The clinical trials included the hormone replacement therapy (HRT) trial,
dietary modification (DM) trial and the calcium and vitamin D supplement (CaD) trial.
Participants were excluded from the clinical trial or WHI-OS if they had a medical
condition with an expected survival below 3 years or were enrolled in other randomized
clinical trials. Further exclusions were made if participants had a previous history of an
invasive cancer or BrCa. Participants not eligible or unwilling to participate in the clinical
trial were enrolled in the WHI-OS.279 Study participants who gave informed consent were
enrolled in the WHI extension study I & II and followed-up between 2005-2010 and
2010-2015, respectively. The study protocol was approved by the institutional review
boards at the clinical centers and written informed consent was obtained from all study
participants.
6.3.2 Data Collection
Participants enrolled in the WHI were requested to complete self-administered
questionnaires at baseline which obtained information on age at screening, race/ethnicity,
education, income and use of hormones. Physical measurements on weight and height
from which body mass index (BMI) was calculated were assessed during clinic visits at
baseline and annually for 9 years in the WHI-DM, and baseline and year 3 of follow-up
in WHI-OS. Smoking and physical activity were assessed through personal habit
questionnaires administered at baseline and updated during follow-up clinic visits only in
participants enrolled in the WHI-DM, at year 1, 3, 6 and 9. Physical activity was reported
as energy expended from recreational activity such as walking, mild, moderate and
strenuous activity and was estimated in MET-hours. Due to a considerable number of
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participants missing information on BMI after BrCa diagnosis, we utilized baseline BMI
in our analyses. We also used physical activity and smoking status at baseline to ensure
consistency of the information used in our analyses.
Usual dietary intake in the past three months was assessed through a selfadministered food frequency questionnaire (FFQ) which was developed from instruments
previously used in dietary intervention studies.284 The FFQ was validated for use in the
WHI and consisted of three sections: (1) 122 foods or food groups soliciting information
on usual dietary intake frequency and portion size, (2) four summary questions on usual
intake of fruits and vegetables and added fat for comparison with the information
obtained from the line items and (3) 19 adjustment questions on nutritional content in
food, preparation methods and added fats. The University of Minnesota Nutrition
Coordinating Center’s nutrition database was used to derive the nutrients from the FFQ
responses.284 Participants with incomplete FFQ were contacted by trained staff to obtain
missing dietary information. FFQs were administered to participants in the WHI-DM
clinical trial at baseline and after one year of follow-up. Subsequently, one third of
participants were randomly selected and were administered FFQs annually for 9 years .
Participants in the WHI-OS were administered FFQs at baseline and after three years of
follow-up.284 In the post-diagnosis dietary assessment, we utilized the first FFQ that was
completed after BrCa diagnosis.175,314 Participants in the WHI-HRT and WHI-CaD
clinical trials were excluded from our analyses because they did not complete FFQs at
follow-up. Our study sample included participants who had a first primary diagnosis of
invasive BrCa during follow-up, completed a FFQ after BrCa diagnosis, were cancer free
before or at baseline (except for non-melanoma skin cancer), had energy intakes between
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≥600 kcal/day and ≤5000 kcal/day, and had FFQ records in the WHI dietary AGE
database (Figure 6.1). Our final analytical sample contained 2,073 women from which
642 deaths from all-causes occurred during a median 15.1 years of follow-up.
6.3.3 Assessment of Dietary AGE Intake
WHI investigators at the Fred Hutchinson Cancer Research Center assigned
dietary AGE values to each food item on the FFQ using a published database. The
database contains NƐ-carboxymethyl-lysine (CML) content of 549 foods and methylglyoxal (MG) contents of selected foods commonly consumed in the northeastern
metropolitan region of the U.S.34 In the database, AGE content was estimated using
enzyme-linked immunosorbent assay (ELISA) based on monoclonal anti-CML antibody
for CML-AGE content and monoclonal anti-MG antibody for MG-AGE content.34 CMLAGE values were assigned to each food item on the FFQ. The CML-AGE are the more
stable and commonly measured of all the AGEs and has been used in our prior chapters
(Chapters 4 and 5) and in previous studies to estimate dietary AGE intake.74 Total CMLAGE values were adjusted for energy intake using the energy density method and
categorized into tertiles, with the lowest tertile representing the lowest intake level and
serving as the referent group in regression analyses.
6.3.4 Covariate Assessment
Potential confounders and risk factors implicated in survival after BrCa diagnosis
were identified through extensive literature review. Identified confounders include age
group at BrCa diagnosis (≤66 years, or >66 years), time from BrCa diagnosis to the
closest FFQ (days), race/ethnicity (non-Hispanic white (NHW), black/African American,
Hispanic/Latino, or Others), income (missing/don’t know, <20,000, 20,000-<50,000, or
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≥50,000), education (missing, high school or less, some college, college or some
postgraduate, or postgraduate), WHI component (WHI-OS, WHI-DM-intervention, or
WHI-DM-control), BrCa stage (localized, regional, distant, or unknown), estrogen
receptor (ER) and progesterone receptor (PR) status (positive, negative, or other), energy
intake (kcal/day), alcohol intake (servings/week), total fat from diet (g/day), red and
processed meat (servings/day), and baseline BMI (kg/m2) (<18.5 or missing, 18.5-<25,
25-<30, or ≥30), physical activity (MET-hours/week) (missing, 0, ≤3, 3.1-8.9, or ≥9),
postmenopausal hormone (PMH) use (never user/missing, past user, or current user) and
smoking status (missing, never, past smoker, or current smoker). We used a directed
acyclic graph (DAG) to identify a minimally sufficient set of confounders to adjust for a
causal interpretation of our results296 (Figure 3.3).
6.3.5 Outcome Assessment
Our study outcomes included death from all-causes, BrCa and CVD. CVD deaths
were defined as deaths from definite coronary heart disease (CHD), cerebrovascular,
pulmonary embolism, possible CHD, other CVD and unknown CVD. WHI outcomes
were self-reported using the medical history update form which was administered twice
yearly to participants in the clinical trials, and annually to participants in the OS. Cause
of death was ascertained through death certificates, medical records, hospitalization and
autopsy reports.281 Unreported deaths and causes of death were ascertained through data
linked to National Death Index of the National Center for Health Statistics.281
6.3.6 Statistical Analyses
Descriptive analyses estimated means and percentages for continuous and
categorical baseline characteristics, respectively. The association between post-diagnosis
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CML-AGE intake and risk of mortality from all-causes, BrCa and CVD was estimated
using a Cox proportional hazards model to calculate hazard ratios (HRs) and 95%
confidence intervals (CIs). Person-time was estimated from the date of diagnosis of
invasive BrCa until death, loss to follow-up, the end of follow-up or whichever occurred
first. We adjusted for the time period between BrCa diagnosis and completion of the
FFQ, where no participants were at risk of death, by including a time-dependent covariate
which stratified status before and after completion of post-diagnosis FFQ. In the simple
model, we adjusted for age group at BrCa diagnosis and energy intake. A second
multivariable Cox model adjusted for DAG identified confounders and included age
group at BrCa diagnosis, energy intake, income, race/ethnicity, WHI components, time
from BrCa diagnosis to FFQ, dietary intake of total fat and red and processed meat. A
third multivariable Cox model adjusted for additional identified potential confounders
including age group at BrCa diagnosis, energy intake, income, race/ethnicity, WHI
components, time from BrCa diagnosis to FFQ, education, BrCa stage, physical activity,
smoking status, BMI, ER status, PR status, PMH use, and alcohol intake. The fourth
multivariable model adjusted for all aforementioned covariates in addition to intakes of
total fat and red and processed meat.
Because dietary changes may occur in the first year after BrCa diagnosis, we
conducted a sensitivity analysis restricting the sample to 1,236 women who completed a
FFQ at least one year after BrCa diagnosis. To assess for effect modification, we
stratified our analyses by fruit and vegetable intake (low intake: <3.39 servings/day,
medium intake: 3.39-5.28 servings/day, or high intake: >5.28 servings/day) and hormone
receptor status (ER, PR and ER/PR combinations).
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Schoenfeld residual test was used to evaluate violation of proportional hazards
(PH) assumption.290 Where PH assumptions were violated, we fitted stratified PH models
for categorical covariates and time dependent PH models for continuous covariates
violating PH assumption. All statistical analyses were conducted using SAS version 9.4
and statistical significance was set at α=0.05.
6.4 RESULTS
After a median follow-up time of 15.1 years, 642 deaths from all-causes were
reported, from which 198 were BrCa-specific and 129 were CVD-specific deaths. The
average daily CML-AGE consumption was 6,647 ± 2279 KU/1000 kcal and ranged from
830 KU/1000 kcal to 20,480 KU/1000 kcal (Table 6.1). A large proportion of women
enrolled in the study were NHWs. Compared to women in the lowest tertile of CMLAGE intake, women in the highest tertile of CML-AGE had higher daily energy intake,
total intake of dietary fat and red and processed meat, were more likely to be younger at
BrCa diagnosis, obese, current smokers, physically inactive, diagnosed with PR-,
regional, and distant BrCa, and die from BrCa (Table 6.1). Women in the highest tertile
of CML-AGE intake had lower intake of fruit and vegetable and were least likely to be
current PMH users, have a college education or higher, or have a higher income. The
results showing HRs and 95% CI for mortality risk across the tertiles of CML-AGE
intake are presented in Table 6.2. After adjusting for DAG-identified confounders,
women in the highest tertile of CML-AGE intake compared to women in the lowest
intake tertile had increased risk of mortality from all-causes (HRT3VST1: 1.49, 95% CI:
1.16-1.91), BrCa (HRT3VST1: 1.83, 95% CI: 1.18-2.83) and CVD (HRT3VST1: 2.17, 95% CI:
1.22-3.85). In multivariable model 3 adjusting for additional identified covariates,
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increased risk was observed in the upper tertiles of CML-AGE intake for all-cause
mortality (HRT3VST1: 1.43, 95% CI: 1.17-1.74), BrCa mortality (HRT3VST1: 1.50, 95% CI:
1.05-2.13) and CVD mortality (HRT3VST1: 1.87, 95% CI: 1.17-2.99). The positive
associations persisted after further adjustment for dietary fat and red and processed meat
intake for all-cause mortality (HRT3VST1: 1.51, 95% CI: 1.17-1.94), BrCa mortality
(HRT3VST1: 1.86, 95% CI: 1.19-2.91) and CVD mortality (HRT3VST1: 2.14, 95% CI: 1.193.84). In sensitivity analysis restricting the sample to 1,236 women who completed a FFQ
at least one year after BrCa diagnosis, the results were unchanged for all-cause mortality
and BrCa mortality. However, the association between CML-AGE intake and CVD
mortality risk was attenuated (HRT3VST1: 1.72, 95% CI: 0.82-3.62) (Table 6.3).
The results of the multivariable Cox proportional hazard regression stratified by
fruit and vegetable intake are presented in Table 6.4. In the fully adjusted models, we saw
positive association between CML-AGE intake and risk of BrCa and CVD mortality
among low consumers of fruits and vegetables (BrCa: HRT3VST1: 2.75, 95%CI: 1.04-7.30
and CVD: HRT3VST1: 2.91, 95%CI: 1.04-8.13).
As shown in Table 6.5, when comparing the highest tertile of CML-AGE intake
to the lowest tertile of intake, increased risk of all-cause mortality was observed among
ER+ (HRT3VST1: 1.46, 95%CI: 1.09-1.96) and ER- (HRT3VST1: 2.10 95%CI: 1.07-4.10)
BrCa. Increased risk of all-cause mortality was also observed in PR+ and PR- BrCa
(HRT3VST1: 1.40, 95%CI: 1.01-1.94 and HRT3VST1: 2.47 95%CI: 1.47-4.15, respectively).
When ER and PR status were combined, there was a significant increase in risk of allcause mortality among ER+ and/or PR+ BrCa (HRT3VST1: 1.45, 95%CI: 1.08-1.94) and
ER- and PR- BrCa (HRT3VST1: 2.59, 95%CI: 1.23-5.44).
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6.5 DISCUSSION
Using data from the large prospective WHI, our results showed that higher levels
of CML-AGE intake compared to lower intake levels were associated with an increased
risk in all-cause mortality, BrCa mortality and CVD mortality in postmenopausal women
diagnosed with invasive BrCa. In stratified analyses, CML-AGE intake was associated
with increased risk of mortality from all-causes among hormone receptor positive (ER+
and/or PR+), and associations were particularly strong for hormone receptor negative
(ER- and PR-) BrCa. Increased risk of mortality from BrCa and CVD was seen among
high CML-AGE consumers who were also low consumers of fruit and vegetable. Though
the CI was wide reflecting a small sample size, our results suggest that the association
between CML-AGE and mortality may be modified by consumption of fruits and
vegetables.
To the best of our knowledge, our study is among the first epidemiological studies
to examine the association between dietary AGEs and mortality among BrCa survivors.
We utilized CML-AGE values of foods which were calculated by researchers in the Fred
Hutchinson Cancer Research Center using a published AGE database. The estimated
average daily CML-AGE intake was similar to the estimates reported in the previous
chapters using data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial (PLCO) (Chapters 4&5), and similar to estimates in a study of healthy older
women.32,302 In accordance with the current study, we found that higher CML-AGE
intake was associated with increased risk of BrCa in the PLCO cohort (Chapter 4).
A meta-analysis on BrCa survivors found null associations between postdiagnosis consumption of fruits and vegetables and all-cause and BrCa mortality.316 On
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the other hand, among women in the WHI DM trial randomized to a diet characterized by
low fat intake and increased intake of fruits, vegetables and grains, reduced risk of
mortality was seen when compared to women in the usual diet comparison group.317 The
high amounts of antioxidants and fiber contained in fruits and vegetables may be
protective of BrCa.107
The Healthy Eating Index (HEI)-2005 is defined by the U.S. Federal Dietary
Guidelines for Americans 2005.318 In studies examining post-diagnosis diet quality as
defined by the HEI-2005, better diet quality was associated with a reduced risk of deaths
from all-causes but not from BrCa specific death in women diagnosed with early stage
BrCa319 and invasive BrCa.314 We previously reported reduced risk of CVD mortality in
the WHI among women diagnosed with BrCa who consumed a more anti-inflammatory
diet after diagnosis compared to those consuming a more pro-inflammatory diet using the
dietary inflammatory index as a measure of inflammatory potential.289 Findings from the
Nurses’ Health Study (NHS) also showed a positive relationship between the Western
dietary pattern and risk of mortality from all-causes in women diagnosed with invasive
BrCa.312 The Western diet has been shown to have high AGE content and is characterized
by high intake of red and processed meat, fried foods and products high in sugar and
fats.34 Chronic diseases and adverse health outcomes have been linked to the Western
diet.34,35,76,320
The adverse effects of AGEs are propagated when deposited in tissue cells and
induce damage to protein structure thereby modifying mechanical and physiological
function. In addition, activation of RAGE promotes oxidative stress and chronic
inflammation through secretion of inflammatory biomarkers which could induce DNA
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damage.78–82 AGEs are also implicated in the production of vasoconstrictor agents and
are implicated in promoting vascular complications.321–323 RAGE has been markedly
expressed in breast tumors88 and increased RAGE expression enhances the proliferation
and invasion of BrCa cells.29,30 High accumulation of CML in BrCa tissues99 and elevated
serum CML levels have been observed in women with BrCa.33 Clinical studies in humans
suggest a link between high AGE plasma levels and CVD outcomes. In patients with type
2 diabetes, elevated serum AGE levels were observed among patients with obstructive
coronary artery disease (CAD) compared to patients without obstructive CAD and
compared to non-diabetic patient with or without obstructive CAD.324 In addition, plasma
CML levels have been linked to the severity of cardiovascular outcomes in patients with
CHF.325 Furthermore, serum AGE level was reported to increase the risk of all-cause
mortality and CVD mortality in women.326
We utilized data from a large prospective study with an adequate sample size,
long follow-up period (median 15.1 years) and information on multiple potential
confounders. As in any prospective cohort study, selection bias from loss to follow-up is
a potential limitation since participants were enrolled in the study for a long period of
time. Measurement error from the FFQ is a possibility, though the error is likely to be
non-differential since dietary information was obtained after BrCa diagnosis in all
subjects. Because diet was assessed from the first FFQ completed post-diagnosis, it is
possible that changes to diet during the follow-up period may have occurred. In our
sensitivity analyses, we excluded women with a post-diagnosis FFQ completed less than
one year after diagnosis and the results were unchanged for all-cause mortality and BrCa
mortality. However, the association for CVD mortality was attenuated and may have
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been due to the smaller sample size and number of CVD deaths. Because our study
included women with a post-diagnosis FFQ, it is likely that women with poorer diet
quality may have died or dropped out of the study before completing the FFQ postdiagnosis. Though information on BrCa treatment was not included in our analyses, we
controlled for BrCa stage and hormone receptor status which might serve as an indicator
for pharmacological treatment.
The database developed by Uribarri et al. which assessed CML-AGE content of
over 500 foods and beverages using ELISA was used to estimate total CML-AGE
intake.34 A definitive approach to measuring AGEs has not yet been established as some
analytical methods produced variations in CML contents for certain foods.100 Thus, the
true AGE content present in food may be under- or over-estimated.74,100 In some previous
studies, estimated dietary AGE intake was correlated with serum AGE levels,75,104,105
though one study which averaged two measurements taken 13 weeks apart of serum
CML measured by ELISA reported no correlation between intake of foods considered
high in dietary AGE and serum CML-AGE.303 Thus far. the Uribarri et al. AGE database
is the most frequently utilized in epidemiologic studies to estimate dietary AGE intake
from FFQ responses,32,294 which will enhance comparability of our results with other
studies.
Our findings suggest that dietary AGEs may contribute to the risk of all-cause
mortality, BrCa mortality and CVD mortality in postmenopausal women diagnosed with
BrCa. Further studies utilizing large datasets are needed to confirm our study findings.
We were unable to explore differential associations by race/ethnicity due to the small
sample size among Black/African American and Hispanic/Latino racial/ethnic groups.
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Future studies on diverse populations are warranted to explore differential associations
based on racial/ethnic groups and BrCa hormone receptor status.
6.6 CONCLUSION
Our study findings suggest an increase in consumption of dietary AGE may
increase the risk of mortality in postmenopausal women diagnosed with BrCa. Formation
of AGEs in food is accelerated through food preparation at high temperatures and
duration of cooking. Therefore, incorporating preparation practices involving cooking at
low temperatures for shorter periods of time, and marinating foods prior to cooking are
strategies that could reduce AGE content in food.34,71 Further studies are needed in this
area to establish the relationship between dietary AGEs and mortality in BrCa survivors.
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6.7 TABLES AND FIGURES

Figure 6.1. Flow chart of participants in the Women’s Health Initiative (WHI)
BrCa: breast cancer; FFQ: food frequency questionnaire; WHI: Women’s Health
Initiative; OS: observational study; DM: dietary modification; AGE: advanced
glycation end-products; CVD: cardiovascular disease; ER: estrogen receptor; PR:
progesterone receptor
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Table 6.1. Baseline characteristics by tertiles of NƐ-carboxymethyl-lysine (CML)-advanced glycation end-products
(AGE) (KU/1000 kcal) intake in the Women’s Health Initiative (WHI)
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CML-AGE, KU/1000 kcal
Years from enrollment to BrCa diagnosis, (SD)
Years from BrCa diagnosis to FFQ, (SD)
Total energy intake, kcal/day (SD)
Servings of alcohol/ week (SD)
Red and processed meat (med servings)/day (SD)
Daily fruit and vegetable intake (med portion)/day (SD)
Total fat intake, g/day (SD)
Age group at BrCa diagnosis, n (%)
≤66 years
>66 years
WHI components, n (%)
WHI-OS
WHI-DM-intervention
WHI-DM- control
Race/ethnicity, n (%)
Non-Hispanic white
Black or African American
Hispanic/Latino
Others
BMI at enrollment (kg/m2), n (%)
<18.5 or missing
18.5-<25
25-<30

Tertile 1
(n=691)
< 5555
2.5 (1.8)
1.5 (1.0)
1483.9 (514.1)
2.6 (6.4)
0.5 (0.4)
5.4 (2.4)
43.0 (21.7)

Tertile 2
(n=690)
5555-< 7309
2.8 (2.0)
1.5 (1.1)
1564.3 (548.6)
1.9 (3.4)
0.7 (0.4)
4.7 (2.2)
56.7 (24.5)

Tertile 3
(n=692)
>7309
3.0 (2.1)
1.6 (1.1)
1579.24 (602.1)
2.1 (3.8)
0.9 (0.6)
3.8 (1.9)
69.0 (31.1)

309 (44.7)
382 (55.3)

343(49.7)
347 (50.3)

357 (51.6)
335 (48.4)

350 (50.7)
202 (29.2)
139 (20.1)

315 (45.7)
148 (21.5)
227 (32.9)

258 (37.3)
94 (13.6)
340 (49.1)

637 (92.2)
26 (3.8)
15 (2.2)
13 (1.9)

633 (91.7)
30 (4.4)
16 (2.3)
11 (1.6)

587 (84.8)
64 (9.3)
24 (3.5)
17 (2.5)

7 (1.0)
270 (39.1)
240 (34.7)

4 (0.6)
237 (34.4)
225 (32.6)

12 (1.7)
164 (23.7)
234 (33.8)
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≥30
Physical activity at enrollment, MET-hours/week, n (%)
Missing
0
≤3
3.1-8.9
≥9
Income, n (%)
Missing or don’t know
<20,000
20,000-<50,000
≥50,000
Education, n (%)
Missing
High school or less
Some college
College or some postgraduate
Postgraduate
Cause of death, n (%)
No death
BrCa death
CVD death
Death from other causes
Cancer stage, n (%)
Localized
Regional
Distant
Unknown
Smoking status at enrollment, n (%)
Missing
Never

174 (25.2)

224 (32.5)

282 (40.8)

37 (5.4)
91 (13.2)
71 (10.3)
157 (22.7)
335 (48.5)

54 (7.8)
87 (12.6)
86 (12.5)
146 (21.2)
317 (45.9)

61 (8.8)
132 (19.1)
90 (13.0)
150 (21.7)
259 (37.4)

33 (4.8)
85 (12.3)
301 (43.6)
272 (39.4)

33 (4.8)
73 (10.6)
289 (41.9)
295 (42.8)

43 (6.2)
89 (12.9)
296 (42.8)
264 (31.8)

8 (1.2)
108 (15.6)
239 (34.6)
199 (28.8)
137 (19.8)

4 (0.6)
106 (15.4)
252 (36.5)
182 (26.4)
146 (21.2)

3 (0.4)
130 (18.8)
280 (40.5)
162 (23.4)
117 (16.9)

492 (71.2)
61 (8.8)
35 (5.1)
103 (14.9)

486 (70.4)
54 (7.8)
46 (6.7)
104 (15.1)

453 (65.5)
83 (12.0)
48 (6.9)
108 (15.6)

527 (76.3)
153 (22.1)
4 (0.6)
7 (1.0)

524 (75.9)
152 (22.0)
5 (0.7)
9 (1.3)

506 (73.1)
173 (25.0)
7 (1.0)
6 (0.9)

6 (0.9)
349 (50.5)

11 (1.6)
320 (46.4)

14 (2.1)
320 (46.2)

Past smoker
Current smoker
ER status, n (%)
Positive
Negative
Other
PR status, n (%)
Positive
Negative
Other
PMH use at enrollment, n (%)
Never user or missing
Past user
Current user

307 (44.4)
29 (4.2)

322 (46.7)
37 (5.4)

319 (46.1)
39 (5.6)

522 (75.5)
95 (13.8)
74 (10.7)

532 (77.1)
93 (13.5)
65 (9.4)

524 (75.7)
94 (13.6)
74 (10.7)

435 (63.0)
167 (24.2)
89 (12.9)

441 (63.9)
172 (24.9)
77 (11.2)

423 (61.1)
180 (26.0)
89 (12.9)

219 (31.7)
89 (12.9)
383 (55.4)

236 (34.2)
80 (11.6)
374 (54.2)

239 (34.5)
100 (14.5)
353 (51.0)

127

AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; BrCa: breast cancer; FFQ: food frequency
questionnaire; WHI: Women’s Health Initiative; OS: observational study; DM: dietary modification; BMI: body mass
index; CVD: cardiovascular disease; ER: estrogen receptor; PR: progesterone receptor; PMH: postmenopausal
hormones

Table 6.2. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐcarboxymethyl-lysine (CML)-advanced glycation end-products (AGE) intake and risk
of all-cause mortality, breast cancer (BrCa) mortality and cardiovascular disease
(CVD) mortality in the Women’s Health Initiative (WHI)

CML-AGE, KU/1000 kcal
All-cause
Death from any cause, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
HR (95%CI)d
BrCa
Death from BrCa, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
HR (95%CI)d
CVDe
Death from CVD, n
HR (95%CI)a
HR (95%CI)b
HR (95%CI)c
HR (95%CI)d

T1
830-5554

CML-AGE Tertiles
T2
T3
5555-7308
7309-20480

199
Ref
Ref
Ref
Ref

204
1.06 (0.87-1.28)
1.06 (0.86-1.31)
1.04 (0.85-1.27)
1.07 (0.87-1.32)

239
1.47 (1.21-1.77)
1.49 (1.16-1.91)
1.43 (1.17-1.74)
1.51 (1.17-1.94)

61
Ref
Ref
Ref
Ref

54
0.87 (0.60-1.25)
0.96 (0.65-1.42)
0.83 (0.57-1.21)
0.93 (0.62-1.39)

83
1.47 (1.05-2.05)
1.83 (1.18-2.83)
1.50 (1.05-2.13)
1.86 (1.19-2.91)

35
Ref
Ref
Ref
Ref

46
1.39 (0.90-2.16)
1.52 (0.95-2.44)
1.46 (0.93-2.30)
1.57 (0.97-2.54)

48
1.84 (1.19-2.85)
2.17 (1.22-3.85)
1.87 (1.17-2.99)
2.14 (1.19-3.84)

AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; DAG:
directed acyclic graph; CVD: cardiovascular disease; BrCa: breast cancer; FFQ: food
frequency questionnaire; BMI: body mass index; ER: estrogen receptor; PR:
progesterone receptor; PMH: postmenopausal hormones; PH: proportional hazard
a
Adjusted for age group at BrCa diagnosis and energy intake
b
Adjusted for DAG identified covariates: age group at BrCa diagnosis, energy intake,
income, race/ethnicity, WHI components, time from BrCa diagnosis to FFQ, dietary
intake of total fat, red and processed meat and covariate of time-dependent status
before and after postdiagnosis FFQ
c
Adjusted for covariates: age group at BrCa diagnosis, energy intake, income,
race/ethnicity, WHI components, time from BrCa diagnosis to FFQ, education,
physical activity, smoking status, BMI, ER status, PR status, BrCa stage, PMH use,
alcohol intake and covariate of time-dependent status before and after postdiagnosis
FFQ
d
Adjusted for all covariates in c and dietary intake of total fat and red and processed
meat
e
Stratified by age group due to PH assumption violation
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Table 6.3. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐcarboxymethyl-lysine (CML)-advanced glycation end-products (AGE) intake and
risk of all-cause mortality, breast cancer (BrCa) mortality and cardiovascular disease
(CVD) mortality among women with food frequency questionnaire (FFQ) completed
at least one year post-diagnosis

CML-AGE, KU/1000 kcal
All-causea
Deaths from any cause, n
HR (95%CI)b
HR (95%CI)c
HR (95%CI)d
HR (95%CI)e
BrCa
Death from BrCa, n
HR (95%CI)b
HR (95%CI)c
HR (95%CI)d
HR (95%CI)e
CVDf
Death from CVD, n
HR (95%CI)b
HR (95%CI)c
HR (95%CI)d
HR (95%CI)e

T1
830-5550

CML-AGE Tertiles
T2
T3
5551-7305
7306-19421

128
Ref
Ref
Ref
Ref

115
0.92 (0.71-1.18)
0.91 (0.70-1.19)
0.93 (0.72-1.21)
0.95 (0.72-1.25)

146
1.42 (1.11-1.80)
1.42 (1.04-1.94)
1.37 (1.06-1.78)
1.42 (1.03-1.96)

36
Ref
Ref
Ref
Ref

29
0.80 (0.49-1.30)
0.85 (0.51-1.43)
0.81 (0.49-1.34)
0.86 (0.50-1.47)

50
1.48 (0.96-2.29)
1.76 (1.01-3.08)
1.76 (1.10-2.82)
1.92 (1.07-3.46)

25
Ref
Ref
Ref
Ref

23
0.94 (0.53-1.66)
1.003 (0.55-1.84)
1.06 (0.59-1.90)
1.07 (0.57-1.99)

30
1.66 (0.98-2.84)
1.76 (0.86-3.58)
1.60 (0.89-2.90)
1.72 (0.82-3.62)

AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; DAG:
directed acyclic graph; CVD: cardiovascular disease; BrCa: breast cancer; FFQ:
food frequency questionnaire; BMI: body mass index; ER: estrogen receptor; PR:
progesterone receptor; PMH: postmenopausal hormones; PH: proportional hazard
a
Adjusted for time-dependent alcohol intake due to PH assumption violation
b
Adjusted for age group at BrCa diagnosis and energy intake
c
Adjusted for DAG identified covariates: age group at BrCa diagnosis, energy
intake, income, race/ethnicity, WHI components, time from BrCa diagnosis to FFQ,
dietary intake of total fat, red and processed meat and covariate of time-dependent
status before and after postdiagnosis FFQ
d
Adjusted for covariates: age group at BrCa diagnosis, energy intake, income,
race/ethnicity, WHI components, time from BrCa diagnosis to FFQ, education,
physical activity, smoking status, BMI, ER status, PR status, BrCa stage, PMH use,
alcohol intake and covariate of time-dependent status before and after postdiagnosis
FFQ
e
Adjusted for all covariates in d and dietary intake of total fat, and red and processed
meat
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f

Stratified by BMI due to PH assumption violation
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Table 6.4. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐ-carboxymethyl-lysine
(CML)-advanced glycation end-products (AGE) intake and risk of all-cause mortality, breast cancer
(BrCa) mortality and cardiovascular disease (CVD) mortality by fruit and vegetable intake in the
Women’s Health Initiative (WHI)
CML-AGE Tertiles

CML-AGE KU/1000 kcal
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T1

T2

T3

830-5554

5555-7308

7309-20480

60
0.82 (0.53-1.26)
0.85 (0.54-1.32)

110
1.31 (0.89-1.94)
1.41 (0.89-2.25)

69
0.92 (0.65-1.30)
0.95 (0.67-1.37)

82
1.38 (0.98-1.96)
1.52 (0.998-2.30)

75
1.35 (0.97-1.87)
1.29 (0.90-1.84)

47
1.64 (1.11-2.42)
1.55 (0.96-2.52)

17

35

Death from any cause
Low intake (n=687) 0.3-3.38 med portion/day
Deaths, n
38
a
HR (95%CI)
Ref
b
HR (95%CI)
Ref
Medium intake (n=694) 3.39-5.28 med portion/day
Deaths, n
75
a
HR (95%CI)
Ref
b
HR (95%CI)
Ref
High Intake (n=692) 5.29-14.29 med portion/day
Deaths, n
86
a
HR (95%CI)
Ref
b
HR (95%CI)
Ref
Death from BrCa
Low intake (n=687) 0.3-3.38 med portion/day
Deaths, n

10

HR (95%CI)a
Ref
b
HR (95%CI)
Ref
Medium intake (n=694) 3.39-5.28 med portion/day
Deaths, n
17
a
HR (95%CI)
Ref
b
HR (95%CI)
Ref
High Intake (n=692) 5.29-14.29 med portion/day
Deaths, n
HR (95%CI)a
HR (95%CI)b

34
Ref
Ref

1.11 (0.49-2.55)
1.33 (0.55-3.08)

1.93 (0.90-4.13)
2.75 (1.04-7.30)

16
0.88 (0.41-1.86)
0.88 (0.40-1.92)

29
2.19 (1.10-4.40)
2.15 (0.95-4.87)

21
0.78 (0.43-1.39)
0.77 (0.41-1.45)

19
1.55 (0.82-2.91)
1.68 (0.77-3.68)

15
1.12 (0.42-2.98)
1.34 (0.49-3.63)

26
1.96 (0.80-4.84)
2.91 (1.04-8.13)

11
1.02 (0.42-2.52)
1.03 (0.40-2.64)

12
2.01 (0.79-5.12)
2.07 (0.66-6.48)

20
2.26 (1.12-4.55)
2.07 (0.97-4.41)

10
2.07 (0.84-5.12)
1.81 (0.59-5.52)

Death from CVD c
Low intake (n=687) 0.3-3.38 med portion/day
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Deaths, n
7
a
HR (95%CI)
Ref
b
HR (95%CI)
Ref
Medium intake (n=694) 3.39-5.28 med portion/day
Deaths, n
12
a
HR (95%CI)
Ref
b
HR (95%CI)
Ref
High Intake (n=692) 5.29-14.29 med portion/day
Deaths, n
HR (95%CI)a
HR (95%CI)b

16
Ref
Ref

AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; DAG: directed acyclic graph;
CVD: cardiovascular disease; BrCa: breast cancer; FFQ: food frequency questionnaire; BMI: body mass
index; ER: estrogen receptor; PR: progesterone receptor; PMH: postmenopausal hormones; PH:

proportional hazard
a
Adjusted for covariates: age group at BrCa diagnosis, energy intake, income, race/ethnicity, WHI
components, time from BrCa diagnosis to FFQ, education, physical activity, smoking status, BMI, ER
status, PR status, BrCa stage, PMH use, alcohol intake and covariate of time-dependent status before and
after postdiagnosis FFQ
b
Adjusted for all covariates in a and dietary intake of total fat, and red and processed meat
c
Stratified by age group at BrCa diagnosis due to PH assumption violation
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Table 6.5. Hazard ratio (HRs) and 95% confidence interval (CI) for tertiles of NƐ-carboxymethyllysine (CML)-advanced glycation end-products (AGE) intake and risk of all-cause mortality by
hormone receptor status in the Women’s Health Initiative (WHI)
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CML-AGE KU/1000 kcal
ER status (n=1,860)
ER+
Death from any cause, n
HR (95%CI)a
HR (95%CI)b
ERDeath from any cause, n
HR (95%CI)a
HR (95%CI)b
PR status (n=1,818)
PR+
Death from any cause, n
HR (95%CI)a
HR (95%CI)b
PRDeath from any cause, n
HR (95%CI)a
HR (95%CI)b
ER/PR combination
ER+/PR+ (n=1,611)
Death from any cause, n

T1
830-5554

CML-AGE Tertiles
T2
5555-7308

T3
7309-20480

145
Ref
Ref

147
0.997 (0.79-1.26)
1.03 (0.80-1.32)

173
1.37 (1.08-1.74)
1.46 (1.09-1.96)

34
Ref
Ref

32
0.81 (0.47-1.40)
0.80 (0.45-1.45)

44
2.15 (1.29-3.60)
2.10 (1.07-4.10)

118
Ref
Ref

121
1.004 (0.77-1.30)
1.02 (0.78-1.35)

140
1.36 (1.04-1.77)
1.40 (1.01-1.94)

57
Ref
Ref

54
1.01 (0.67-1.52)
1.14 (0.74-1.75)

71
1.91 (1.27-2.87)
2.47 (1.47-4.15)

148

151

180

HR (95%CI)a
HR (95%CI)b
ER- and PR- (n=243)
Death from any cause, n
HR (95%CI)a
HR (95%CI)b

Ref
Ref

1.01 (0.80-1.28)
1.04 (0.81-1.33)

1.40 (1.10-1.77)
1.45 (1.08-1.94)

29
Ref
Ref

28
0.79 (0.44-1.43)
0.89 (0.47-1.68)

37
2.05 (1.17-3.62)
2.59 (1.23-5.44)
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AGE: advanced glycation end-products; CML: NƐ-carboxymethyl-lysine; DAG: directed acyclic
graph; CVD: cardiovascular disease; BrCa: breast cancer; FFQ: food frequency questionnaire; BMI:
body mass index; ER: estrogen receptor; PR: progesterone receptor; PMH: postmenopausal
hormones; PH: proportional hazard
a
Adjusted for covariates: age group at BrCa diagnosis, energy intake, income, race/ethnicity, WHI
components, time from BrCa diagnosis to FFQ, education, physical activity, smoking status, BMI,
BrCa stage, PMH use, alcohol intake, covariate of time-dependent status before and after
postdiagnosis FFQ (for ER/PR combination model), ER status (for PR model) and PR status (for ER
model)
b
Adjusted for all covariates in c and dietary intake of total fat, and red and processed meat

CHAPTER 7
DIETARY ADVANCED GLYCATION END-PRODUCTS (AGES) AND
BREAST CANCER RISK AND SURVIVAL: A DISCUSSION OF
RESULTS
7.1 SUMMARY OF RESULTS
Breast cancer (BrCa) is the most commonly diagnosed malignancy and second
leading cause of cancer death after lung cancer in women in the United States.2 Over the
past two decades, BrCa incidence rates have increased while mortality rates have
declined.3 Early detection which prompts early management and treatment3 and advances
in therapeutic management have contributed to improved health outcomes.5–7 Studies
examining the influence of diet on BrCa risk and survival are ongoing and some evidence
suggest a role of diet in BrCa prevention.10
The overall aim of the dissertation was to examine the relationship between a
putative dietary risk factor, NƐ-carboxymethyl-lysine (CML)-AGE, and BrCa risk and
survival using data from two large prospective cohort studies. Utilizing data from the
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), we assigned and
quantified CML-AGE values to each food item on the dietary questionnaire (DQX) and
examined the association between dietary AGE intake and BrCa risk. We further
examined if the relationship differed by race/ethnicity, obesity status, fruit and vegetable
intake, invasiveness and hormone receptor status. Using data from the Women’s Health
Initiative (WHI), we examined the association between post-diagnosis intake of dietary
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AGEs and all-cause mortality, BrCa mortality and CVD mortality in postmenopausal
women diagnosed with invasive BrCa.
In the PLCO, animal protein and dietary fatty acids were strongly correlated with
CML-AGE intake. Among all women in the PLCO, fats and oil such as margarine and
cheese sauce, and red meat were the highest contributors to total daily CML-AGE intake,
contributing about 21% and 15 %, respectively, while fruits contributed the least amount
(0.3%). When stratified by race/ethnicity, red meat and mixed foods represented a high
proportion of CML-AGE intake among non-Hispanic white (NHW) women (15%), white
and processed meat in non-Hispanic black (NHB) women (16%), and red and white meat
among women of Other races/ethnicities (14% and 13%, respectively). The results
indicate that major dietary sources of CML-AGE may be different among the
races/ethnicities.
Women in the highest quintile of CML-AGE intake had a 30% increased risk of
BrCa compared to women in the lowest quintile in the PLCO, with a significant linear
trend across quintiles. In stratified analyses, the risk was more prominent in NHW
women, and women diagnosed with in situ and hormone receptor positive (ER+/PR+)
BrCa. Though we observed stronger positive associations for CML-AGE and BrCa
among obese participants (than among normal weight or overweight subjects) and high
consumers of fruits and vegetables (than among low or moderate consumers), the
associations were not significant.
Using data from the WHI, we assessed associations between dietary AGE and
mortality risk after a diagnosis of invasive BrCa. Findings showed that women in the
highest level of CML-AGE intake had a 51% increased risk of all-cause mortality when
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compared to women in the lowest intake level. We also observed an increased risk in
BrCa mortality and cardiovascular disease (CVD) mortality. After stratifying by fruit and
vegetable consumption, the increase in mortality risk from BrCa and CVD was more
prominent in low consumers of fruits and vegetables than in moderate or high consumers.
However, the estimates produced wide CIs and a chance finding cannot be completely
ruled out. Furthermore, we stratified the results by hormone receptor status and found
increased risk of all-cause mortality among women diagnosed with hormone receptor
positive BrCa and among those with hormone receptor negative BrCa.
7.2 POTENTIAL MECHANISM OF ACTION
The link between AGEs and pathogenesis is supported by studies showing
development and progression of disease states in high AGE environments.327 Detrimental
effects of AGEs occur through several mechanisms. AGEs form cross-linkages with
intracellular and extracellular proteins to cause modifications in the normal structure
thereby promoting changes in mechanical and physiological function.77,328 Receptor for
AGE (RAGE) are expressed on the surface of a variety of cells and on activation, induce
a cascade of signaling pathways. RAGE activation promotes oxidative stress and chronic
inflammation which could induce DNA damage.78–82
AGEs promote inflammation and oxidative stress conditions.329 Studies report
that the presence of circulating inflammatory biomarkers promote tumor progression and
metastasis11 and increases the risk of BrCa.12,13 Increased RAGE expression can enhance
the proliferation and invasion of BrCa cells.29,30 High accumulation of CML in BrCa
tissues99 and elevated serum CML levels in women with BrCa33 have also been observed.

138

Accumulation of AGEs may promote production of vasoconstrictor agents
causing damage to vasculature and promoting vascular complications.321–323 The direct
effects of AGEs on the myocardium are mediated through crosslinking of proteins to
promote vascular and myocardial damage.323,330,331 Activation of RAGE on endothelial
cells and smooth muscle cells also induces inflammation and oxidative stress.323,332,333
Clinical studies show that AGEs may be important in the progression of CVD
complications334 and serum AGE level was reported to be associated with the risk of allcause mortality and CVD mortality in women.326 Thus, AGEs may be a useful marker in
assessing the severity of CVD.335
7.3 STRENGTHS AND LIMITATIONS
We utilized two large prospective datasets with adequate sample size, long
follow-up period and information on multiple confounders. As in any prospective cohort
study, selection bias from loss to follow-up is a potential limitation since participants
were enrolled in the study for a long period of time.
In examination of post-diagnosis diet using data from the WHI, post-diagnosis
food frequency questionnaires (FFQ) were available for only women enrolled in the
WHI-observational study (OS) and WHI-dietary modification (DM) trial and resulted in a
smaller analytical sample size. As a result, we were unable to assess for mortality risk in
NHB and Other racial/ethnic groups due to limited sample size. Although we evaluated
the risk of all-cause mortality by hormone receptor status, we were unable to assess for
BrCa and CVD specific mortality by hormone receptor status due to the small number of
BrCa and CVD deaths. Measurement error from the FFQ is a possibility, though the error
is likely to be non-differential since dietary information was obtained prior to the
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occurrence of BrCa in the PLCO and mortality in the WHI. In the PLCO, we utilized
only the DQX completed at baseline among the intervention arm to enhance uniformity
of the dietary assessment. Similarly, in the WHI we utilized baseline information on
BMI, physical activity and smoking status due to a considerable number of missing data
on post-diagnosis information.
The database developed by Uribarri et al. which assessed CML-AGE content of
over 500 foods and beverages using ELISA34 was used to estimate total CML-AGE
intake in the PLCO and WHI. A definitive approach to measuring AGEs is yet to be
established as some analytical methods produced variations in CML contents for certain
foods.100 Thus, the true AGE content present in food may be under- or overestimated.74,100 In some previous studies, estimated dietary AGE intake was correlated
with serum AGE levels,75,104,105 though one study which averaged two measurements
taken 13 weeks apart of serum CML measured by ELISA reported no correlation
between intake of foods considered high in dietary AGE and serum CML-AGE.303
Presently, the Uribarri et al. AGE database is the most frequently utilized in
epidemiologic studies to estimate dietary AGE intake from FFQ responses,32,294 which
will enhance comparability of our results with other studies.
7.4 PUBLIC HEALTH SIGNIFICANCE
The role of diet in relation to BrCa is being studied extensively. Few studies have
attempted to study dietary exposure of AGEs in relation to BrCa risk and survival. Our
study attempted to fill this gap and is among the first to prospectively examine the role of
dietary AGEs in BrCa risk and survival by estimating AGE contents in food using a
published database.

140

The Western diet is characterized by high intake of red and processed meat, fried
foods and fatty foods and was demonstrated by Uribarri et al. to contain high levels of
AGEs.34 Foods high in animal protein and fat were identified to contain high CML-AGE
contents. Such food products include meat, cheese or butter. On the other hand, fruits and
vegetables were reported to be low in AGE content.
Our study shows that increasing intake of dietary CML-AGE increases the risk of
developing BrCa in women. We found evidence of an increased risk of in situ and
hormone receptor positive BrCa. Hormone receptor positive cancers comprise over 70%
of BrCa diagnoses3 and decreasing dietary AGE intake may be an important intervention
in reducing the burden of BrCa. NHW have only slightly higher BrCa incidence rates
than NHB populations across all age groups, while incidence rates are higher among
younger NHBs.3 We found an increased risk of BrCa in NHW women but did not find
enough evidence among NHBs and other races, possibly due to the sample size
limitation.
Among postmenopausal women diagnosed with invasive BrCa, we found CMLAGE intake increased the risk of mortality from all-causes, BrCa and CVD. Women
diagnosed with hormone receptor positive and negative BrCa were at an increased risk of
mortality from all-causes with higher CML-AGE intake. Associations between CMLAGE and BrCa and CVD mortality appeared to be modified by fruit and vegetable intake,
with highest risk observed among those with low intake of fruits and vegetables, though
our estimates were imprecise given the wide confidence intervals. Thus, adopting a diet
low in AGEs and high in fruits and vegetables may be a strategy to improve survival
outcomes from BrCa specific and CVD specific deaths.
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Dietary changes after BrCa diagnosis are reported in about 31% of women.336 The
changes include reducing intake of animal fat and red meat and increasing the
consumption of fruits and vegetables. Adopting a low AGE diet may be important in
improving health outcomes in BrCa survivors. In addition to reducing intake of animal
protein and fat34 as were shown in our study to be strongly correlated with CML-AGEs,
adopting healthier cooking methods can also reduce AGE formation in cooked foods.
Low temperatures and moist heat such as steaming, poaching or boiling, as opposed to
high heat methods such as frying, or grilling could considerably reduce generation of
AGEs in foods. Also, shorter cooking times limit AGE formation. For example, chicken
breast poached in medium heat for 7 minutes contains 1,101 CML-AGE KU/100g as
compared to 4,938 CML-AGE KU/100g contained in chicken breast pan fried at high
temperature for 13 minutes.34 Furthermore, preparation of foods with spices and acidic
marinades such as vinegar and citrus juices before cooking may help to inhibit the
formation of AGEs in food products.34,327
Overall, public health interventions geared at improving diet and food preparation
practices may be beneficial in BrCa prevention and control.
7.5 SUGGESTIONS FOR FUTURE RESEARCH
Our study is among the first to prospectively investigate the role of dietary AGEs
in BrCa risk and survival by estimating CML-AGE contents in foods using a published
AGE database. Further studies are needed to replicate our findings and establish the role
of dietary AGEs in BrCa risk and survival. The PLCO and WHI datasets consisted
mostly of NHW women. In BrCa risk assessment using the PLCO, our results were not
significant among NHB and other races and may be due to the smaller sample size and
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number of BrCa cases. Similarly, in the WHI, we were unable to explore differential
associations by race/ethnicity due to the small sample size among Black/African
American and other races/ethnicities. Future studies using more racially diverse
populations will allow exploration of differential associations by race/ethnicity.
In the WHI, we found dietary AGEs may contribute to the risk of all-cause
mortality, BrCa mortality and CVD mortality in postmenopausal women diagnosed with
BrCa. We found significant associations in the stratified analyses by hormone receptor
status and fruit and vegetable intake which may have been a chance finding given the
multiple comparisons. Further studies utilizing larger datasets are needed to confirm our
study findings.
A recent paper highlighted differences in AGE content of foods when using
different laboratory techniques (ELISA vs. HPLC-MS/MS)337 and recommended the use
of a different AGE food composition database published by Scheijen et al. which
contains estimates on only 190 food items.102 Some of the largest differences were seen
for butter which has high CML-AGE content in the Uribarri et al. database, but very low
content in the Scheijen et al. database. Given that the Uribarri et al. database contains
almost three times as many food items and has been used more often in epidemiologic
studies, we decided to use the Uribarri et al. database to enhance comparability with other
studies. However, future studies comparing the dietary AGE estimates from the two
databases are warranted.
7.6 CONCLUSION
In this large prospective study assessing BrCa risk and survival, increased risk of
overall BrCa, in situ and hormone receptor positive BrCa was observed among women in
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the highest intake level of dietary AGE. In postmenopausal women who had been
diagnosed with BrCa, higher post-diagnosis CML-AGE intake was associated with an
increased risk of mortality from all-causes, BrCa and CVD. In addition, there was
evidence that the association between CML-AGE intake and increased risk of mortality
from BrCa and CVD was particularly strong among low consumers of fruit and
vegetables.
Our findings suggest that limiting the consumption of dietary AGEs may reduce
the risk of BrCa and improve survival outcomes after BrCa diagnosis. AGE intake can be
reduced through limiting the consumption of foods high in AGE content and
incorporating healthier cooking practices. Adopting these strategies may be an important
dietary intervention in BrCa prevention and control.
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